#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=CYP2A6 genetic variation alters striatal-cingulate circuits, network hubs and executive processing in smokers
#Text=Background
#Text=Variation in the CYP2A6 gene alters the rate of nicotine metabolic inactivation and is associated with smoking behaviors and cessation success rates.
1-1	0-6	CYP2A6	_	
1-2	7-14	genetic	_	
1-3	15-24	variation	_	
1-4	25-31	alters	_	
1-5	32-50	striatal-cingulate	_	
1-6	51-59	circuits	_	
1-7	59-60	,	_	
1-8	61-68	network	_	
1-9	69-73	hubs	_	
1-10	74-77	and	_	
1-11	78-87	executive	_	
1-12	88-98	processing	_	
1-13	99-101	in	_	
1-14	102-109	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
1-15	110-120	Background	_	
1-16	121-130	Variation	_	
1-17	131-133	in	_	
1-18	134-137	the	_	
1-19	138-144	CYP2A6	_	
1-20	145-149	gene	_	
1-21	150-156	alters	_	
1-22	157-160	the	_	
1-23	161-165	rate	_	
1-24	166-168	of	_	
1-25	169-177	nicotine	_	
1-26	178-187	metabolic	_	
1-27	188-200	inactivation	_	
1-28	201-204	and	_	
1-29	205-207	is	_	
1-30	208-218	associated	_	
1-31	219-223	with	_	
1-32	224-231	smoking	_	
1-33	232-241	behaviors	_	
1-34	242-245	and	_	
1-35	246-255	cessation	_	
1-36	256-263	success	_	
1-37	264-269	rates	_	
1-38	269-270	.	_	

#Text=The underlying neurobiological mechanisms of this genetic influence remain unknown.
2-1	271-274	The	_	
2-2	275-285	underlying	_	
2-3	286-301	neurobiological	_	
2-4	302-312	mechanisms	_	
2-5	313-315	of	_	
2-6	316-320	this	_	
2-7	321-328	genetic	_	
2-8	329-338	influence	_	
2-9	339-345	remain	_	
2-10	346-353	unknown	_	
2-11	353-354	.	_	

#Text=Methods
#Text=Intrinsic functional connectivity strength (FCS), a whole brain, data driven, graph theory based method, was applied to resting state fMRI data in 66 smokers and 92 nonsmokers.
3-1	355-362	Methods	_	
3-2	363-372	Intrinsic	_	
3-3	373-383	functional	_	
3-4	384-396	connectivity	_	
3-5	397-405	strength	_	
3-6	406-407	(	_	
3-7	407-410	FCS	_	
3-8	410-411	)	_	
3-9	411-412	,	_	
3-10	413-414	a	_	
3-11	415-420	whole	_	
3-12	421-426	brain	_	
3-13	426-427	,	_	
3-14	428-432	data	_	
3-15	433-439	driven	_	
3-16	439-440	,	_	
3-17	441-446	graph	_	
3-18	447-453	theory	_	
3-19	454-459	based	_	
3-20	460-466	method	_	
3-21	466-467	,	_	
3-22	468-471	was	_	
3-23	472-479	applied	_	
3-24	480-482	to	_	
3-25	483-490	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[1]	
3-26	491-496	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[1]	
3-27	497-501	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[1]	
3-28	502-506	data	_	
3-29	507-509	in	_	
3-30	510-512	66	_	
3-31	513-520	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
3-32	521-524	and	_	
3-33	525-527	92	_	
3-34	528-538	nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
3-35	538-539	.	_	

#Text=A subset of subjects (n=23/20; smokers/nonsmokers) performed the Monetary Incentive Delay (MID) task, probing reward anticipation and a Go/NoGo task, probing response inhibition, on two occasions, in the presence and absence of a nicotine patch.
4-1	540-541	A	_	
4-2	542-548	subset	_	
4-3	549-551	of	_	
4-4	552-560	subjects	_	
4-5	561-562	(	_	
4-6	562-563	n	_	
4-7	563-564	=	_	
4-8	564-566	23	_	
4-9	566-567	/	_	
4-10	567-569	20	_	
4-11	569-570	;	_	
4-12	571-578	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
4-13	578-579	/	_	
4-14	579-589	nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
4-15	589-590	)	_	
4-16	591-600	performed	_	
4-17	601-604	the	_	
4-18	605-613	Monetary	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-19	614-623	Incentive	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-20	624-629	Delay	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-21	630-631	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-22	631-634	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-23	634-635	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
4-24	636-640	task	_	
4-25	640-641	,	_	
4-26	642-649	probing	_	
4-27	650-656	reward	_	
4-28	657-669	anticipation	_	
4-29	670-673	and	_	
4-30	674-675	a	_	
4-31	676-678	Go	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[3]	
4-32	678-679	/	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[3]	
4-33	679-683	NoGo	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[3]	
4-34	684-688	task	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[3]	
4-35	688-689	,	_	
4-36	690-697	probing	_	
4-37	698-706	response	_	
4-38	707-717	inhibition	_	
4-39	717-718	,	_	
4-40	719-721	on	_	
4-41	722-725	two	_	
4-42	726-735	occasions	_	
4-43	735-736	,	_	
4-44	737-739	in	_	
4-45	740-743	the	_	
4-46	744-752	presence	_	
4-47	753-756	and	_	
4-48	757-764	absence	_	
4-49	765-767	of	_	
4-50	768-769	a	_	
4-51	770-778	nicotine	_	
4-52	779-784	patch	_	
4-53	784-785	.	_	

#Text=Results
#Text=A significant CYP2A6 genotype × Smoking effect was found in the dorsal anterior cingulate cortex (dACC) and ventral striatum (VS), such that the normal (vs. slow) genotype individuals showed greater FCS in smokers but not nonsmokers.
5-1	786-793	Results	_	
5-2	794-795	A	_	
5-3	796-807	significant	_	
5-4	808-814	CYP2A6	_	
5-5	815-823	genotype	_	
5-6	824-825	×	_	
5-7	826-833	Smoking	_	
5-8	834-840	effect	_	
5-9	841-844	was	_	
5-10	845-850	found	_	
5-11	851-853	in	_	
5-12	854-857	the	_	
5-13	858-864	dorsal	_	
5-14	865-873	anterior	_	
5-15	874-883	cingulate	_	
5-16	884-890	cortex	_	
5-17	891-892	(	_	
5-18	892-896	dACC	_	
5-19	896-897	)	_	
5-20	898-901	and	_	
5-21	902-909	ventral	_	
5-22	910-918	striatum	_	
5-23	919-920	(	_	
5-24	920-922	VS	_	
5-25	922-923	)	_	
5-26	923-924	,	_	
5-27	925-929	such	_	
5-28	930-934	that	_	
5-29	935-938	the	_	
5-30	939-945	normal	_	
5-31	946-947	(	_	
5-32	947-949	vs	_	
5-33	949-950	.	_	
5-34	951-955	slow	_	
5-35	955-956	)	_	
5-36	957-965	genotype	_	
5-37	966-977	individuals	_	
5-38	978-984	showed	_	
5-39	985-992	greater	_	
5-40	993-996	FCS	_	
5-41	997-999	in	_	
5-42	1000-1007	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
5-43	1008-1011	but	_	
5-44	1012-1015	not	_	
5-45	1016-1026	nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
5-46	1026-1027	.	_	

#Text=FCS was negatively associated with nicotine dependence severity in slow metabolizers.
6-1	1028-1031	FCS	_	
6-2	1032-1035	was	_	
6-3	1036-1046	negatively	_	
6-4	1047-1057	associated	_	
6-5	1058-1062	with	_	
6-6	1063-1071	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[4]	
6-7	1072-1082	dependence	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[4]	
6-8	1083-1091	severity	_	
6-9	1092-1094	in	_	
6-10	1095-1099	slow	_	
6-11	1100-1112	metabolizers	_	
6-12	1112-1113	.	_	

#Text=Both hubs were biased by inputs from the insula identified from seed-based connectivity.
7-1	1114-1118	Both	_	
7-2	1119-1123	hubs	_	
7-3	1124-1128	were	_	
7-4	1129-1135	biased	_	
7-5	1136-1138	by	_	
7-6	1139-1145	inputs	_	
7-7	1146-1150	from	_	
7-8	1151-1154	the	_	
7-9	1155-1161	insula	_	
7-10	1162-1172	identified	_	
7-11	1173-1177	from	_	
7-12	1178-1188	seed-based	_	
7-13	1189-1201	connectivity	_	
7-14	1201-1202	.	_	

#Text=Similar Gene × Environment interactions were seen in VS during smoking abstinence when subjects performed the MID task and in dACC when they performed the Go/NoGo task; both reductions were “normalized” in smokers (and increased in nonsmokers) following acute nicotine administration.
8-1	1203-1210	Similar	_	
8-2	1211-1215	Gene	_	
8-3	1216-1217	×	_	
8-4	1218-1229	Environment	_	
8-5	1230-1242	interactions	_	
8-6	1243-1247	were	_	
8-7	1248-1252	seen	_	
8-8	1253-1255	in	_	
8-9	1256-1258	VS	_	
8-10	1259-1265	during	_	
8-11	1266-1273	smoking	_	
8-12	1274-1284	abstinence	_	
8-13	1285-1289	when	_	
8-14	1290-1298	subjects	_	
8-15	1299-1308	performed	_	
8-16	1309-1312	the	_	
8-17	1313-1316	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]	
8-18	1317-1321	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]	
8-19	1322-1325	and	_	
8-20	1326-1328	in	_	
8-21	1329-1333	dACC	_	
8-22	1334-1338	when	_	
8-23	1339-1343	they	_	
8-24	1344-1353	performed	_	
8-25	1354-1357	the	_	
8-26	1358-1360	Go	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[6]	
8-27	1360-1361	/	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[6]	
8-28	1361-1365	NoGo	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[6]	
8-29	1366-1370	task	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[6]	
8-30	1370-1371	;	_	
8-31	1372-1376	both	_	
8-32	1377-1387	reductions	_	
8-33	1388-1392	were	_	
8-34	1393-1394	“	_	
8-35	1394-1404	normalized	_	
8-36	1404-1405	”	_	
8-37	1406-1408	in	_	
8-38	1409-1416	smokers	_	
8-39	1417-1418	(	_	
8-40	1418-1421	and	_	
8-41	1422-1431	increased	_	
8-42	1432-1434	in	_	
8-43	1435-1445	nonsmokers	_	
8-44	1445-1446	)	_	
8-45	1447-1456	following	_	
8-46	1457-1462	acute	_	
8-47	1463-1471	nicotine	_	
8-48	1472-1486	administration	_	
8-49	1486-1487	.	_	

#Text=Conclusions
#Text=Since the CYP2A6 effect was seen only in smokers, these data suggest that the rate of nicotine metabolism, and thus the concentration of nicotine presented to brain over the course of nicotine addiction, shapes brain circuits that, among other functions, compute reward and impulsivity processes.
9-1	1488-1499	Conclusions	_	
9-2	1500-1505	Since	_	
9-3	1506-1509	the	_	
9-4	1510-1516	CYP2A6	_	
9-5	1517-1523	effect	_	
9-6	1524-1527	was	_	
9-7	1528-1532	seen	_	
9-8	1533-1537	only	_	
9-9	1538-1540	in	_	
9-10	1541-1548	smokers	_	
9-11	1548-1549	,	_	
9-12	1550-1555	these	_	
9-13	1556-1560	data	_	
9-14	1561-1568	suggest	_	
9-15	1569-1573	that	_	
9-16	1574-1577	the	_	
9-17	1578-1582	rate	_	
9-18	1583-1585	of	_	
9-19	1586-1594	nicotine	_	
9-20	1595-1605	metabolism	_	
9-21	1605-1606	,	_	
9-22	1607-1610	and	_	
9-23	1611-1615	thus	_	
9-24	1616-1619	the	_	
9-25	1620-1633	concentration	_	
9-26	1634-1636	of	_	
9-27	1637-1645	nicotine	_	
9-28	1646-1655	presented	_	
9-29	1656-1658	to	_	
9-30	1659-1664	brain	_	
9-31	1665-1669	over	_	
9-32	1670-1673	the	_	
9-33	1674-1680	course	_	
9-34	1681-1683	of	_	
9-35	1684-1692	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[7]	
9-36	1693-1702	addiction	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[7]	
9-37	1702-1703	,	_	
9-38	1704-1710	shapes	_	
9-39	1711-1716	brain	_	
9-40	1717-1725	circuits	_	
9-41	1726-1730	that	_	
9-42	1730-1731	,	_	
9-43	1732-1737	among	_	
9-44	1738-1743	other	_	
9-45	1744-1753	functions	_	
9-46	1753-1754	,	_	
9-47	1755-1762	compute	_	
9-48	1763-1769	reward	_	
9-49	1770-1773	and	_	
9-50	1774-1785	impulsivity	_	
9-51	1786-1795	processes	_	
9-52	1795-1796	.	_	

#Text=Introduction
#Text=Nicotine is the principal addictive component in tobacco that maintains smoking behavior.
10-1	1797-1809	Introduction	_	
10-2	1810-1818	Nicotine	_	
10-3	1819-1821	is	_	
10-4	1822-1825	the	_	
10-5	1826-1835	principal	_	
10-6	1836-1845	addictive	_	
10-7	1846-1855	component	_	
10-8	1856-1858	in	_	
10-9	1859-1866	tobacco	_	
10-10	1867-1871	that	_	
10-11	1872-1881	maintains	_	
10-12	1882-1889	smoking	_	
10-13	1890-1898	behavior	_	
10-14	1898-1899	.	_	

#Text=Nicotine (and other drug) dependence induces neuroplastic alterations in brain circuits, which in turn contribute to the altered behavioral and cognitive processes seen in dependent individuals that impact their ability to stop smoking.
11-1	1900-1908	Nicotine	_	
11-2	1909-1910	(	_	
11-3	1910-1913	and	_	
11-4	1914-1919	other	_	
11-5	1920-1924	drug	_	
11-6	1924-1925	)	_	
11-7	1926-1936	dependence	_	
11-8	1937-1944	induces	_	
11-9	1945-1957	neuroplastic	_	
11-10	1958-1969	alterations	_	
11-11	1970-1972	in	_	
11-12	1973-1978	brain	_	
11-13	1979-1987	circuits	_	
11-14	1987-1988	,	_	
11-15	1989-1994	which	_	
11-16	1995-1997	in	_	
11-17	1998-2002	turn	_	
11-18	2003-2013	contribute	_	
11-19	2014-2016	to	_	
11-20	2017-2020	the	_	
11-21	2021-2028	altered	_	
11-22	2029-2039	behavioral	_	
11-23	2040-2043	and	_	
11-24	2044-2053	cognitive	_	
11-25	2054-2063	processes	_	
11-26	2064-2068	seen	_	
11-27	2069-2071	in	_	
11-28	2072-2081	dependent	_	
11-29	2082-2093	individuals	_	
11-30	2094-2098	that	_	
11-31	2099-2105	impact	_	
11-32	2106-2111	their	_	
11-33	2112-2119	ability	_	
11-34	2120-2122	to	_	
11-35	2123-2127	stop	_	
11-36	2128-2135	smoking	_	
11-37	2135-2136	.	_	

#Text=However, identifying the neuroanatomical loci and then mechanistically linking these dependence-induced neuroadaptations and genetic influences with their behavioral consequences remains very poorly understood.
12-1	2137-2144	However	_	
12-2	2144-2145	,	_	
12-3	2146-2157	identifying	_	
12-4	2158-2161	the	_	
12-5	2162-2177	neuroanatomical	_	
12-6	2178-2182	loci	_	
12-7	2183-2186	and	_	
12-8	2187-2191	then	_	
12-9	2192-2207	mechanistically	_	
12-10	2208-2215	linking	_	
12-11	2216-2221	these	_	
12-12	2222-2240	dependence-induced	_	
12-13	2241-2257	neuroadaptations	_	
12-14	2258-2261	and	_	
12-15	2262-2269	genetic	_	
12-16	2270-2280	influences	_	
12-17	2281-2285	with	_	
12-18	2286-2291	their	_	
12-19	2292-2302	behavioral	_	
12-20	2303-2315	consequences	_	
12-21	2316-2323	remains	_	
12-22	2324-2328	very	_	
12-23	2329-2335	poorly	_	
12-24	2336-2346	understood	_	
12-25	2346-2347	.	_	

#Text=With the consistently poor outcomes following treatment for nicotine dependence, empirically based neurobiological mechanisms have the potential to improve treatment efficacy via individualized treatment optimization along with the discovery of novel drug targets.
13-1	2348-2352	With	_	
13-2	2353-2356	the	_	
13-3	2357-2369	consistently	_	
13-4	2370-2374	poor	_	
13-5	2375-2383	outcomes	_	
13-6	2384-2393	following	_	
13-7	2394-2403	treatment	_	
13-8	2404-2407	for	_	
13-9	2408-2416	nicotine	_	
13-10	2417-2427	dependence	_	
13-11	2427-2428	,	_	
13-12	2429-2440	empirically	_	
13-13	2441-2446	based	_	
13-14	2447-2462	neurobiological	_	
13-15	2463-2473	mechanisms	_	
13-16	2474-2478	have	_	
13-17	2479-2482	the	_	
13-18	2483-2492	potential	_	
13-19	2493-2495	to	_	
13-20	2496-2503	improve	_	
13-21	2504-2513	treatment	_	
13-22	2514-2522	efficacy	_	
13-23	2523-2526	via	_	
13-24	2527-2541	individualized	_	
13-25	2542-2551	treatment	_	
13-26	2552-2564	optimization	_	
13-27	2565-2570	along	_	
13-28	2571-2575	with	_	
13-29	2576-2579	the	_	
13-30	2580-2589	discovery	_	
13-31	2590-2592	of	_	
13-32	2593-2598	novel	_	
13-33	2599-2603	drug	_	
13-34	2604-2611	targets	_	
13-35	2611-2612	.	_	

#Text=The hepatic enzyme cytochrome P450 (CYP2A6) is the main metabolic pathway responsible for nicotine inactivation and clearance; CYP2A6 is expressed at very low levels in the human brain, or not at all.
14-1	2613-2616	The	_	
14-2	2617-2624	hepatic	_	
14-3	2625-2631	enzyme	_	
14-4	2632-2642	cytochrome	_	
14-5	2643-2647	P450	_	
14-6	2648-2649	(	_	
14-7	2649-2655	CYP2A6	_	
14-8	2655-2656	)	_	
14-9	2657-2659	is	_	
14-10	2660-2663	the	_	
14-11	2664-2668	main	_	
14-12	2669-2678	metabolic	_	
14-13	2679-2686	pathway	_	
14-14	2687-2698	responsible	_	
14-15	2699-2702	for	_	
14-16	2703-2711	nicotine	_	
14-17	2712-2724	inactivation	_	
14-18	2725-2728	and	_	
14-19	2729-2738	clearance	_	
14-20	2738-2739	;	_	
14-21	2740-2746	CYP2A6	_	
14-22	2747-2749	is	_	
14-23	2750-2759	expressed	_	
14-24	2760-2762	at	_	
14-25	2763-2767	very	_	
14-26	2768-2771	low	_	
14-27	2772-2778	levels	_	
14-28	2779-2781	in	_	
14-29	2782-2785	the	_	
14-30	2786-2791	human	_	
14-31	2792-2797	brain	_	
14-32	2797-2798	,	_	
14-33	2799-2801	or	_	
14-34	2802-2805	not	_	
14-35	2806-2808	at	_	
14-36	2809-2812	all	_	
14-37	2812-2813	.	_	

#Text=Variation in the CYP2A6 gene alters the rate of nicotine metabolism, with the slow genotype reducing nicotine metabolism more than 50%.
15-1	2814-2823	Variation	_	
15-2	2824-2826	in	_	
15-3	2827-2830	the	_	
15-4	2831-2837	CYP2A6	_	
15-5	2838-2842	gene	_	
15-6	2843-2849	alters	_	
15-7	2850-2853	the	_	
15-8	2854-2858	rate	_	
15-9	2859-2861	of	_	
15-10	2862-2870	nicotine	_	
15-11	2871-2881	metabolism	_	
15-12	2881-2882	,	_	
15-13	2883-2887	with	_	
15-14	2888-2891	the	_	
15-15	2892-2896	slow	_	
15-16	2897-2905	genotype	_	
15-17	2906-2914	reducing	_	
15-18	2915-2923	nicotine	_	
15-19	2924-2934	metabolism	_	
15-20	2935-2939	more	_	
15-21	2940-2944	than	_	
15-22	2945-2948	50%	_	
15-23	2948-2949	.	_	

#Text=Smokers with the reduced (slow and intermediate) CYP2A6 genotype start smoking earlier in life, become dependent quicker, but smoke fewer cigarettes and have a higher likelihood of quitting smoking.
16-1	2950-2957	Smokers	_	
16-2	2958-2962	with	_	
16-3	2963-2966	the	_	
16-4	2967-2974	reduced	_	
16-5	2975-2976	(	_	
16-6	2976-2980	slow	_	
16-7	2981-2984	and	_	
16-8	2985-2997	intermediate	_	
16-9	2997-2998	)	_	
16-10	2999-3005	CYP2A6	_	
16-11	3006-3014	genotype	_	
16-12	3015-3020	start	_	
16-13	3021-3028	smoking	_	
16-14	3029-3036	earlier	_	
16-15	3037-3039	in	_	
16-16	3040-3044	life	_	
16-17	3044-3045	,	_	
16-18	3046-3052	become	_	
16-19	3053-3062	dependent	_	
16-20	3063-3070	quicker	_	
16-21	3070-3071	,	_	
16-22	3072-3075	but	_	
16-23	3076-3081	smoke	_	
16-24	3082-3087	fewer	_	
16-25	3088-3098	cigarettes	_	
16-26	3099-3102	and	_	
16-27	3103-3107	have	_	
16-28	3108-3109	a	_	
16-29	3110-3116	higher	_	
16-30	3117-3127	likelihood	_	
16-31	3128-3130	of	_	
16-32	3131-3139	quitting	_	
16-33	3140-3147	smoking	_	
16-34	3147-3148	.	_	

#Text=Slow metabolizers have higher quit success rates when using either placebo or transdermal nicotine replacement therapy (NRT, i.e. nicotine patch) vs. varenicline (Chantix®) usage, but have greater adverse effects from varenicline, while normal genotype individuals respond better to varenicline than to NRT.
17-1	3149-3153	Slow	_	
17-2	3154-3166	metabolizers	_	
17-3	3167-3171	have	_	
17-4	3172-3178	higher	_	
17-5	3179-3183	quit	_	
17-6	3184-3191	success	_	
17-7	3192-3197	rates	_	
17-8	3198-3202	when	_	
17-9	3203-3208	using	_	
17-10	3209-3215	either	_	
17-11	3216-3223	placebo	_	
17-12	3224-3226	or	_	
17-13	3227-3238	transdermal	_	
17-14	3239-3247	nicotine	_	
17-15	3248-3259	replacement	_	
17-16	3260-3267	therapy	_	
17-17	3268-3269	(	_	
17-18	3269-3272	NRT	_	
17-19	3272-3273	,	_	
17-20	3274-3277	i.e	_	
17-21	3277-3278	.	_	
17-22	3279-3287	nicotine	_	
17-23	3288-3293	patch	_	
17-24	3293-3294	)	_	
17-25	3295-3297	vs	_	
17-26	3297-3298	.	_	
17-27	3299-3310	varenicline	_	
17-28	3311-3312	(	_	
17-29	3312-3319	Chantix	_	
17-30	3319-3320	®	_	
17-31	3320-3321	)	_	
17-32	3322-3327	usage	_	
17-33	3327-3328	,	_	
17-34	3329-3332	but	_	
17-35	3333-3337	have	_	
17-36	3338-3345	greater	_	
17-37	3346-3353	adverse	_	
17-38	3354-3361	effects	_	
17-39	3362-3366	from	_	
17-40	3367-3378	varenicline	_	
17-41	3378-3379	,	_	
17-42	3380-3385	while	_	
17-43	3386-3392	normal	_	
17-44	3393-3401	genotype	_	
17-45	3402-3413	individuals	_	
17-46	3414-3421	respond	_	
17-47	3422-3428	better	_	
17-48	3429-3431	to	_	
17-49	3432-3443	varenicline	_	
17-50	3444-3448	than	_	
17-51	3449-3451	to	_	
17-52	3452-3455	NRT	_	
17-53	3455-3456	.	_	

#Text=Thus these CYP2A6 genetic effects on cessation persist months after being nicotine free, suggesting that genetic variations in this metabolic pathway likely created long-lasting brain changes that result in these differential smoking phenotypes and treatment response differences.
18-1	3457-3461	Thus	_	
18-2	3462-3467	these	_	
18-3	3468-3474	CYP2A6	_	
18-4	3475-3482	genetic	_	
18-5	3483-3490	effects	_	
18-6	3491-3493	on	_	
18-7	3494-3503	cessation	_	
18-8	3504-3511	persist	_	
18-9	3512-3518	months	_	
18-10	3519-3524	after	_	
18-11	3525-3530	being	_	
18-12	3531-3539	nicotine	_	
18-13	3540-3544	free	_	
18-14	3544-3545	,	_	
18-15	3546-3556	suggesting	_	
18-16	3557-3561	that	_	
18-17	3562-3569	genetic	_	
18-18	3570-3580	variations	_	
18-19	3581-3583	in	_	
18-20	3584-3588	this	_	
18-21	3589-3598	metabolic	_	
18-22	3599-3606	pathway	_	
18-23	3607-3613	likely	_	
18-24	3614-3621	created	_	
18-25	3622-3634	long-lasting	_	
18-26	3635-3640	brain	_	
18-27	3641-3648	changes	_	
18-28	3649-3653	that	_	
18-29	3654-3660	result	_	
18-30	3661-3663	in	_	
18-31	3664-3669	these	_	
18-32	3670-3682	differential	_	
18-33	3683-3690	smoking	_	
18-34	3691-3701	phenotypes	_	
18-35	3702-3705	and	_	
18-36	3706-3715	treatment	_	
18-37	3716-3724	response	_	
18-38	3725-3736	differences	_	
18-39	3736-3737	.	_	

#Text=The underlying neurobiological mechanisms of the impact of this genetically variable pharmacokinetic (PK) enzyme on smoking-related behaviors and neuroplasticity are largely unknown.
19-1	3738-3741	The	_	
19-2	3742-3752	underlying	_	
19-3	3753-3768	neurobiological	_	
19-4	3769-3779	mechanisms	_	
19-5	3780-3782	of	_	
19-6	3783-3786	the	_	
19-7	3787-3793	impact	_	
19-8	3794-3796	of	_	
19-9	3797-3801	this	_	
19-10	3802-3813	genetically	_	
19-11	3814-3822	variable	_	
19-12	3823-3838	pharmacokinetic	_	
19-13	3839-3840	(	_	
19-14	3840-3842	PK	_	
19-15	3842-3843	)	_	
19-16	3844-3850	enzyme	_	
19-17	3851-3853	on	_	
19-18	3854-3869	smoking-related	_	
19-19	3870-3879	behaviors	_	
19-20	3880-3883	and	_	
19-21	3884-3899	neuroplasticity	_	
19-22	3900-3903	are	_	
19-23	3904-3911	largely	_	
19-24	3912-3919	unknown	_	
19-25	3919-3920	.	_	

#Text=Only a single study has been published, which reported that slow metabolizing smokers have reduced limbic responses to smoking cues.
20-1	3921-3925	Only	_	
20-2	3926-3927	a	_	
20-3	3928-3934	single	_	
20-4	3935-3940	study	_	
20-5	3941-3944	has	_	
20-6	3945-3949	been	_	
20-7	3950-3959	published	_	
20-8	3959-3960	,	_	
20-9	3961-3966	which	_	
20-10	3967-3975	reported	_	
20-11	3976-3980	that	_	
20-12	3981-3985	slow	_	
20-13	3986-3998	metabolizing	_	
20-14	3999-4006	smokers	_	
20-15	4007-4011	have	_	
20-16	4012-4019	reduced	_	
20-17	4020-4026	limbic	_	
20-18	4027-4036	responses	_	
20-19	4037-4039	to	_	
20-20	4040-4047	smoking	_	
20-21	4048-4052	cues	_	
20-22	4052-4053	.	_	

#Text=However, both human and preclinical data indicate the importance of PK influences on drug addiction – both the rate of drug onset (primarily influenced by route of delivery) and offset (primarily influenced by biotransformation and distribution).
21-1	4054-4061	However	_	
21-2	4061-4062	,	_	
21-3	4063-4067	both	_	
21-4	4068-4073	human	_	
21-5	4074-4077	and	_	
21-6	4078-4089	preclinical	_	
21-7	4090-4094	data	_	
21-8	4095-4103	indicate	_	
21-9	4104-4107	the	_	
21-10	4108-4118	importance	_	
21-11	4119-4121	of	_	
21-12	4122-4124	PK	_	
21-13	4125-4135	influences	_	
21-14	4136-4138	on	_	
21-15	4139-4143	drug	_	
21-16	4144-4153	addiction	_	
21-17	4154-4155	–	_	
21-18	4156-4160	both	_	
21-19	4161-4164	the	_	
21-20	4165-4169	rate	_	
21-21	4170-4172	of	_	
21-22	4173-4177	drug	_	
21-23	4178-4183	onset	_	
21-24	4184-4185	(	_	
21-25	4185-4194	primarily	_	
21-26	4195-4205	influenced	_	
21-27	4206-4208	by	_	
21-28	4209-4214	route	_	
21-29	4215-4217	of	_	
21-30	4218-4226	delivery	_	
21-31	4226-4227	)	_	
21-32	4228-4231	and	_	
21-33	4232-4238	offset	_	
21-34	4239-4240	(	_	
21-35	4240-4249	primarily	_	
21-36	4250-4260	influenced	_	
21-37	4261-4263	by	_	
21-38	4264-4281	biotransformation	_	
21-39	4282-4285	and	_	
21-40	4286-4298	distribution	_	
21-41	4298-4299	)	_	
21-42	4299-4300	.	_	

#Text=Smoking (relative to nicotine patch) delivers nicotine to the brain in seconds, while genetically variable rates of nicotine inactivation by CYP2A6 leads to variable offset time, both of which may result in rapid and long lasting neuroplastic effects and differential abuse potential.
22-1	4301-4308	Smoking	_	
22-2	4309-4310	(	_	
22-3	4310-4318	relative	_	
22-4	4319-4321	to	_	
22-5	4322-4330	nicotine	_	
22-6	4331-4336	patch	_	
22-7	4336-4337	)	_	
22-8	4338-4346	delivers	_	
22-9	4347-4355	nicotine	_	
22-10	4356-4358	to	_	
22-11	4359-4362	the	_	
22-12	4363-4368	brain	_	
22-13	4369-4371	in	_	
22-14	4372-4379	seconds	_	
22-15	4379-4380	,	_	
22-16	4381-4386	while	_	
22-17	4387-4398	genetically	_	
22-18	4399-4407	variable	_	
22-19	4408-4413	rates	_	
22-20	4414-4416	of	_	
22-21	4417-4425	nicotine	_	
22-22	4426-4438	inactivation	_	
22-23	4439-4441	by	_	
22-24	4442-4448	CYP2A6	_	
22-25	4449-4454	leads	_	
22-26	4455-4457	to	_	
22-27	4458-4466	variable	_	
22-28	4467-4473	offset	_	
22-29	4474-4478	time	_	
22-30	4478-4479	,	_	
22-31	4480-4484	both	_	
22-32	4485-4487	of	_	
22-33	4488-4493	which	_	
22-34	4494-4497	may	_	
22-35	4498-4504	result	_	
22-36	4505-4507	in	_	
22-37	4508-4513	rapid	_	
22-38	4514-4517	and	_	
22-39	4518-4522	long	_	
22-40	4523-4530	lasting	_	
22-41	4531-4543	neuroplastic	_	
22-42	4544-4551	effects	_	
22-43	4552-4555	and	_	
22-44	4556-4568	differential	_	
22-45	4569-4574	abuse	_	
22-46	4575-4584	potential	_	
22-47	4584-4585	.	_	

#Text=Indeed, the rapid onset of action for both nicotine and cocaine preferentially engage mesocorticolimbic (MCL) circuits to promote neurobehavioral plasticity.
23-1	4586-4592	Indeed	_	
23-2	4592-4593	,	_	
23-3	4594-4597	the	_	
23-4	4598-4603	rapid	_	
23-5	4604-4609	onset	_	
23-6	4610-4612	of	_	
23-7	4613-4619	action	_	
23-8	4620-4623	for	_	
23-9	4624-4628	both	_	
23-10	4629-4637	nicotine	_	
23-11	4638-4641	and	_	
23-12	4642-4649	cocaine	_	
23-13	4650-4664	preferentially	_	
23-14	4665-4671	engage	_	
23-15	4672-4689	mesocorticolimbic	_	
23-16	4690-4691	(	_	
23-17	4691-4694	MCL	_	
23-18	4694-4695	)	_	
23-19	4696-4704	circuits	_	
23-20	4705-4707	to	_	
23-21	4708-4715	promote	_	
23-22	4716-4731	neurobehavioral	_	
23-23	4732-4742	plasticity	_	
23-24	4742-4743	.	_	

#Text=In contrast, variation in the ‘off-time’ can alter the abuse and dependence of drugs from a number of classes, including cocaine, benzodiazepines and nicotine.
24-1	4744-4746	In	_	
24-2	4747-4755	contrast	_	
24-3	4755-4756	,	_	
24-4	4757-4766	variation	_	
24-5	4767-4769	in	_	
24-6	4770-4773	the	_	
24-7	4774-4775	‘	_	
24-8	4775-4783	off-time	_	
24-9	4783-4784	’	_	
24-10	4785-4788	can	_	
24-11	4789-4794	alter	_	
24-12	4795-4798	the	_	
24-13	4799-4804	abuse	_	
24-14	4805-4808	and	_	
24-15	4809-4819	dependence	_	
24-16	4820-4822	of	_	
24-17	4823-4828	drugs	_	
24-18	4829-4833	from	_	
24-19	4834-4835	a	_	
24-20	4836-4842	number	_	
24-21	4843-4845	of	_	
24-22	4846-4853	classes	_	
24-23	4853-4854	,	_	
24-24	4855-4864	including	_	
24-25	4865-4872	cocaine	_	
24-26	4872-4873	,	_	
24-27	4874-4889	benzodiazepines	_	
24-28	4890-4893	and	_	
24-29	4894-4902	nicotine	_	
24-30	4902-4903	.	_	

#Text=For example, while both cocaine and methylphenidate have high affinity for the dopamine transporter and reach the brain rapidly after intravenous administration, cocaine’s shorter duration of action, due to rapid removal from brain, both promotes and enables its frequent use, while methylphenidate has a much longer duration of action due to its slower brain clearance and has a much lower abuse profile.
25-1	4904-4907	For	_	
25-2	4908-4915	example	_	
25-3	4915-4916	,	_	
25-4	4917-4922	while	_	
25-5	4923-4927	both	_	
25-6	4928-4935	cocaine	_	
25-7	4936-4939	and	_	
25-8	4940-4955	methylphenidate	_	
25-9	4956-4960	have	_	
25-10	4961-4965	high	_	
25-11	4966-4974	affinity	_	
25-12	4975-4978	for	_	
25-13	4979-4982	the	_	
25-14	4983-4991	dopamine	_	
25-15	4992-5003	transporter	_	
25-16	5004-5007	and	_	
25-17	5008-5013	reach	_	
25-18	5014-5017	the	_	
25-19	5018-5023	brain	_	
25-20	5024-5031	rapidly	_	
25-21	5032-5037	after	_	
25-22	5038-5049	intravenous	_	
25-23	5050-5064	administration	_	
25-24	5064-5065	,	_	
25-25	5066-5073	cocaine	_	
25-26	5073-5074	’	_	
25-27	5074-5075	s	_	
25-28	5076-5083	shorter	_	
25-29	5084-5092	duration	_	
25-30	5093-5095	of	_	
25-31	5096-5102	action	_	
25-32	5102-5103	,	_	
25-33	5104-5107	due	_	
25-34	5108-5110	to	_	
25-35	5111-5116	rapid	_	
25-36	5117-5124	removal	_	
25-37	5125-5129	from	_	
25-38	5130-5135	brain	_	
25-39	5135-5136	,	_	
25-40	5137-5141	both	_	
25-41	5142-5150	promotes	_	
25-42	5151-5154	and	_	
25-43	5155-5162	enables	_	
25-44	5163-5166	its	_	
25-45	5167-5175	frequent	_	
25-46	5176-5179	use	_	
25-47	5179-5180	,	_	
25-48	5181-5186	while	_	
25-49	5187-5202	methylphenidate	_	
25-50	5203-5206	has	_	
25-51	5207-5208	a	_	
25-52	5209-5213	much	_	
25-53	5214-5220	longer	_	
25-54	5221-5229	duration	_	
25-55	5230-5232	of	_	
25-56	5233-5239	action	_	
25-57	5240-5243	due	_	
25-58	5244-5246	to	_	
25-59	5247-5250	its	_	
25-60	5251-5257	slower	_	
25-61	5258-5263	brain	_	
25-62	5264-5273	clearance	_	
25-63	5274-5277	and	_	
25-64	5278-5281	has	_	
25-65	5282-5283	a	_	
25-66	5284-5288	much	_	
25-67	5289-5294	lower	_	
25-68	5295-5300	abuse	_	
25-69	5301-5308	profile	_	
25-70	5308-5309	.	_	

#Text=Since smokers with the slow metabolism CYP2A6 genotype have relatively constant nicotine plasma levels throughout the day, while those with faster metabolism likely experience a greater surge in plasma nicotine with each cigarette, and as changes in PK can change fundamental neurobiological mechanisms, we reasoned that CYP2A6-induced modifications in brain nicotine concentration differentially alters nicotinic receptor function and in turn, modifies brain circuits that contribute to the development and/or maintenance of nicotine addiction and its plasticity-related behavioral and cognitive profile.
26-1	5310-5315	Since	_	
26-2	5316-5323	smokers	_	
26-3	5324-5328	with	_	
26-4	5329-5332	the	_	
26-5	5333-5337	slow	_	
26-6	5338-5348	metabolism	_	
26-7	5349-5355	CYP2A6	_	
26-8	5356-5364	genotype	_	
26-9	5365-5369	have	_	
26-10	5370-5380	relatively	_	
26-11	5381-5389	constant	_	
26-12	5390-5398	nicotine	_	
26-13	5399-5405	plasma	_	
26-14	5406-5412	levels	_	
26-15	5413-5423	throughout	_	
26-16	5424-5427	the	_	
26-17	5428-5431	day	_	
26-18	5431-5432	,	_	
26-19	5433-5438	while	_	
26-20	5439-5444	those	_	
26-21	5445-5449	with	_	
26-22	5450-5456	faster	_	
26-23	5457-5467	metabolism	_	
26-24	5468-5474	likely	_	
26-25	5475-5485	experience	_	
26-26	5486-5487	a	_	
26-27	5488-5495	greater	_	
26-28	5496-5501	surge	_	
26-29	5502-5504	in	_	
26-30	5505-5511	plasma	_	
26-31	5512-5520	nicotine	_	
26-32	5521-5525	with	_	
26-33	5526-5530	each	_	
26-34	5531-5540	cigarette	_	
26-35	5540-5541	,	_	
26-36	5542-5545	and	_	
26-37	5546-5548	as	_	
26-38	5549-5556	changes	_	
26-39	5557-5559	in	_	
26-40	5560-5562	PK	_	
26-41	5563-5566	can	_	
26-42	5567-5573	change	_	
26-43	5574-5585	fundamental	_	
26-44	5586-5601	neurobiological	_	
26-45	5602-5612	mechanisms	_	
26-46	5612-5613	,	_	
26-47	5614-5616	we	_	
26-48	5617-5625	reasoned	_	
26-49	5626-5630	that	_	
26-50	5631-5637	CYP2A6	_	
26-51	5637-5638	-	_	
26-52	5638-5645	induced	_	
26-53	5646-5659	modifications	_	
26-54	5660-5662	in	_	
26-55	5663-5668	brain	_	
26-56	5669-5677	nicotine	_	
26-57	5678-5691	concentration	_	
26-58	5692-5706	differentially	_	
26-59	5707-5713	alters	_	
26-60	5714-5723	nicotinic	_	
26-61	5724-5732	receptor	_	
26-62	5733-5741	function	_	
26-63	5742-5745	and	_	
26-64	5746-5748	in	_	
26-65	5749-5753	turn	_	
26-66	5753-5754	,	_	
26-67	5755-5763	modifies	_	
26-68	5764-5769	brain	_	
26-69	5770-5778	circuits	_	
26-70	5779-5783	that	_	
26-71	5784-5794	contribute	_	
26-72	5795-5797	to	_	
26-73	5798-5801	the	_	
26-74	5802-5813	development	_	
26-75	5814-5817	and	_	
26-76	5817-5818	/	_	
26-77	5818-5820	or	_	
26-78	5821-5832	maintenance	_	
26-79	5833-5835	of	_	
26-80	5836-5844	nicotine	_	
26-81	5845-5854	addiction	_	
26-82	5855-5858	and	_	
26-83	5859-5862	its	_	
26-84	5863-5881	plasticity-related	_	
26-85	5882-5892	behavioral	_	
26-86	5893-5896	and	_	
26-87	5897-5906	cognitive	_	
26-88	5907-5914	profile	_	
26-89	5914-5915	.	_	

#Text=We also reasoned that this would occur only among smokers, while those not exposed to nicotine would have no genotype-induced neuroplastic differences, leading to significant and meaningful Gene × Environment (CYP2A6-smoking) interactions.
27-1	5916-5918	We	_	
27-2	5919-5923	also	_	
27-3	5924-5932	reasoned	_	
27-4	5933-5937	that	_	
27-5	5938-5942	this	_	
27-6	5943-5948	would	_	
27-7	5949-5954	occur	_	
27-8	5955-5959	only	_	
27-9	5960-5965	among	_	
27-10	5966-5973	smokers	_	
27-11	5973-5974	,	_	
27-12	5975-5980	while	_	
27-13	5981-5986	those	_	
27-14	5987-5990	not	_	
27-15	5991-5998	exposed	_	
27-16	5999-6001	to	_	
27-17	6002-6010	nicotine	_	
27-18	6011-6016	would	_	
27-19	6017-6021	have	_	
27-20	6022-6024	no	_	
27-21	6025-6041	genotype-induced	_	
27-22	6042-6054	neuroplastic	_	
27-23	6055-6066	differences	_	
27-24	6066-6067	,	_	
27-25	6068-6075	leading	_	
27-26	6076-6078	to	_	
27-27	6079-6090	significant	_	
27-28	6091-6094	and	_	
27-29	6095-6105	meaningful	_	
27-30	6106-6110	Gene	_	
27-31	6111-6112	×	_	
27-32	6113-6124	Environment	_	
27-33	6125-6126	(	_	
27-34	6126-6132	CYP2A6	_	
27-35	6132-6133	-	_	
27-36	6133-6140	smoking	_	
27-37	6140-6141	)	_	
27-38	6142-6154	interactions	_	
27-39	6154-6155	.	_	

#Text=However, as smokers present with a spectrum of altered behaviors and neuronal circuits, we could not a priori predict those circuits that might be most sensitive to variable nicotine exposure.
28-1	6156-6163	However	_	
28-2	6163-6164	,	_	
28-3	6165-6167	as	_	
28-4	6168-6175	smokers	_	
28-5	6176-6183	present	_	
28-6	6184-6188	with	_	
28-7	6189-6190	a	_	
28-8	6191-6199	spectrum	_	
28-9	6200-6202	of	_	
28-10	6203-6210	altered	_	
28-11	6211-6220	behaviors	_	
28-12	6221-6224	and	_	
28-13	6225-6233	neuronal	_	
28-14	6234-6242	circuits	_	
28-15	6242-6243	,	_	
28-16	6244-6246	we	_	
28-17	6247-6252	could	_	
28-18	6253-6256	not	_	
28-19	6257-6258	a	_	
28-20	6259-6265	priori	_	
28-21	6266-6273	predict	_	
28-22	6274-6279	those	_	
28-23	6280-6288	circuits	_	
28-24	6289-6293	that	_	
28-25	6294-6299	might	_	
28-26	6300-6302	be	_	
28-27	6303-6307	most	_	
28-28	6308-6317	sensitive	_	
28-29	6318-6320	to	_	
28-30	6321-6329	variable	_	
28-31	6330-6338	nicotine	_	
28-32	6339-6347	exposure	_	
28-33	6347-6348	.	_	

#Text=We thus interrogated the effects of CYP2A6 genotype on whole brain network topological organization using resting state functional connectivity (rsFC) and a data driven analytical graph theory metric, functional connectivity strength (FCS).
29-1	6349-6351	We	_	
29-2	6352-6356	thus	_	
29-3	6357-6369	interrogated	_	
29-4	6370-6373	the	_	
29-5	6374-6381	effects	_	
29-6	6382-6384	of	_	
29-7	6385-6391	CYP2A6	_	
29-8	6392-6400	genotype	_	
29-9	6401-6403	on	_	
29-10	6404-6409	whole	_	
29-11	6410-6415	brain	_	
29-12	6416-6423	network	_	
29-13	6424-6435	topological	_	
29-14	6436-6448	organization	_	
29-15	6449-6454	using	_	
29-16	6455-6462	resting	_	
29-17	6463-6468	state	_	
29-18	6469-6479	functional	_	
29-19	6480-6492	connectivity	_	
29-20	6493-6494	(	_	
29-21	6494-6498	rsFC	_	
29-22	6498-6499	)	_	
29-23	6500-6503	and	_	
29-24	6504-6505	a	_	
29-25	6506-6510	data	_	
29-26	6511-6517	driven	_	
29-27	6518-6528	analytical	_	
29-28	6529-6534	graph	_	
29-29	6535-6541	theory	_	
29-30	6542-6548	metric	_	
29-31	6548-6549	,	_	
29-32	6550-6560	functional	_	
29-33	6561-6573	connectivity	_	
29-34	6574-6582	strength	_	
29-35	6583-6584	(	_	
29-36	6584-6587	FCS	_	
29-37	6587-6588	)	_	
29-38	6588-6589	.	_	

#Text=High FCS of a region is thought to reflect high nodal activity, thought to reflect regions of high neuronal integration.
30-1	6590-6594	High	_	
30-2	6595-6598	FCS	_	
30-3	6599-6601	of	_	
30-4	6602-6603	a	_	
30-5	6604-6610	region	_	
30-6	6611-6613	is	_	
30-7	6614-6621	thought	_	
30-8	6622-6624	to	_	
30-9	6625-6632	reflect	_	
30-10	6633-6637	high	_	
30-11	6638-6643	nodal	_	
30-12	6644-6652	activity	_	
30-13	6652-6653	,	_	
30-14	6654-6661	thought	_	
30-15	6662-6664	to	_	
30-16	6665-6672	reflect	_	
30-17	6673-6680	regions	_	
30-18	6681-6683	of	_	
30-19	6684-6688	high	_	
30-20	6689-6697	neuronal	_	
30-21	6698-6709	integration	_	
30-22	6709-6710	.	_	

#Text=To complement this data driven network approach, we also considered smoking status (smoker vs. nonsmoker), current level of smoking (cigarettes per day, CPD) and nicotine dependence severity (Fagerstrom Test for Nicotine Dependence, FTND).
31-1	6711-6713	To	_	
31-2	6714-6724	complement	_	
31-3	6725-6729	this	_	
31-4	6730-6734	data	_	
31-5	6735-6741	driven	_	
31-6	6742-6749	network	_	
31-7	6750-6758	approach	_	
31-8	6758-6759	,	_	
31-9	6760-6762	we	_	
31-10	6763-6767	also	_	
31-11	6768-6778	considered	_	
31-12	6779-6786	smoking	_	
31-13	6787-6793	status	_	
31-14	6794-6795	(	_	
31-15	6795-6801	smoker	_	
31-16	6802-6804	vs	_	
31-17	6804-6805	.	_	
31-18	6806-6815	nonsmoker	_	
31-19	6815-6816	)	_	
31-20	6816-6817	,	_	
31-21	6818-6825	current	_	
31-22	6826-6831	level	_	
31-23	6832-6834	of	_	
31-24	6835-6842	smoking	_	
31-25	6843-6844	(	_	
31-26	6844-6854	cigarettes	_	
31-27	6855-6858	per	_	
31-28	6859-6862	day	_	
31-29	6862-6863	,	_	
31-30	6864-6867	CPD	_	
31-31	6867-6868	)	_	
31-32	6869-6872	and	_	
31-33	6873-6881	nicotine	_	
31-34	6882-6892	dependence	_	
31-35	6893-6901	severity	_	
31-36	6902-6903	(	_	
31-37	6903-6913	Fagerstrom	_	
31-38	6914-6918	Test	_	
31-39	6919-6922	for	_	
31-40	6923-6931	Nicotine	_	
31-41	6932-6942	Dependence	_	
31-42	6942-6943	,	_	
31-43	6944-6948	FTND	_	
31-44	6948-6949	)	_	
31-45	6949-6950	.	_	

#Text=We hypothesized that the CYP2A6 genotype would, among smokers but not among nonsmokers, 1) influence brain FCS; 2) alter FCS within nodes of the MCL dopamine system; and 3) modulate neuronal computations and cognitive processes, specifically reward processing and inhibitory control.
32-1	6951-6953	We	_	
32-2	6954-6966	hypothesized	_	
32-3	6967-6971	that	_	
32-4	6972-6975	the	_	
32-5	6976-6982	CYP2A6	_	
32-6	6983-6991	genotype	_	
32-7	6992-6997	would	_	
32-8	6997-6998	,	_	
32-9	6999-7004	among	_	
32-10	7005-7012	smokers	_	
32-11	7013-7016	but	_	
32-12	7017-7020	not	_	
32-13	7021-7026	among	_	
32-14	7027-7037	nonsmokers	_	
32-15	7037-7038	,	_	
32-16	7039-7040	1	_	
32-17	7040-7041	)	_	
32-18	7042-7051	influence	_	
32-19	7052-7057	brain	_	
32-20	7058-7061	FCS	_	
32-21	7061-7062	;	_	
32-22	7063-7064	2	_	
32-23	7064-7065	)	_	
32-24	7066-7071	alter	_	
32-25	7072-7075	FCS	_	
32-26	7076-7082	within	_	
32-27	7083-7088	nodes	_	
32-28	7089-7091	of	_	
32-29	7092-7095	the	_	
32-30	7096-7099	MCL	_	
32-31	7100-7108	dopamine	_	
32-32	7109-7115	system	_	
32-33	7115-7116	;	_	
32-34	7117-7120	and	_	
32-35	7121-7122	3	_	
32-36	7122-7123	)	_	
32-37	7124-7132	modulate	_	
32-38	7133-7141	neuronal	_	
32-39	7142-7154	computations	_	
32-40	7155-7158	and	_	
32-41	7159-7168	cognitive	_	
32-42	7169-7178	processes	_	
32-43	7178-7179	,	_	
32-44	7180-7192	specifically	_	
32-45	7193-7199	reward	_	
32-46	7200-7210	processing	_	
32-47	7211-7214	and	_	
32-48	7215-7225	inhibitory	_	
32-49	7226-7233	control	_	
32-50	7233-7234	.	_	

#Text=To test these hypotheses, we genotyped smokers and nonsmokers for the CYP2A6 polymorphism and subsequently classified them as normal, intermediate or slow nicotine metabolizers.
33-1	7235-7237	To	_	
33-2	7238-7242	test	_	
33-3	7243-7248	these	_	
33-4	7249-7259	hypotheses	_	
33-5	7259-7260	,	_	
33-6	7261-7263	we	_	
33-7	7264-7273	genotyped	_	
33-8	7274-7281	smokers	_	
33-9	7282-7285	and	_	
33-10	7286-7296	nonsmokers	_	
33-11	7297-7300	for	_	
33-12	7301-7304	the	_	
33-13	7305-7311	CYP2A6	_	
33-14	7312-7324	polymorphism	_	
33-15	7325-7328	and	_	
33-16	7329-7341	subsequently	_	
33-17	7342-7352	classified	_	
33-18	7353-7357	them	_	
33-19	7358-7360	as	_	
33-20	7361-7367	normal	_	
33-21	7367-7368	,	_	
33-22	7369-7381	intermediate	_	
33-23	7382-7384	or	_	
33-24	7385-7389	slow	_	
33-25	7390-7398	nicotine	_	
33-26	7399-7411	metabolizers	_	
33-27	7411-7412	.	_	

#Text=In addition to acquiring resting state BOLD data, a subset of smokers and nonsmokers also performed the MID reward task and a Go/NoGo response inhibition task on two sessions-once while wearing a nicotine patch and once after 12 hours of smoking abstinence.
34-1	7413-7415	In	_	
34-2	7416-7424	addition	_	
34-3	7425-7427	to	_	
34-4	7428-7437	acquiring	_	
34-5	7438-7445	resting	_	
34-6	7446-7451	state	_	
34-7	7452-7456	BOLD	_	
34-8	7457-7461	data	_	
34-9	7461-7462	,	_	
34-10	7463-7464	a	_	
34-11	7465-7471	subset	_	
34-12	7472-7474	of	_	
34-13	7475-7482	smokers	_	
34-14	7483-7486	and	_	
34-15	7487-7497	nonsmokers	_	
34-16	7498-7502	also	_	
34-17	7503-7512	performed	_	
34-18	7513-7516	the	_	
34-19	7517-7520	MID	_	
34-20	7521-7527	reward	_	
34-21	7528-7532	task	_	
34-22	7533-7536	and	_	
34-23	7537-7538	a	_	
34-24	7539-7541	Go	_	
34-25	7541-7542	/	_	
34-26	7542-7546	NoGo	_	
34-27	7547-7555	response	_	
34-28	7556-7566	inhibition	_	
34-29	7567-7571	task	_	
34-30	7572-7574	on	_	
34-31	7575-7578	two	_	
34-32	7579-7592	sessions-once	_	
34-33	7593-7598	while	_	
34-34	7599-7606	wearing	_	
34-35	7607-7608	a	_	
34-36	7609-7617	nicotine	_	
34-37	7618-7623	patch	_	
34-38	7624-7627	and	_	
34-39	7628-7632	once	_	
34-40	7633-7638	after	_	
34-41	7639-7641	12	_	
34-42	7642-7647	hours	_	
34-43	7648-7650	of	_	
34-44	7651-7658	smoking	_	
34-45	7659-7669	abstinence	_	
34-46	7669-7670	.	_	

#Text=Methods and Materials
#Text=Participants
#Text=Resting state BOLD fMRI data were acquired from non-treatment seeking smokers (n=66) and nonsmokers (n=92), matched by age, sex, IQ and race (Table 1).
35-1	7671-7678	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]	
35-2	7679-7682	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]	
35-3	7683-7692	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]	
35-4	7693-7705	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-5	7706-7713	Resting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[10]	
35-6	7714-7719	state	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[10]	
35-7	7720-7724	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[10]	
35-8	7725-7729	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[10]	
35-9	7730-7734	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-10	7735-7739	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-11	7740-7748	acquired	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-12	7749-7753	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-13	7754-7767	non-treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-14	7768-7775	seeking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-15	7776-7783	smokers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[11]	
35-16	7784-7785	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-17	7785-7786	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-18	7786-7787	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-19	7787-7789	66	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-20	7789-7790	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-21	7791-7794	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-22	7795-7805	nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
35-23	7806-7807	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-24	7807-7808	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-25	7808-7809	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-26	7809-7811	92	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-27	7811-7812	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-28	7812-7813	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-29	7814-7821	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-30	7822-7824	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-31	7825-7828	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-32	7828-7829	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-33	7830-7833	sex	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-34	7833-7834	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-35	7835-7837	IQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-36	7838-7841	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-37	7842-7846	race	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-38	7847-7848	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-39	7848-7853	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-40	7854-7855	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-41	7855-7856	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-42	7856-7857	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Subjects were selected from a large cohort of individuals who gave written informed consent under protocols approved by the NIDA-IRP IRB.
36-1	7858-7866	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-2	7867-7871	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-3	7872-7880	selected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-4	7881-7885	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-5	7886-7887	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-6	7888-7893	large	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-7	7894-7900	cohort	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-8	7901-7903	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-9	7904-7915	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-10	7916-7919	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-11	7920-7924	gave	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-12	7925-7932	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-13	7933-7941	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-14	7942-7949	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-15	7950-7955	under	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-16	7956-7965	protocols	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-17	7966-7974	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-18	7975-7977	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-19	7978-7981	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-20	7982-7990	NIDA-IRP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-21	7991-7994	IRB	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-22	7994-7995	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=IRB approval for CYP2A6 genotyping was granted at the University of Toronto.
37-1	7996-7999	IRB	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
37-2	8000-8008	approval	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
37-3	8009-8012	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
37-4	8013-8019	CYP2A6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
37-5	8020-8030	genotyping	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
37-6	8031-8034	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
37-7	8035-8042	granted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
37-8	8043-8045	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
37-9	8046-8049	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
37-10	8050-8060	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
37-11	8061-8063	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
37-12	8064-8071	Toronto	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
37-13	8071-8072	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=A subset of smokers (n=23; 15 normal and 8 reduced metabolizers) and nonsmokers (n=20; 9 normal and 11 reduced) also performed two fMRI tasks following resting BOLD data acquisition: the Monetary Incentive Delay (MID) task, which assesses neuronal activity during anticipation of and outcome for monetary rewards, and a Go/NoGo task assessing response inhibition.
38-1	8073-8074	A	_	
38-2	8075-8081	subset	_	
38-3	8082-8084	of	_	
38-4	8085-8092	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
38-5	8093-8094	(	_	
38-6	8094-8095	n	_	
38-7	8095-8096	=	_	
38-8	8096-8098	23	_	
38-9	8098-8099	;	_	
38-10	8100-8102	15	_	
38-11	8103-8109	normal	_	
38-12	8110-8113	and	_	
38-13	8114-8115	8	_	
38-14	8116-8123	reduced	_	
38-15	8124-8136	metabolizers	_	
38-16	8136-8137	)	_	
38-17	8138-8141	and	_	
38-18	8142-8152	nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
38-19	8153-8154	(	_	
38-20	8154-8155	n	_	
38-21	8155-8156	=	_	
38-22	8156-8158	20	_	
38-23	8158-8159	;	_	
38-24	8160-8161	9	_	
38-25	8162-8168	normal	_	
38-26	8169-8172	and	_	
38-27	8173-8175	11	_	
38-28	8176-8183	reduced	_	
38-29	8183-8184	)	_	
38-30	8185-8189	also	_	
38-31	8190-8199	performed	_	
38-32	8200-8203	two	_	
38-33	8204-8208	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
38-34	8209-8214	tasks	_	
38-35	8215-8224	following	_	
38-36	8225-8232	resting	_	
38-37	8233-8237	BOLD	_	
38-38	8238-8242	data	_	
38-39	8243-8254	acquisition	_	
38-40	8254-8255	:	_	
38-41	8256-8259	the	_	
38-42	8260-8268	Monetary	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[14]	
38-43	8269-8278	Incentive	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[14]	
38-44	8279-8284	Delay	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[14]	
38-45	8285-8286	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[14]	
38-46	8286-8289	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[14]	
38-47	8289-8290	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[14]	
38-48	8291-8295	task	_	
38-49	8295-8296	,	_	
38-50	8297-8302	which	_	
38-51	8303-8311	assesses	_	
38-52	8312-8320	neuronal	_	
38-53	8321-8329	activity	_	
38-54	8330-8336	during	_	
38-55	8337-8349	anticipation	_	
38-56	8350-8352	of	_	
38-57	8353-8356	and	_	
38-58	8357-8364	outcome	_	
38-59	8365-8368	for	_	
38-60	8369-8377	monetary	_	
38-61	8378-8385	rewards	_	
38-62	8385-8386	,	_	
38-63	8387-8390	and	_	
38-64	8391-8392	a	_	
38-65	8393-8395	Go	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[15]	
38-66	8395-8396	/	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[15]	
38-67	8396-8400	NoGo	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[15]	
38-68	8401-8405	task	_	
38-69	8406-8415	assessing	_	
38-70	8416-8424	response	_	
38-71	8425-8435	inhibition	_	
38-72	8435-8436	.	_	

#Text=See SI for details of fMRI data acquisition and preprocessing and voxel-based morphometry (VBM) data analyses and results.
39-1	8437-8440	See	_	
39-2	8441-8443	SI	_	
39-3	8444-8447	for	_	
39-4	8448-8455	details	_	
39-5	8456-8458	of	_	
39-6	8459-8463	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
39-7	8464-8468	data	_	
39-8	8469-8480	acquisition	_	
39-9	8481-8484	and	_	
39-10	8485-8498	preprocessing	_	
39-11	8499-8502	and	_	
39-12	8503-8514	voxel-based	_	
39-13	8515-8526	morphometry	_	
39-14	8527-8528	(	_	
39-15	8528-8531	VBM	_	
39-16	8531-8532	)	_	
39-17	8533-8537	data	_	
39-18	8538-8546	analyses	_	
39-19	8547-8550	and	_	
39-20	8551-8558	results	_	
39-21	8558-8559	.	_	

#Text=Genotyping
#Text=Genomic DNA was extracted from blood samples and genotyped for CYP2A6 as described.
40-1	8560-8570	Genotyping	_	
40-2	8571-8578	Genomic	_	
40-3	8579-8582	DNA	_	
40-4	8583-8586	was	_	
40-5	8587-8596	extracted	_	
40-6	8597-8601	from	_	
40-7	8602-8607	blood	_	
40-8	8608-8615	samples	_	
40-9	8616-8619	and	_	
40-10	8620-8629	genotyped	_	
40-11	8630-8633	for	_	
40-12	8634-8640	CYP2A6	_	
40-13	8641-8643	as	_	
40-14	8644-8653	described	_	
40-15	8653-8654	.	_	

#Text=Based on the impact of enzymatic activity, subjects were grouped into normal, intermediate and slow metabolizers.
41-1	8655-8660	Based	_	
41-2	8661-8663	on	_	
41-3	8664-8667	the	_	
41-4	8668-8674	impact	_	
41-5	8675-8677	of	_	
41-6	8678-8687	enzymatic	_	
41-7	8688-8696	activity	_	
41-8	8696-8697	,	_	
41-9	8698-8706	subjects	_	
41-10	8707-8711	were	_	
41-11	8712-8719	grouped	_	
41-12	8720-8724	into	_	
41-13	8725-8731	normal	_	
41-14	8731-8732	,	_	
41-15	8733-8745	intermediate	_	
41-16	8746-8749	and	_	
41-17	8750-8754	slow	_	
41-18	8755-8767	metabolizers	_	
41-19	8767-8768	.	_	

#Text=Due to the more limited cohort size available for task data, we combined the slow and intermediate genotype groups into a single reduced genotype group for task analysis.
42-1	8769-8772	Due	_	
42-2	8773-8775	to	_	
42-3	8776-8779	the	_	
42-4	8780-8784	more	_	
42-5	8785-8792	limited	_	
42-6	8793-8799	cohort	_	
42-7	8800-8804	size	_	
42-8	8805-8814	available	_	
42-9	8815-8818	for	_	
42-10	8819-8823	task	_	
42-11	8824-8828	data	_	
42-12	8828-8829	,	_	
42-13	8830-8832	we	_	
42-14	8833-8841	combined	_	
42-15	8842-8845	the	_	
42-16	8846-8850	slow	_	
42-17	8851-8854	and	_	
42-18	8855-8867	intermediate	_	
42-19	8868-8876	genotype	_	
42-20	8877-8883	groups	_	
42-21	8884-8888	into	_	
42-22	8889-8890	a	_	
42-23	8891-8897	single	_	
42-24	8898-8905	reduced	_	
42-25	8906-8914	genotype	_	
42-26	8915-8920	group	_	
42-27	8921-8924	for	_	
42-28	8925-8929	task	_	
42-29	8930-8938	analysis	_	
42-30	8938-8939	.	_	

#Text=FCS analysis
#Text=FCS, defined as the sum of functional connectivity between any one voxel and all other brain voxels, was computed for each subject from 6 min of BOLD fMRI acquired with subjects’ eyes open.
43-1	8940-8943	FCS	_	
43-2	8944-8952	analysis	_	
43-3	8953-8956	FCS	_	
43-4	8956-8957	,	_	
43-5	8958-8965	defined	_	
43-6	8966-8968	as	_	
43-7	8969-8972	the	_	
43-8	8973-8976	sum	_	
43-9	8977-8979	of	_	
43-10	8980-8990	functional	_	
43-11	8991-9003	connectivity	_	
43-12	9004-9011	between	_	
43-13	9012-9015	any	_	
43-14	9016-9019	one	_	
43-15	9020-9025	voxel	_	
43-16	9026-9029	and	_	
43-17	9030-9033	all	_	
43-18	9034-9039	other	_	
43-19	9040-9045	brain	_	
43-20	9046-9052	voxels	_	
43-21	9052-9053	,	_	
43-22	9054-9057	was	_	
43-23	9058-9066	computed	_	
43-24	9067-9070	for	_	
43-25	9071-9075	each	_	
43-26	9076-9083	subject	_	
43-27	9084-9088	from	_	
43-28	9089-9090	6	_	
43-29	9091-9094	min	_	
43-30	9095-9097	of	_	
43-31	9098-9102	BOLD	_	
43-32	9103-9107	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
43-33	9108-9116	acquired	_	
43-34	9117-9121	with	_	
43-35	9122-9130	subjects	_	
43-36	9130-9131	’	_	
43-37	9132-9136	eyes	_	
43-38	9137-9141	open	_	
43-39	9141-9142	.	_	

#Text=Functional connectivity between voxels was measured using Pearson correlation in MATLAB (The MathWorks Inc, Natick, Massachusetts).
44-1	9143-9153	Functional	_	
44-2	9154-9166	connectivity	_	
44-3	9167-9174	between	_	
44-4	9175-9181	voxels	_	
44-5	9182-9185	was	_	
44-6	9186-9194	measured	_	
44-7	9195-9200	using	_	
44-8	9201-9208	Pearson	_	
44-9	9209-9220	correlation	_	
44-10	9221-9223	in	_	
44-11	9224-9230	MATLAB	_	
44-12	9231-9232	(	_	
44-13	9232-9235	The	_	
44-14	9236-9245	MathWorks	_	
44-15	9246-9249	Inc	_	
44-16	9249-9250	,	_	
44-17	9251-9257	Natick	_	
44-18	9257-9258	,	_	
44-19	9259-9272	Massachusetts	_	
44-20	9272-9273	)	_	
44-21	9273-9274	.	_	

#Text=FCS was computed after thresholding the correlation map at r > 0.25.
45-1	9275-9278	FCS	_	
45-2	9279-9282	was	_	
45-3	9283-9291	computed	_	
45-4	9292-9297	after	_	
45-5	9298-9310	thresholding	_	
45-6	9311-9314	the	_	
45-7	9315-9326	correlation	_	
45-8	9327-9330	map	_	
45-9	9331-9333	at	_	
45-10	9334-9335	r	_	
45-11	9336-9337	>	_	
45-12	9338-9342	0.25	_	
45-13	9342-9343	.	_	

#Text=A voxel-wise threshold of P < 0.01 and a spatial-extent of 30 contiguous voxels were determined via Monte Carlo simulation to provide a corrected threshold of P < 0.05.
46-1	9344-9345	A	_	
46-2	9346-9356	voxel-wise	_	
46-3	9357-9366	threshold	_	
46-4	9367-9369	of	_	
46-5	9370-9371	P	_	
46-6	9372-9373	<	_	
46-7	9374-9378	0.01	_	
46-8	9379-9382	and	_	
46-9	9383-9384	a	_	
46-10	9385-9399	spatial-extent	_	
46-11	9400-9402	of	_	
46-12	9403-9405	30	_	
46-13	9406-9416	contiguous	_	
46-14	9417-9423	voxels	_	
46-15	9424-9428	were	_	
46-16	9429-9439	determined	_	
46-17	9440-9443	via	_	
46-18	9444-9449	Monte	_	
46-19	9450-9455	Carlo	_	
46-20	9456-9466	simulation	_	
46-21	9467-9469	to	_	
46-22	9470-9477	provide	_	
46-23	9478-9479	a	_	
46-24	9480-9489	corrected	_	
46-25	9490-9499	threshold	_	
46-26	9500-9502	of	_	
46-27	9503-9504	P	_	
46-28	9505-9506	<	_	
46-29	9507-9511	0.05	_	
46-30	9511-9512	.	_	

#Text=MID and Go/NoGo tasks
#Text=Subjects performed two tasks on two occasions, separated by 1–7 days.
47-1	9513-9516	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	
47-2	9517-9520	and	_	
47-3	9521-9523	Go	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[16]	
47-4	9523-9524	/	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[16]	
47-5	9524-9528	NoGo	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[16]	
47-6	9529-9534	tasks	_	
47-7	9535-9543	Subjects	_	
47-8	9544-9553	performed	_	
47-9	9554-9557	two	_	
47-10	9558-9563	tasks	_	
47-11	9564-9566	on	_	
47-12	9567-9570	two	_	
47-13	9571-9580	occasions	_	
47-14	9580-9581	,	_	
47-15	9582-9591	separated	_	
47-16	9592-9594	by	_	
47-17	9595-9596	1	_	
47-18	9596-9597	–	_	
47-19	9597-9598	7	_	
47-20	9599-9603	days	_	
47-21	9603-9604	.	_	

#Text=A nicotine or placebo patch was placed, in random order, 2–9 hours prior to scanning.
48-1	9605-9606	A	_	
48-2	9607-9615	nicotine	_	
48-3	9616-9618	or	_	
48-4	9619-9626	placebo	_	
48-5	9627-9632	patch	_	
48-6	9633-9636	was	_	
48-7	9637-9643	placed	_	
48-8	9643-9644	,	_	
48-9	9645-9647	in	_	
48-10	9648-9654	random	_	
48-11	9655-9660	order	_	
48-12	9660-9661	,	_	
48-13	9662-9663	2	_	
48-14	9663-9664	–	_	
48-15	9664-9665	9	_	
48-16	9666-9671	hours	_	
48-17	9672-9677	prior	_	
48-18	9678-9680	to	_	
48-19	9681-9689	scanning	_	
48-20	9689-9690	.	_	

#Text=Trials in the MID task included four sequential stimuli: PRIME-1 (gain, loss or neutral), PRIME-2 (win/loss magnitude), TARGET, and FEEDBACK; a button press was required to the TARGET.
49-1	9691-9697	Trials	_	
49-2	9698-9700	in	_	
49-3	9701-9704	the	_	
49-4	9705-9708	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	
49-5	9709-9713	task	_	
49-6	9714-9722	included	_	
49-7	9723-9727	four	_	
49-8	9728-9738	sequential	_	
49-9	9739-9746	stimuli	_	
49-10	9746-9747	:	_	
49-11	9748-9753	PRIME	_	
49-12	9753-9754	-	_	
49-13	9754-9755	1	_	
49-14	9756-9757	(	_	
49-15	9757-9761	gain	_	
49-16	9761-9762	,	_	
49-17	9763-9767	loss	_	
49-18	9768-9770	or	_	
49-19	9771-9778	neutral	_	
49-20	9778-9779	)	_	
49-21	9779-9780	,	_	
49-22	9781-9786	PRIME	_	
49-23	9786-9787	-	_	
49-24	9787-9788	2	_	
49-25	9789-9790	(	_	
49-26	9790-9793	win	_	
49-27	9793-9794	/	_	
49-28	9794-9798	loss	_	
49-29	9799-9808	magnitude	_	
49-30	9808-9809	)	_	
49-31	9809-9810	,	_	
49-32	9811-9817	TARGET	_	
49-33	9817-9818	,	_	
49-34	9819-9822	and	_	
49-35	9823-9831	FEEDBACK	_	
49-36	9831-9832	;	_	
49-37	9833-9834	a	_	
49-38	9835-9841	button	_	
49-39	9842-9847	press	_	
49-40	9848-9851	was	_	
49-41	9852-9860	required	_	
49-42	9861-9863	to	_	
49-43	9864-9867	the	_	
49-44	9868-9874	TARGET	_	
49-45	9874-9875	.	_	

#Text=For the Go/NoGo task, subjects viewed a serial stream of alternating ‘X’ and ‘Y’ letters and were to respond to each target while the stimulus was present on the screen.
50-1	9876-9879	For	_	
50-2	9880-9883	the	_	
50-3	9884-9886	Go	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[17]	
50-4	9886-9887	/	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[17]	
50-5	9887-9891	NoGo	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[17]	
50-6	9892-9896	task	_	
50-7	9896-9897	,	_	
50-8	9898-9906	subjects	_	
50-9	9907-9913	viewed	_	
50-10	9914-9915	a	_	
50-11	9916-9922	serial	_	
50-12	9923-9929	stream	_	
50-13	9930-9932	of	_	
50-14	9933-9944	alternating	_	
50-15	9945-9946	‘	_	
50-16	9946-9947	X	_	
50-17	9947-9948	’	_	
50-18	9949-9952	and	_	
50-19	9953-9954	‘	_	
50-20	9954-9955	Y	_	
50-21	9955-9956	’	_	
50-22	9957-9964	letters	_	
50-23	9965-9968	and	_	
50-24	9969-9973	were	_	
50-25	9974-9976	to	_	
50-26	9977-9984	respond	_	
50-27	9985-9987	to	_	
50-28	9988-9992	each	_	
50-29	9993-9999	target	_	
50-30	10000-10005	while	_	
50-31	10006-10009	the	_	
50-32	10010-10018	stimulus	_	
50-33	10019-10022	was	_	
50-34	10023-10030	present	_	
50-35	10031-10033	on	_	
50-36	10034-10037	the	_	
50-37	10038-10044	screen	_	
50-38	10044-10045	.	_	

#Text=NoGo stimuli, in which the target stimuli did not alternate (e.g.
51-1	10046-10050	NoGo	_	
51-2	10051-10058	stimuli	_	
51-3	10058-10059	,	_	
51-4	10060-10062	in	_	
51-5	10063-10068	which	_	
51-6	10069-10072	the	_	
51-7	10073-10079	target	_	
51-8	10080-10087	stimuli	_	
51-9	10088-10091	did	_	
51-10	10092-10095	not	_	
51-11	10096-10105	alternate	_	
51-12	10106-10107	(	_	
51-13	10107-10110	e.g	_	
51-14	10110-10111	.	_	

#Text=X, X), required response inhibition.
52-1	10112-10113	X	_	
52-2	10113-10114	,	_	
52-3	10115-10116	X	_	
52-4	10116-10117	)	_	
52-5	10117-10118	,	_	
52-6	10119-10127	required	_	
52-7	10128-10136	response	_	
52-8	10137-10147	inhibition	_	
52-9	10147-10148	.	_	

#Text=Since we had strong a priori interest in the ventral striatum (VS) for the MID task and dorsal anterior cingulate cortex (dACC) for the Go/NoGo task, we did region of interest analysis and small volume correction (Pcorrected < 0.05) using respectively, a striatal atlas (http://fsl.fmrib.ox.ac.uk/fsl) and dACC mask.
53-1	10149-10154	Since	_	
53-2	10155-10157	we	_	
53-3	10158-10161	had	_	
53-4	10162-10168	strong	_	
53-5	10169-10170	a	_	
53-6	10171-10177	priori	_	
53-7	10178-10186	interest	_	
53-8	10187-10189	in	_	
53-9	10190-10193	the	_	
53-10	10194-10201	ventral	_	
53-11	10202-10210	striatum	_	
53-12	10211-10212	(	_	
53-13	10212-10214	VS	_	
53-14	10214-10215	)	_	
53-15	10216-10219	for	_	
53-16	10220-10223	the	_	
53-17	10224-10227	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	
53-18	10228-10232	task	_	
53-19	10233-10236	and	_	
53-20	10237-10243	dorsal	_	
53-21	10244-10252	anterior	_	
53-22	10253-10262	cingulate	_	
53-23	10263-10269	cortex	_	
53-24	10270-10271	(	_	
53-25	10271-10275	dACC	_	
53-26	10275-10276	)	_	
53-27	10277-10280	for	_	
53-28	10281-10284	the	_	
53-29	10285-10287	Go	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[18]	
53-30	10287-10288	/	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[18]	
53-31	10288-10292	NoGo	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[18]	
53-32	10293-10297	task	_	
53-33	10297-10298	,	_	
53-34	10299-10301	we	_	
53-35	10302-10305	did	_	
53-36	10306-10312	region	_	
53-37	10313-10315	of	_	
53-38	10316-10324	interest	_	
53-39	10325-10333	analysis	_	
53-40	10334-10337	and	_	
53-41	10338-10343	small	_	
53-42	10344-10350	volume	_	
53-43	10351-10361	correction	_	
53-44	10362-10363	(	_	
53-45	10363-10373	Pcorrected	_	
53-46	10374-10375	<	_	
53-47	10376-10380	0.05	_	
53-48	10380-10381	)	_	
53-49	10382-10387	using	_	
53-50	10388-10400	respectively	_	
53-51	10400-10401	,	_	
53-52	10402-10403	a	_	
53-53	10404-10412	striatal	_	
53-54	10413-10418	atlas	_	
53-55	10419-10420	(	_	
53-56	10420-10424	http	_	
53-57	10424-10425	:	_	
53-58	10425-10426	/	_	
53-59	10426-10427	/	_	
53-60	10427-10445	fsl.fmrib.ox.ac.uk	_	
53-61	10445-10446	/	_	
53-62	10446-10449	fsl	_	
53-63	10449-10450	)	_	
53-64	10451-10454	and	_	
53-65	10455-10459	dACC	_	
53-66	10460-10464	mask	_	
53-67	10464-10465	.	_	

#Text=Statistical analysis
#Text=A 3 (Genotype) × 2 (Smokers, Nonsmokers) ANCOVA was performed on whole brain FCS maps, using age, gender, IQ, race and years of education as covariates.
54-1	10466-10477	Statistical	_	
54-2	10478-10486	analysis	_	
54-3	10487-10488	A	_	
54-4	10489-10490	3	_	
54-5	10491-10492	(	_	
54-6	10492-10500	Genotype	_	
54-7	10500-10501	)	_	
54-8	10502-10503	×	_	
54-9	10504-10505	2	_	
54-10	10506-10507	(	_	
54-11	10507-10514	Smokers	_	
54-12	10514-10515	,	_	
54-13	10516-10526	Nonsmokers	_	
54-14	10526-10527	)	_	
54-15	10528-10534	ANCOVA	_	
54-16	10535-10538	was	_	
54-17	10539-10548	performed	_	
54-18	10549-10551	on	_	
54-19	10552-10557	whole	_	
54-20	10558-10563	brain	_	
54-21	10564-10567	FCS	_	
54-22	10568-10572	maps	_	
54-23	10572-10573	,	_	
54-24	10574-10579	using	_	
54-25	10580-10583	age	_	
54-26	10583-10584	,	_	
54-27	10585-10591	gender	_	
54-28	10591-10592	,	_	
54-29	10593-10595	IQ	_	
54-30	10595-10596	,	_	
54-31	10597-10601	race	_	
54-32	10602-10605	and	_	
54-33	10606-10611	years	_	
54-34	10612-10614	of	_	
54-35	10615-10624	education	_	
54-36	10625-10627	as	_	
54-37	10628-10638	covariates	_	
54-38	10638-10639	.	_	

#Text=Post-hoc one-way ANOVA and two-tailed independent t-tests identified differences between groups.
55-1	10640-10648	Post-hoc	_	
55-2	10649-10656	one-way	_	
55-3	10657-10662	ANOVA	_	
55-4	10663-10666	and	_	
55-5	10667-10677	two-tailed	_	
55-6	10678-10689	independent	_	
55-7	10690-10697	t-tests	_	
55-8	10698-10708	identified	_	
55-9	10709-10720	differences	_	
55-10	10721-10728	between	_	
55-11	10729-10735	groups	_	
55-12	10735-10736	.	_	

#Text=MID and Go/NoGo tasks were analyzed using GLM.
56-1	10737-10740	MID	_	
56-2	10741-10744	and	_	
56-3	10745-10747	Go	_	
56-4	10747-10748	/	_	
56-5	10748-10752	NoGo	_	
56-6	10753-10758	tasks	_	
56-7	10759-10763	were	_	
56-8	10764-10772	analyzed	_	
56-9	10773-10778	using	_	
56-10	10779-10782	GLM	_	
56-11	10782-10783	.	_	

#Text=Associations between FCS in regions showing significant GENOTYPE × SMOKING interactions and FTND/CPD were tested using Pearson’s correlation analyses.
57-1	10784-10796	Associations	_	
57-2	10797-10804	between	_	
57-3	10805-10808	FCS	_	
57-4	10809-10811	in	_	
57-5	10812-10819	regions	_	
57-6	10820-10827	showing	_	
57-7	10828-10839	significant	_	
57-8	10840-10848	GENOTYPE	_	
57-9	10849-10850	×	_	
57-10	10851-10858	SMOKING	_	
57-11	10859-10871	interactions	_	
57-12	10872-10875	and	_	
57-13	10876-10880	FTND	_	
57-14	10880-10881	/	_	
57-15	10881-10884	CPD	_	
57-16	10885-10889	were	_	
57-17	10890-10896	tested	_	
57-18	10897-10902	using	_	
57-19	10903-10910	Pearson	_	
57-20	10910-10911	’	_	
57-21	10911-10912	s	_	
57-22	10913-10924	correlation	_	
57-23	10925-10933	analyses	_	
57-24	10933-10934	.	_	

#Text=The mean FCS in these regions was regressed against age, IQ and years of education.
58-1	10935-10938	The	_	
58-2	10939-10943	mean	_	
58-3	10944-10947	FCS	_	
58-4	10948-10950	in	_	
58-5	10951-10956	these	_	
58-6	10957-10964	regions	_	
58-7	10965-10968	was	_	
58-8	10969-10978	regressed	_	
58-9	10979-10986	against	_	
58-10	10987-10990	age	_	
58-11	10990-10991	,	_	
58-12	10992-10994	IQ	_	
58-13	10995-10998	and	_	
58-14	10999-11004	years	_	
58-15	11005-11007	of	_	
58-16	11008-11017	education	_	
58-17	11017-11018	.	_	

#Text=One and two way ANOVAs followed by Tukey’s t-test for multiple comparisons and frequency analyses (Pearson’s χ2-test) were conducted (SPSS 20, IBM, Armonk, New York) to compare demographic and behavioral characteristics among groups.
59-1	11019-11022	One	_	
59-2	11023-11026	and	_	
59-3	11027-11030	two	_	
59-4	11031-11034	way	_	
59-5	11035-11041	ANOVAs	_	
59-6	11042-11050	followed	_	
59-7	11051-11053	by	_	
59-8	11054-11059	Tukey	_	
59-9	11059-11060	’	_	
59-10	11060-11061	s	_	
59-11	11062-11068	t-test	_	
59-12	11069-11072	for	_	
59-13	11073-11081	multiple	_	
59-14	11082-11093	comparisons	_	
59-15	11094-11097	and	_	
59-16	11098-11107	frequency	_	
59-17	11108-11116	analyses	_	
59-18	11117-11118	(	_	
59-19	11118-11125	Pearson	_	
59-20	11125-11126	’	_	
59-21	11126-11127	s	_	
59-22	11128-11130	χ2	_	
59-23	11130-11131	-	_	
59-24	11131-11135	test	_	
59-25	11135-11136	)	_	
59-26	11137-11141	were	_	
59-27	11142-11151	conducted	_	
59-28	11152-11153	(	_	
59-29	11153-11157	SPSS	_	
59-30	11158-11160	20	_	
59-31	11160-11161	,	_	
59-32	11162-11165	IBM	_	
59-33	11165-11166	,	_	
59-34	11167-11173	Armonk	_	
59-35	11173-11174	,	_	
59-36	11175-11178	New	_	
59-37	11179-11183	York	_	
59-38	11183-11184	)	_	
59-39	11185-11187	to	_	
59-40	11188-11195	compare	_	
59-41	11196-11207	demographic	_	
59-42	11208-11211	and	_	
59-43	11212-11222	behavioral	_	
59-44	11223-11238	characteristics	_	
59-45	11239-11244	among	_	
59-46	11245-11251	groups	_	
59-47	11251-11252	.	_	

#Text=Results
#Text=Demographics, genotypes and behavioral characteristics
#Text=For the entire sample, there was no significant difference in the frequency distribution of the three CYP2A6 groups between smokers and nonsmokers (P = 0.36) and the CYP2A6 genotype frequency distributions were in Hardy-Weinberg equilibrium for both groups.
60-1	11253-11260	Results	_	
60-2	11261-11273	Demographics	_	
60-3	11273-11274	,	_	
60-4	11275-11284	genotypes	_	
60-5	11285-11288	and	_	
60-6	11289-11299	behavioral	_	
60-7	11300-11315	characteristics	_	
60-8	11316-11319	For	_	
60-9	11320-11323	the	_	
60-10	11324-11330	entire	_	
60-11	11331-11337	sample	_	
60-12	11337-11338	,	_	
60-13	11339-11344	there	_	
60-14	11345-11348	was	_	
60-15	11349-11351	no	_	
60-16	11352-11363	significant	_	
60-17	11364-11374	difference	_	
60-18	11375-11377	in	_	
60-19	11378-11381	the	_	
60-20	11382-11391	frequency	_	
60-21	11392-11404	distribution	_	
60-22	11405-11407	of	_	
60-23	11408-11411	the	_	
60-24	11412-11417	three	_	
60-25	11418-11424	CYP2A6	_	
60-26	11425-11431	groups	_	
60-27	11432-11439	between	_	
60-28	11440-11447	smokers	_	
60-29	11448-11451	and	_	
60-30	11452-11462	nonsmokers	_	
60-31	11463-11464	(	_	
60-32	11464-11465	P	_	
60-33	11466-11467	=	_	
60-34	11468-11472	0.36	_	
60-35	11472-11473	)	_	
60-36	11474-11477	and	_	
60-37	11478-11481	the	_	
60-38	11482-11488	CYP2A6	_	
60-39	11489-11497	genotype	_	
60-40	11498-11507	frequency	_	
60-41	11508-11521	distributions	_	
60-42	11522-11526	were	_	
60-43	11527-11529	in	_	
60-44	11530-11544	Hardy-Weinberg	_	
60-45	11545-11556	equilibrium	_	
60-46	11557-11560	for	_	
60-47	11561-11565	both	_	
60-48	11566-11572	groups	_	
60-49	11572-11573	.	_	

#Text=The samples were well matched, although nonsmokers had higher verbal IQ (P = 0.002) and years of education (P = 0.004) than smokers, which did not differ between the three genotype groups in either cohort.
61-1	11574-11577	The	_	
61-2	11578-11585	samples	_	
61-3	11586-11590	were	_	
61-4	11591-11595	well	_	
61-5	11596-11603	matched	_	
61-6	11603-11604	,	_	
61-7	11605-11613	although	_	
61-8	11614-11624	nonsmokers	_	
61-9	11625-11628	had	_	
61-10	11629-11635	higher	_	
61-11	11636-11642	verbal	_	
61-12	11643-11645	IQ	_	
61-13	11646-11647	(	_	
61-14	11647-11648	P	_	
61-15	11649-11650	=	_	
61-16	11651-11656	0.002	_	
61-17	11656-11657	)	_	
61-18	11658-11661	and	_	
61-19	11662-11667	years	_	
61-20	11668-11670	of	_	
61-21	11671-11680	education	_	
61-22	11681-11682	(	_	
61-23	11682-11683	P	_	
61-24	11684-11685	=	_	
61-25	11686-11691	0.004	_	
61-26	11691-11692	)	_	
61-27	11693-11697	than	_	
61-28	11698-11705	smokers	_	
61-29	11705-11706	,	_	
61-30	11707-11712	which	_	
61-31	11713-11716	did	_	
61-32	11717-11720	not	_	
61-33	11721-11727	differ	_	
61-34	11728-11735	between	_	
61-35	11736-11739	the	_	
61-36	11740-11745	three	_	
61-37	11746-11754	genotype	_	
61-38	11755-11761	groups	_	
61-39	11762-11764	in	_	
61-40	11765-11771	either	_	
61-41	11772-11778	cohort	_	
61-42	11778-11779	.	_	

#Text=As expected, there was a significant difference in CPD (P = 0.04) between the three genotype smoker groups, such that slow (vs. normal) genotype smokers smoked fewer cigarettes (P = 0.003) (See Table 1 for details).
62-1	11780-11782	As	_	
62-2	11783-11791	expected	_	
62-3	11791-11792	,	_	
62-4	11793-11798	there	_	
62-5	11799-11802	was	_	
62-6	11803-11804	a	_	
62-7	11805-11816	significant	_	
62-8	11817-11827	difference	_	
62-9	11828-11830	in	_	
62-10	11831-11834	CPD	_	
62-11	11835-11836	(	_	
62-12	11836-11837	P	_	
62-13	11838-11839	=	_	
62-14	11840-11844	0.04	_	
62-15	11844-11845	)	_	
62-16	11846-11853	between	_	
62-17	11854-11857	the	_	
62-18	11858-11863	three	_	
62-19	11864-11872	genotype	_	
62-20	11873-11879	smoker	_	
62-21	11880-11886	groups	_	
62-22	11886-11887	,	_	
62-23	11888-11892	such	_	
62-24	11893-11897	that	_	
62-25	11898-11902	slow	_	
62-26	11903-11904	(	_	
62-27	11904-11906	vs	_	
62-28	11906-11907	.	_	
62-29	11908-11914	normal	_	
62-30	11914-11915	)	_	
62-31	11916-11924	genotype	_	
62-32	11925-11932	smokers	_	
62-33	11933-11939	smoked	_	
62-34	11940-11945	fewer	_	
62-35	11946-11956	cigarettes	_	
62-36	11957-11958	(	_	
62-37	11958-11959	P	_	
62-38	11960-11961	=	_	
62-39	11962-11967	0.003	_	
62-40	11967-11968	)	_	
62-41	11969-11970	(	_	
62-42	11970-11973	See	_	
62-43	11974-11979	Table	_	
62-44	11980-11981	1	_	
62-45	11982-11985	for	_	
62-46	11986-11993	details	_	
62-47	11993-11994	)	_	
62-48	11994-11995	.	_	

#Text=Groups were generally well matched in the task subgroup as well except that smokers and reduced genotype individuals both had lower IQ and fewer years of education than nonsmokers (see Table 2).
63-1	11996-12002	Groups	_	
63-2	12003-12007	were	_	
63-3	12008-12017	generally	_	
63-4	12018-12022	well	_	
63-5	12023-12030	matched	_	
63-6	12031-12033	in	_	
63-7	12034-12037	the	_	
63-8	12038-12042	task	_	
63-9	12043-12051	subgroup	_	
63-10	12052-12054	as	_	
63-11	12055-12059	well	_	
63-12	12060-12066	except	_	
63-13	12067-12071	that	_	
63-14	12072-12079	smokers	_	
63-15	12080-12083	and	_	
63-16	12084-12091	reduced	_	
63-17	12092-12100	genotype	_	
63-18	12101-12112	individuals	_	
63-19	12113-12117	both	_	
63-20	12118-12121	had	_	
63-21	12122-12127	lower	_	
63-22	12128-12130	IQ	_	
63-23	12131-12134	and	_	
63-24	12135-12140	fewer	_	
63-25	12141-12146	years	_	
63-26	12147-12149	of	_	
63-27	12150-12159	education	_	
63-28	12160-12164	than	_	
63-29	12165-12175	nonsmokers	_	
63-30	12176-12177	(	_	
63-31	12177-12180	see	_	
63-32	12181-12186	Table	_	
63-33	12187-12188	2	_	
63-34	12188-12189	)	_	
63-35	12189-12190	.	_	

#Text=Additionally, there was no difference in the frequency distribution of the four groups (P = 0.18) with the CYP2A6 genotype frequency distributions were in Hardy-Weinberg equilibrium.
64-1	12191-12203	Additionally	_	
64-2	12203-12204	,	_	
64-3	12205-12210	there	_	
64-4	12211-12214	was	_	
64-5	12215-12217	no	_	
64-6	12218-12228	difference	_	
64-7	12229-12231	in	_	
64-8	12232-12235	the	_	
64-9	12236-12245	frequency	_	
64-10	12246-12258	distribution	_	
64-11	12259-12261	of	_	
64-12	12262-12265	the	_	
64-13	12266-12270	four	_	
64-14	12271-12277	groups	_	
64-15	12278-12279	(	_	
64-16	12279-12280	P	_	
64-17	12281-12282	=	_	
64-18	12283-12287	0.18	_	
64-19	12287-12288	)	_	
64-20	12289-12293	with	_	
64-21	12294-12297	the	_	
64-22	12298-12304	CYP2A6	_	
64-23	12305-12313	genotype	_	
64-24	12314-12323	frequency	_	
64-25	12324-12337	distributions	_	
64-26	12338-12342	were	_	
64-27	12343-12345	in	_	
64-28	12346-12360	Hardy-Weinberg	_	
64-29	12361-12372	equilibrium	_	
64-30	12372-12373	.	_	

#Text=FCS and correlation with smoking behaviors
#Text=FCS was utilized as a metric of regional connectivity strength.
65-1	12374-12377	FCS	_	
65-2	12378-12381	and	_	
65-3	12382-12393	correlation	_	
65-4	12394-12398	with	_	
65-5	12399-12406	smoking	_	
65-6	12407-12416	behaviors	_	
65-7	12417-12420	FCS	_	
65-8	12421-12424	was	_	
65-9	12425-12433	utilized	_	
65-10	12434-12436	as	_	
65-11	12437-12438	a	_	
65-12	12439-12445	metric	_	
65-13	12446-12448	of	_	
65-14	12449-12457	regional	_	
65-15	12458-12470	connectivity	_	
65-16	12471-12479	strength	_	
65-17	12479-12480	.	_	

#Text=A 3 × 2 ANCOVA on whole brain FCS revealed a significant CYP2A6 GENOTYPE × SMOKING status interaction in only two brain regions, the dACC and left VS (Pcorrected < 0.05) (Fig. 1A and Supplementary Table 1).
66-1	12481-12482	A	_	
66-2	12483-12484	3	_	
66-3	12485-12486	×	_	
66-4	12487-12488	2	_	
66-5	12489-12495	ANCOVA	_	
66-6	12496-12498	on	_	
66-7	12499-12504	whole	_	
66-8	12505-12510	brain	_	
66-9	12511-12514	FCS	_	
66-10	12515-12523	revealed	_	
66-11	12524-12525	a	_	
66-12	12526-12537	significant	_	
66-13	12538-12544	CYP2A6	_	
66-14	12545-12553	GENOTYPE	_	
66-15	12554-12555	×	_	
66-16	12556-12563	SMOKING	_	
66-17	12564-12570	status	_	
66-18	12571-12582	interaction	_	
66-19	12583-12585	in	_	
66-20	12586-12590	only	_	
66-21	12591-12594	two	_	
66-22	12595-12600	brain	_	
66-23	12601-12608	regions	_	
66-24	12608-12609	,	_	
66-25	12610-12613	the	_	
66-26	12614-12618	dACC	_	
66-27	12619-12622	and	_	
66-28	12623-12627	left	_	
66-29	12628-12630	VS	_	
66-30	12631-12632	(	_	
66-31	12632-12642	Pcorrected	_	
66-32	12643-12644	<	_	
66-33	12645-12649	0.05	_	
66-34	12649-12650	)	_	
66-35	12651-12652	(	_	
66-36	12652-12655	Fig	_	
66-37	12655-12656	.	_	
66-38	12657-12659	1A	_	
66-39	12660-12663	and	_	
66-40	12664-12677	Supplementary	_	
66-41	12678-12683	Table	_	
66-42	12684-12685	1	_	
66-43	12685-12686	)	_	
66-44	12686-12687	.	_	

#Text=Based on their anatomical overlap with the FCS analysis, post-hoc analyses (whole brain, voxel-wise, one-way ANCOVA, followed by two sample t-test) suggest that in both brain regions smokers with the normal metabolizer genotype had higher FCS than a) all nonsmoker groups and b) smokers with the slow metabolizing genotype (Fig. 1 B–C).
67-1	12688-12693	Based	_	
67-2	12694-12696	on	_	
67-3	12697-12702	their	_	
67-4	12703-12713	anatomical	_	
67-5	12714-12721	overlap	_	
67-6	12722-12726	with	_	
67-7	12727-12730	the	_	
67-8	12731-12734	FCS	_	
67-9	12735-12743	analysis	_	
67-10	12743-12744	,	_	
67-11	12745-12753	post-hoc	_	
67-12	12754-12762	analyses	_	
67-13	12763-12764	(	_	
67-14	12764-12769	whole	_	
67-15	12770-12775	brain	_	
67-16	12775-12776	,	_	
67-17	12777-12787	voxel-wise	_	
67-18	12787-12788	,	_	
67-19	12789-12796	one-way	_	
67-20	12797-12803	ANCOVA	_	
67-21	12803-12804	,	_	
67-22	12805-12813	followed	_	
67-23	12814-12816	by	_	
67-24	12817-12820	two	_	
67-25	12821-12827	sample	_	
67-26	12828-12834	t-test	_	
67-27	12834-12835	)	_	
67-28	12836-12843	suggest	_	
67-29	12844-12848	that	_	
67-30	12849-12851	in	_	
67-31	12852-12856	both	_	
67-32	12857-12862	brain	_	
67-33	12863-12870	regions	_	
67-34	12871-12878	smokers	_	
67-35	12879-12883	with	_	
67-36	12884-12887	the	_	
67-37	12888-12894	normal	_	
67-38	12895-12906	metabolizer	_	
67-39	12907-12915	genotype	_	
67-40	12916-12919	had	_	
67-41	12920-12926	higher	_	
67-42	12927-12930	FCS	_	
67-43	12931-12935	than	_	
67-44	12936-12937	a	_	
67-45	12937-12938	)	_	
67-46	12939-12942	all	_	
67-47	12943-12952	nonsmoker	_	
67-48	12953-12959	groups	_	
67-49	12960-12963	and	_	
67-50	12964-12965	b	_	
67-51	12965-12966	)	_	
67-52	12967-12974	smokers	_	
67-53	12975-12979	with	_	
67-54	12980-12983	the	_	
67-55	12984-12988	slow	_	
67-56	12989-13001	metabolizing	_	
67-57	13002-13010	genotype	_	
67-58	13011-13012	(	_	
67-59	13012-13015	Fig	_	
67-60	13015-13016	.	_	
67-61	13017-13018	1	_	
67-62	13019-13022	B–C	_	
67-63	13022-13023	)	_	
67-64	13023-13024	.	_	

#Text=Importantly, there was no effect of the CYP2A6 genotype on FCS among nonsmokers.
68-1	13025-13036	Importantly	_	
68-2	13036-13037	,	_	
68-3	13038-13043	there	_	
68-4	13044-13047	was	_	
68-5	13048-13050	no	_	
68-6	13051-13057	effect	_	
68-7	13058-13060	of	_	
68-8	13061-13064	the	_	
68-9	13065-13071	CYP2A6	_	
68-10	13072-13080	genotype	_	
68-11	13081-13083	on	_	
68-12	13084-13087	FCS	_	
68-13	13088-13093	among	_	
68-14	13094-13104	nonsmokers	_	
68-15	13104-13105	.	_	

#Text=Exploratory correlation analysis between FCS and dependence severity (FTND) revealed a negative correlation in both hub regions in the slow but not in the normal or intermediate genotype groups, i.e. as smoking dependence increased, FCS decreased in VS (r = −0.51, P = 0.01) and dACC (r = −0.44, P = 0.04) (Fig. 1 D–E).
69-1	13106-13117	Exploratory	_	
69-2	13118-13129	correlation	_	
69-3	13130-13138	analysis	_	
69-4	13139-13146	between	_	
69-5	13147-13150	FCS	_	
69-6	13151-13154	and	_	
69-7	13155-13165	dependence	_	
69-8	13166-13174	severity	_	
69-9	13175-13176	(	_	
69-10	13176-13180	FTND	_	
69-11	13180-13181	)	_	
69-12	13182-13190	revealed	_	
69-13	13191-13192	a	_	
69-14	13193-13201	negative	_	
69-15	13202-13213	correlation	_	
69-16	13214-13216	in	_	
69-17	13217-13221	both	_	
69-18	13222-13225	hub	_	
69-19	13226-13233	regions	_	
69-20	13234-13236	in	_	
69-21	13237-13240	the	_	
69-22	13241-13245	slow	_	
69-23	13246-13249	but	_	
69-24	13250-13253	not	_	
69-25	13254-13256	in	_	
69-26	13257-13260	the	_	
69-27	13261-13267	normal	_	
69-28	13268-13270	or	_	
69-29	13271-13283	intermediate	_	
69-30	13284-13292	genotype	_	
69-31	13293-13299	groups	_	
69-32	13299-13300	,	_	
69-33	13301-13304	i.e	_	
69-34	13304-13305	.	_	
69-35	13306-13308	as	_	
69-36	13309-13316	smoking	_	
69-37	13317-13327	dependence	_	
69-38	13328-13337	increased	_	
69-39	13337-13338	,	_	
69-40	13339-13342	FCS	_	
69-41	13343-13352	decreased	_	
69-42	13353-13355	in	_	
69-43	13356-13358	VS	_	
69-44	13359-13360	(	_	
69-45	13360-13361	r	_	
69-46	13362-13363	=	_	
69-47	13364-13365	−	_	
69-48	13365-13369	0.51	_	
69-49	13369-13370	,	_	
69-50	13371-13372	P	_	
69-51	13373-13374	=	_	
69-52	13375-13379	0.01	_	
69-53	13379-13380	)	_	
69-54	13381-13384	and	_	
69-55	13385-13389	dACC	_	
69-56	13390-13391	(	_	
69-57	13391-13392	r	_	
69-58	13393-13394	=	_	
69-59	13395-13396	−	_	
69-60	13396-13400	0.44	_	
69-61	13400-13401	,	_	
69-62	13402-13403	P	_	
69-63	13404-13405	=	_	
69-64	13406-13410	0.04	_	
69-65	13410-13411	)	_	
69-66	13412-13413	(	_	
69-67	13413-13416	Fig	_	
69-68	13416-13417	.	_	
69-69	13418-13419	1	_	
69-70	13420-13423	D–E	_	
69-71	13423-13424	)	_	
69-72	13424-13425	.	_	

#Text=These data recapitulate negative correlations in these addiction-related regions previously identified using different analytical strategies and samples.
70-1	13426-13431	These	_	
70-2	13432-13436	data	_	
70-3	13437-13449	recapitulate	_	
70-4	13450-13458	negative	_	
70-5	13459-13471	correlations	_	
70-6	13472-13474	in	_	
70-7	13475-13480	these	_	
70-8	13481-13498	addiction-related	_	
70-9	13499-13506	regions	_	
70-10	13507-13517	previously	_	
70-11	13518-13528	identified	_	
70-12	13529-13534	using	_	
70-13	13535-13544	different	_	
70-14	13545-13555	analytical	_	
70-15	13556-13566	strategies	_	
70-16	13567-13570	and	_	
70-17	13571-13578	samples	_	
70-18	13578-13579	.	_	

#Text=Finally, there was no relationship between FCS and CPD across the three genotype groups.
71-1	13580-13587	Finally	_	
71-2	13587-13588	,	_	
71-3	13589-13594	there	_	
71-4	13595-13598	was	_	
71-5	13599-13601	no	_	
71-6	13602-13614	relationship	_	
71-7	13615-13622	between	_	
71-8	13623-13626	FCS	_	
71-9	13627-13630	and	_	
71-10	13631-13634	CPD	_	
71-11	13635-13641	across	_	
71-12	13642-13645	the	_	
71-13	13646-13651	three	_	
71-14	13652-13660	genotype	_	
71-15	13661-13667	groups	_	
71-16	13667-13668	.	_	

#Text=To determine those brain circuits contributing to the above GENOTYPE × SMOKING interaction on FCS, we next used the identified dACC and VS regions as seeds in a functional connectivity analysis.
72-1	13669-13671	To	_	
72-2	13672-13681	determine	_	
72-3	13682-13687	those	_	
72-4	13688-13693	brain	_	
72-5	13694-13702	circuits	_	
72-6	13703-13715	contributing	_	
72-7	13716-13718	to	_	
72-8	13719-13722	the	_	
72-9	13723-13728	above	_	
72-10	13729-13737	GENOTYPE	_	
72-11	13738-13739	×	_	
72-12	13740-13747	SMOKING	_	
72-13	13748-13759	interaction	_	
72-14	13760-13762	on	_	
72-15	13763-13766	FCS	_	
72-16	13766-13767	,	_	
72-17	13768-13770	we	_	
72-18	13771-13775	next	_	
72-19	13776-13780	used	_	
72-20	13781-13784	the	_	
72-21	13785-13795	identified	_	
72-22	13796-13800	dACC	_	
72-23	13801-13804	and	_	
72-24	13805-13807	VS	_	
72-25	13808-13815	regions	_	
72-26	13816-13818	as	_	
72-27	13819-13824	seeds	_	
72-28	13825-13827	in	_	
72-29	13828-13829	a	_	
72-30	13830-13840	functional	_	
72-31	13841-13853	connectivity	_	
72-32	13854-13862	analysis	_	
72-33	13862-13863	.	_	

#Text=We identified a functional circuit between the dACC and bilateral insula and posterior cingulate cortex that contributed to the dACC FCS hub finding (Fig. 2A), while a functional circuit between the VS and bilateral insula and dACC contributed to the VS interaction (Fig. 2B) (Pcorrected < 0.05)
#Text=Task-induced striatal and dACC activity
#Text=To addressed the functional consequences of the above GENOTYPE × SMOKING alterations relevant to nicotine dependence, a subset of smokers and nonsmokers (n=43) performed the MID reward task and the Go/NoGo response inhibition task on two separate occasions, in the presence and absence of an acute nicotine patch.
73-1	13864-13866	We	_	
73-2	13867-13877	identified	_	
73-3	13878-13879	a	_	
73-4	13880-13890	functional	_	
73-5	13891-13898	circuit	_	
73-6	13899-13906	between	_	
73-7	13907-13910	the	_	
73-8	13911-13915	dACC	_	
73-9	13916-13919	and	_	
73-10	13920-13929	bilateral	_	
73-11	13930-13936	insula	_	
73-12	13937-13940	and	_	
73-13	13941-13950	posterior	_	
73-14	13951-13960	cingulate	_	
73-15	13961-13967	cortex	_	
73-16	13968-13972	that	_	
73-17	13973-13984	contributed	_	
73-18	13985-13987	to	_	
73-19	13988-13991	the	_	
73-20	13992-13996	dACC	_	
73-21	13997-14000	FCS	_	
73-22	14001-14004	hub	_	
73-23	14005-14012	finding	_	
73-24	14013-14014	(	_	
73-25	14014-14017	Fig	_	
73-26	14017-14018	.	_	
73-27	14019-14021	2A	_	
73-28	14021-14022	)	_	
73-29	14022-14023	,	_	
73-30	14024-14029	while	_	
73-31	14030-14031	a	_	
73-32	14032-14042	functional	_	
73-33	14043-14050	circuit	_	
73-34	14051-14058	between	_	
73-35	14059-14062	the	_	
73-36	14063-14065	VS	_	
73-37	14066-14069	and	_	
73-38	14070-14079	bilateral	_	
73-39	14080-14086	insula	_	
73-40	14087-14090	and	_	
73-41	14091-14095	dACC	_	
73-42	14096-14107	contributed	_	
73-43	14108-14110	to	_	
73-44	14111-14114	the	_	
73-45	14115-14117	VS	_	
73-46	14118-14129	interaction	_	
73-47	14130-14131	(	_	
73-48	14131-14134	Fig	_	
73-49	14134-14135	.	_	
73-50	14136-14138	2B	_	
73-51	14138-14139	)	_	
73-52	14140-14141	(	_	
73-53	14141-14151	Pcorrected	_	
73-54	14152-14153	<	_	
73-55	14154-14158	0.05	_	
73-56	14158-14159	)	_	
73-57	14160-14172	Task-induced	_	
73-58	14173-14181	striatal	_	
73-59	14182-14185	and	_	
73-60	14186-14190	dACC	_	
73-61	14191-14199	activity	_	
73-62	14200-14202	To	_	
73-63	14203-14212	addressed	_	
73-64	14213-14216	the	_	
73-65	14217-14227	functional	_	
73-66	14228-14240	consequences	_	
73-67	14241-14243	of	_	
73-68	14244-14247	the	_	
73-69	14248-14253	above	_	
73-70	14254-14262	GENOTYPE	_	
73-71	14263-14264	×	_	
73-72	14265-14272	SMOKING	_	
73-73	14273-14284	alterations	_	
73-74	14285-14293	relevant	_	
73-75	14294-14296	to	_	
73-76	14297-14305	nicotine	_	
73-77	14306-14316	dependence	_	
73-78	14316-14317	,	_	
73-79	14318-14319	a	_	
73-80	14320-14326	subset	_	
73-81	14327-14329	of	_	
73-82	14330-14337	smokers	_	
73-83	14338-14341	and	_	
73-84	14342-14352	nonsmokers	_	
73-85	14353-14354	(	_	
73-86	14354-14355	n	_	
73-87	14355-14356	=	_	
73-88	14356-14358	43	_	
73-89	14358-14359	)	_	
73-90	14360-14369	performed	_	
73-91	14370-14373	the	_	
73-92	14374-14377	MID	_	
73-93	14378-14384	reward	_	
73-94	14385-14389	task	_	
73-95	14390-14393	and	_	
73-96	14394-14397	the	_	
73-97	14398-14400	Go	_	
73-98	14400-14401	/	_	
73-99	14401-14405	NoGo	_	
73-100	14406-14414	response	_	
73-101	14415-14425	inhibition	_	
73-102	14426-14430	task	_	
73-103	14431-14433	on	_	
73-104	14434-14437	two	_	
73-105	14438-14446	separate	_	
73-106	14447-14456	occasions	_	
73-107	14456-14457	,	_	
73-108	14458-14460	in	_	
73-109	14461-14464	the	_	
73-110	14465-14473	presence	_	
73-111	14474-14477	and	_	
73-112	14478-14485	absence	_	
73-113	14486-14488	of	_	
73-114	14489-14491	an	_	
73-115	14492-14497	acute	_	
73-116	14498-14506	nicotine	_	
73-117	14507-14512	patch	_	
73-118	14512-14513	.	_	

#Text=A standard general linear model (GLM) approach was used in the analysis.
74-1	14514-14515	A	_	
74-2	14516-14524	standard	_	
74-3	14525-14532	general	_	
74-4	14533-14539	linear	_	
74-5	14540-14545	model	_	
74-6	14546-14547	(	_	
74-7	14547-14550	GLM	_	
74-8	14550-14551	)	_	
74-9	14552-14560	approach	_	
74-10	14561-14564	was	_	
74-11	14565-14569	used	_	
74-12	14570-14572	in	_	
74-13	14573-14576	the	_	
74-14	14577-14585	analysis	_	
74-15	14585-14586	.	_	

#Text=MID
#Text=Consistent with previous reports in both healthy individuals and smokers, subjects showed greater VS activation in the anticipatory gain compared with the neutral reward expectation condition (there was no effect in the [loss-neutral] condition).
75-1	14587-14590	MID	_	
75-2	14591-14601	Consistent	_	
75-3	14602-14606	with	_	
75-4	14607-14615	previous	_	
75-5	14616-14623	reports	_	
75-6	14624-14626	in	_	
75-7	14627-14631	both	_	
75-8	14632-14639	healthy	_	
75-9	14640-14651	individuals	_	
75-10	14652-14655	and	_	
75-11	14656-14663	smokers	_	
75-12	14663-14664	,	_	
75-13	14665-14673	subjects	_	
75-14	14674-14680	showed	_	
75-15	14681-14688	greater	_	
75-16	14689-14691	VS	_	
75-17	14692-14702	activation	_	
75-18	14703-14705	in	_	
75-19	14706-14709	the	_	
75-20	14710-14722	anticipatory	_	
75-21	14723-14727	gain	_	
75-22	14728-14736	compared	_	
75-23	14737-14741	with	_	
75-24	14742-14745	the	_	
75-25	14746-14753	neutral	_	
75-26	14754-14760	reward	_	
75-27	14761-14772	expectation	_	
75-28	14773-14782	condition	_	
75-29	14783-14784	(	_	
75-30	14784-14789	there	_	
75-31	14790-14793	was	_	
75-32	14794-14796	no	_	
75-33	14797-14803	effect	_	
75-34	14804-14806	in	_	
75-35	14807-14810	the	_	
75-36	14811-14812	[	_	
75-37	14812-14824	loss-neutral	_	
75-38	14824-14825	]	_	
75-39	14826-14835	condition	_	
75-40	14835-14836	)	_	
75-41	14836-14837	.	_	

#Text=Consistent with the pattern seen in the FCS analysis (Fig. 1), there was a significant GENOTYPE × SMOKING interaction in VS activation in the placebo patch (abstinent) condition such that there was less activation in smokers with the reduced (slow and intermediate) versus normal metabolizing genotype, which was, once again, not seen in nonsmokers (Fig. 3A).
76-1	14838-14848	Consistent	_	
76-2	14849-14853	with	_	
76-3	14854-14857	the	_	
76-4	14858-14865	pattern	_	
76-5	14866-14870	seen	_	
76-6	14871-14873	in	_	
76-7	14874-14877	the	_	
76-8	14878-14881	FCS	_	
76-9	14882-14890	analysis	_	
76-10	14891-14892	(	_	
76-11	14892-14895	Fig	_	
76-12	14895-14896	.	_	
76-13	14897-14898	1	_	
76-14	14898-14899	)	_	
76-15	14899-14900	,	_	
76-16	14901-14906	there	_	
76-17	14907-14910	was	_	
76-18	14911-14912	a	_	
76-19	14913-14924	significant	_	
76-20	14925-14933	GENOTYPE	_	
76-21	14934-14935	×	_	
76-22	14936-14943	SMOKING	_	
76-23	14944-14955	interaction	_	
76-24	14956-14958	in	_	
76-25	14959-14961	VS	_	
76-26	14962-14972	activation	_	
76-27	14973-14975	in	_	
76-28	14976-14979	the	_	
76-29	14980-14987	placebo	_	
76-30	14988-14993	patch	_	
76-31	14994-14995	(	_	
76-32	14995-15004	abstinent	_	
76-33	15004-15005	)	_	
76-34	15006-15015	condition	_	
76-35	15016-15020	such	_	
76-36	15021-15025	that	_	
76-37	15026-15031	there	_	
76-38	15032-15035	was	_	
76-39	15036-15040	less	_	
76-40	15041-15051	activation	_	
76-41	15052-15054	in	_	
76-42	15055-15062	smokers	_	
76-43	15063-15067	with	_	
76-44	15068-15071	the	_	
76-45	15072-15079	reduced	_	
76-46	15080-15081	(	_	
76-47	15081-15085	slow	_	
76-48	15086-15089	and	_	
76-49	15090-15102	intermediate	_	
76-50	15102-15103	)	_	
76-51	15104-15110	versus	_	
76-52	15111-15117	normal	_	
76-53	15118-15130	metabolizing	_	
76-54	15131-15139	genotype	_	
76-55	15139-15140	,	_	
76-56	15141-15146	which	_	
76-57	15147-15150	was	_	
76-58	15150-15151	,	_	
76-59	15152-15156	once	_	
76-60	15157-15162	again	_	
76-61	15162-15163	,	_	
76-62	15164-15167	not	_	
76-63	15168-15172	seen	_	
76-64	15173-15175	in	_	
76-65	15176-15186	nonsmokers	_	
76-66	15187-15188	(	_	
76-67	15188-15191	Fig	_	
76-68	15191-15192	.	_	
76-69	15193-15195	3A	_	
76-70	15195-15196	)	_	
76-71	15196-15197	.	_	

#Text=In contrast, NRT administration appeared to ‘reverse’ the reduced VS response in smokers such that there was now no longer a genotype specific signal difference when anticipating gains.
77-1	15198-15200	In	_	
77-2	15201-15209	contrast	_	
77-3	15209-15210	,	_	
77-4	15211-15214	NRT	_	
77-5	15215-15229	administration	_	
77-6	15230-15238	appeared	_	
77-7	15239-15241	to	_	
77-8	15242-15243	‘	_	
77-9	15243-15250	reverse	_	
77-10	15250-15251	’	_	
77-11	15252-15255	the	_	
77-12	15256-15263	reduced	_	
77-13	15264-15266	VS	_	
77-14	15267-15275	response	_	
77-15	15276-15278	in	_	
77-16	15279-15286	smokers	_	
77-17	15287-15291	such	_	
77-18	15292-15296	that	_	
77-19	15297-15302	there	_	
77-20	15303-15306	was	_	
77-21	15307-15310	now	_	
77-22	15311-15313	no	_	
77-23	15314-15320	longer	_	
77-24	15321-15322	a	_	
77-25	15323-15331	genotype	_	
77-26	15332-15340	specific	_	
77-27	15341-15347	signal	_	
77-28	15348-15358	difference	_	
77-29	15359-15363	when	_	
77-30	15364-15376	anticipating	_	
77-31	15377-15382	gains	_	
77-32	15382-15383	.	_	

#Text=Go/NoGo
#Text=Consistent with that seen in the MID task, smokers with the reduced genotype showed reduced dACC activity during unsuccessful inhibitions (Fig. 3B) when they were in the abstinent state than normal metabolizers.
78-1	15384-15386	Go	_	
78-2	15386-15387	/	_	
78-3	15387-15391	NoGo	_	
78-4	15392-15402	Consistent	_	
78-5	15403-15407	with	_	
78-6	15408-15412	that	_	
78-7	15413-15417	seen	_	
78-8	15418-15420	in	_	
78-9	15421-15424	the	_	
78-10	15425-15428	MID	_	
78-11	15429-15433	task	_	
78-12	15433-15434	,	_	
78-13	15435-15442	smokers	_	
78-14	15443-15447	with	_	
78-15	15448-15451	the	_	
78-16	15452-15459	reduced	_	
78-17	15460-15468	genotype	_	
78-18	15469-15475	showed	_	
78-19	15476-15483	reduced	_	
78-20	15484-15488	dACC	_	
78-21	15489-15497	activity	_	
78-22	15498-15504	during	_	
78-23	15505-15517	unsuccessful	_	
78-24	15518-15529	inhibitions	_	
78-25	15530-15531	(	_	
78-26	15531-15534	Fig	_	
78-27	15534-15535	.	_	
78-28	15536-15538	3B	_	
78-29	15538-15539	)	_	
78-30	15540-15544	when	_	
78-31	15545-15549	they	_	
78-32	15550-15554	were	_	
78-33	15555-15557	in	_	
78-34	15558-15561	the	_	
78-35	15562-15571	abstinent	_	
78-36	15572-15577	state	_	
78-37	15578-15582	than	_	
78-38	15583-15589	normal	_	
78-39	15590-15602	metabolizers	_	
78-40	15602-15603	.	_	

#Text=Acute NRT again appeared to enhance activation in this group up to that of the normal genotype group.
79-1	15604-15609	Acute	_	
79-2	15610-15613	NRT	_	
79-3	15614-15619	again	_	
79-4	15620-15628	appeared	_	
79-5	15629-15631	to	_	
79-6	15632-15639	enhance	_	
79-7	15640-15650	activation	_	
79-8	15651-15653	in	_	
79-9	15654-15658	this	_	
79-10	15659-15664	group	_	
79-11	15665-15667	up	_	
79-12	15668-15670	to	_	
79-13	15671-15675	that	_	
79-14	15676-15678	of	_	
79-15	15679-15682	the	_	
79-16	15683-15689	normal	_	
79-17	15690-15698	genotype	_	
79-18	15699-15704	group	_	
79-19	15704-15705	.	_	

#Text=Consistent with the metabolic role of the CYP enzyme, task activity was enhanced by NRT in nonsmokers, but only in the reduced metabolizers.
80-1	15706-15716	Consistent	_	
80-2	15717-15721	with	_	
80-3	15722-15725	the	_	
80-4	15726-15735	metabolic	_	
80-5	15736-15740	role	_	
80-6	15741-15743	of	_	
80-7	15744-15747	the	_	
80-8	15748-15751	CYP	_	
80-9	15752-15758	enzyme	_	
80-10	15758-15759	,	_	
80-11	15760-15764	task	_	
80-12	15765-15773	activity	_	
80-13	15774-15777	was	_	
80-14	15778-15786	enhanced	_	
80-15	15787-15789	by	_	
80-16	15790-15793	NRT	_	
80-17	15794-15796	in	_	
80-18	15797-15807	nonsmokers	_	
80-19	15807-15808	,	_	
80-20	15809-15812	but	_	
80-21	15813-15817	only	_	
80-22	15818-15820	in	_	
80-23	15821-15824	the	_	
80-24	15825-15832	reduced	_	
80-25	15833-15845	metabolizers	_	
80-26	15845-15846	.	_	

#Text=Finally, there was a main effect of CYP2A6 GENOTYPE in bilateral precentral gyrus and bilateral anterior insula, such that the normal genotype group had higher FCS than those with the slow and intermediate genotypes, regardless of smoking status (Fig. 4 A, C).
81-1	15847-15854	Finally	_	
81-2	15854-15855	,	_	
81-3	15856-15861	there	_	
81-4	15862-15865	was	_	
81-5	15866-15867	a	_	
81-6	15868-15872	main	_	
81-7	15873-15879	effect	_	
81-8	15880-15882	of	_	
81-9	15883-15889	CYP2A6	_	
81-10	15890-15898	GENOTYPE	_	
81-11	15899-15901	in	_	
81-12	15902-15911	bilateral	_	
81-13	15912-15922	precentral	_	
81-14	15923-15928	gyrus	_	
81-15	15929-15932	and	_	
81-16	15933-15942	bilateral	_	
81-17	15943-15951	anterior	_	
81-18	15952-15958	insula	_	
81-19	15958-15959	,	_	
81-20	15960-15964	such	_	
81-21	15965-15969	that	_	
81-22	15970-15973	the	_	
81-23	15974-15980	normal	_	
81-24	15981-15989	genotype	_	
81-25	15990-15995	group	_	
81-26	15996-15999	had	_	
81-27	16000-16006	higher	_	
81-28	16007-16010	FCS	_	
81-29	16011-16015	than	_	
81-30	16016-16021	those	_	
81-31	16022-16026	with	_	
81-32	16027-16030	the	_	
81-33	16031-16035	slow	_	
81-34	16036-16039	and	_	
81-35	16040-16052	intermediate	_	
81-36	16053-16062	genotypes	_	
81-37	16062-16063	,	_	
81-38	16064-16074	regardless	_	
81-39	16075-16077	of	_	
81-40	16078-16085	smoking	_	
81-41	16086-16092	status	_	
81-42	16093-16094	(	_	
81-43	16094-16097	Fig	_	
81-44	16097-16098	.	_	
81-45	16099-16100	4	_	
81-46	16101-16102	A	_	
81-47	16102-16103	,	_	
81-48	16104-16105	C	_	
81-49	16105-16106	)	_	
81-50	16106-16107	.	_	

#Text=There was also a main effect of SMOKING in the bilateral superior temporal gyrus, with smokers showing decreased FCS across the three genotypes (Fig. 4 B, D and Supplemental Table 1).
82-1	16108-16113	There	_	
82-2	16114-16117	was	_	
82-3	16118-16122	also	_	
82-4	16123-16124	a	_	
82-5	16125-16129	main	_	
82-6	16130-16136	effect	_	
82-7	16137-16139	of	_	
82-8	16140-16147	SMOKING	_	
82-9	16148-16150	in	_	
82-10	16151-16154	the	_	
82-11	16155-16164	bilateral	_	
82-12	16165-16173	superior	_	
82-13	16174-16182	temporal	_	
82-14	16183-16188	gyrus	_	
82-15	16188-16189	,	_	
82-16	16190-16194	with	_	
82-17	16195-16202	smokers	_	
82-18	16203-16210	showing	_	
82-19	16211-16220	decreased	_	
82-20	16221-16224	FCS	_	
82-21	16225-16231	across	_	
82-22	16232-16235	the	_	
82-23	16236-16241	three	_	
82-24	16242-16251	genotypes	_	
82-25	16252-16253	(	_	
82-26	16253-16256	Fig	_	
82-27	16256-16257	.	_	
82-28	16258-16259	4	_	
82-29	16260-16261	B	_	
82-30	16261-16262	,	_	
82-31	16263-16264	D	_	
82-32	16265-16268	and	_	
82-33	16269-16281	Supplemental	_	
82-34	16282-16287	Table	_	
82-35	16288-16289	1	_	
82-36	16289-16290	)	_	
82-37	16290-16291	.	_	

#Text=Discussion
#Text=Alterations in the environment can modulate the influence of genetics upon behavioral outcomes, including nicotine addiction.
83-1	16292-16302	Discussion	_	
83-2	16303-16314	Alterations	_	
83-3	16315-16317	in	_	
83-4	16318-16321	the	_	
83-5	16322-16333	environment	_	
83-6	16334-16337	can	_	
83-7	16338-16346	modulate	_	
83-8	16347-16350	the	_	
83-9	16351-16360	influence	_	
83-10	16361-16363	of	_	
83-11	16364-16372	genetics	_	
83-12	16373-16377	upon	_	
83-13	16378-16388	behavioral	_	
83-14	16389-16397	outcomes	_	
83-15	16397-16398	,	_	
83-16	16399-16408	including	_	
83-17	16409-16417	nicotine	_	
83-18	16418-16427	addiction	_	
83-19	16427-16428	.	_	

#Text=Individuals with the slow CYP2A6 genotype, which leads to higher levels and/or longer durations of plasma and brain nicotine after smoking, display distinct smoking behaviors compared to those with the normal genotype, including levels of dependence and quit rates.
84-1	16429-16440	Individuals	_	
84-2	16441-16445	with	_	
84-3	16446-16449	the	_	
84-4	16450-16454	slow	_	
84-5	16455-16461	CYP2A6	_	
84-6	16462-16470	genotype	_	
84-7	16470-16471	,	_	
84-8	16472-16477	which	_	
84-9	16478-16483	leads	_	
84-10	16484-16486	to	_	
84-11	16487-16493	higher	_	
84-12	16494-16500	levels	_	
84-13	16501-16504	and	_	
84-14	16504-16505	/	_	
84-15	16505-16507	or	_	
84-16	16508-16514	longer	_	
84-17	16515-16524	durations	_	
84-18	16525-16527	of	_	
84-19	16528-16534	plasma	_	
84-20	16535-16538	and	_	
84-21	16539-16544	brain	_	
84-22	16545-16553	nicotine	_	
84-23	16554-16559	after	_	
84-24	16560-16567	smoking	_	
84-25	16567-16568	,	_	
84-26	16569-16576	display	_	
84-27	16577-16585	distinct	_	
84-28	16586-16593	smoking	_	
84-29	16594-16603	behaviors	_	
84-30	16604-16612	compared	_	
84-31	16613-16615	to	_	
84-32	16616-16621	those	_	
84-33	16622-16626	with	_	
84-34	16627-16630	the	_	
84-35	16631-16637	normal	_	
84-36	16638-16646	genotype	_	
84-37	16646-16647	,	_	
84-38	16648-16657	including	_	
84-39	16658-16664	levels	_	
84-40	16665-16667	of	_	
84-41	16668-16678	dependence	_	
84-42	16679-16682	and	_	
84-43	16683-16687	quit	_	
84-44	16688-16693	rates	_	
84-45	16693-16694	.	_	

#Text=To understand the neurobiological mechanisms underlying this altered smoking phenotype and in service of potential clinical implications, we examined the effect of CYP2A6, smoking status and their interaction on brain intrinsic functional connectivity and task-induced activity.
85-1	16695-16697	To	_	
85-2	16698-16708	understand	_	
85-3	16709-16712	the	_	
85-4	16713-16728	neurobiological	_	
85-5	16729-16739	mechanisms	_	
85-6	16740-16750	underlying	_	
85-7	16751-16755	this	_	
85-8	16756-16763	altered	_	
85-9	16764-16771	smoking	_	
85-10	16772-16781	phenotype	_	
85-11	16782-16785	and	_	
85-12	16786-16788	in	_	
85-13	16789-16796	service	_	
85-14	16797-16799	of	_	
85-15	16800-16809	potential	_	
85-16	16810-16818	clinical	_	
85-17	16819-16831	implications	_	
85-18	16831-16832	,	_	
85-19	16833-16835	we	_	
85-20	16836-16844	examined	_	
85-21	16845-16848	the	_	
85-22	16849-16855	effect	_	
85-23	16856-16858	of	_	
85-24	16859-16865	CYP2A6	_	
85-25	16865-16866	,	_	
85-26	16867-16874	smoking	_	
85-27	16875-16881	status	_	
85-28	16882-16885	and	_	
85-29	16886-16891	their	_	
85-30	16892-16903	interaction	_	
85-31	16904-16906	on	_	
85-32	16907-16912	brain	_	
85-33	16913-16922	intrinsic	_	
85-34	16923-16933	functional	_	
85-35	16934-16946	connectivity	_	
85-36	16947-16950	and	_	
85-37	16951-16963	task-induced	_	
85-38	16964-16972	activity	_	
85-39	16972-16973	.	_	

#Text=We found that in smokers CYP2A6 modified neuronal circuits involved in computations during the processing of both reward and response inhibition, and critically, does so consistent with the underlying resting network strength, supporting a behaviorally relevant and phenotype specific consequence of this GENOTYPE × SMOKING network interaction.
86-1	16974-16976	We	_	
86-2	16977-16982	found	_	
86-3	16983-16987	that	_	
86-4	16988-16990	in	_	
86-5	16991-16998	smokers	_	
86-6	16999-17005	CYP2A6	_	
86-7	17006-17014	modified	_	
86-8	17015-17023	neuronal	_	
86-9	17024-17032	circuits	_	
86-10	17033-17041	involved	_	
86-11	17042-17044	in	_	
86-12	17045-17057	computations	_	
86-13	17058-17064	during	_	
86-14	17065-17068	the	_	
86-15	17069-17079	processing	_	
86-16	17080-17082	of	_	
86-17	17083-17087	both	_	
86-18	17088-17094	reward	_	
86-19	17095-17098	and	_	
86-20	17099-17107	response	_	
86-21	17108-17118	inhibition	_	
86-22	17118-17119	,	_	
86-23	17120-17123	and	_	
86-24	17124-17134	critically	_	
86-25	17134-17135	,	_	
86-26	17136-17140	does	_	
86-27	17141-17143	so	_	
86-28	17144-17154	consistent	_	
86-29	17155-17159	with	_	
86-30	17160-17163	the	_	
86-31	17164-17174	underlying	_	
86-32	17175-17182	resting	_	
86-33	17183-17190	network	_	
86-34	17191-17199	strength	_	
86-35	17199-17200	,	_	
86-36	17201-17211	supporting	_	
86-37	17212-17213	a	_	
86-38	17214-17226	behaviorally	_	
86-39	17227-17235	relevant	_	
86-40	17236-17239	and	_	
86-41	17240-17249	phenotype	_	
86-42	17250-17258	specific	_	
86-43	17259-17270	consequence	_	
86-44	17271-17273	of	_	
86-45	17274-17278	this	_	
86-46	17279-17287	GENOTYPE	_	
86-47	17288-17289	×	_	
86-48	17290-17297	SMOKING	_	
86-49	17298-17305	network	_	
86-50	17306-17317	interaction	_	
86-51	17317-17318	.	_	

#Text=Using FCS, a data driven, graph theory network metric coupled with a whole brain search, we found significant GENOTYPE × SMOKING interactions localized within two key striatal-cingulate circuit components, the VS and dACC, such that FCS in both regions was highest in the normal metabolizing smokers.
87-1	17319-17324	Using	_	
87-2	17325-17328	FCS	_	
87-3	17328-17329	,	_	
87-4	17330-17331	a	_	
87-5	17332-17336	data	_	
87-6	17337-17343	driven	_	
87-7	17343-17344	,	_	
87-8	17345-17350	graph	_	
87-9	17351-17357	theory	_	
87-10	17358-17365	network	_	
87-11	17366-17372	metric	_	
87-12	17373-17380	coupled	_	
87-13	17381-17385	with	_	
87-14	17386-17387	a	_	
87-15	17388-17393	whole	_	
87-16	17394-17399	brain	_	
87-17	17400-17406	search	_	
87-18	17406-17407	,	_	
87-19	17408-17410	we	_	
87-20	17411-17416	found	_	
87-21	17417-17428	significant	_	
87-22	17429-17437	GENOTYPE	_	
87-23	17438-17439	×	_	
87-24	17440-17447	SMOKING	_	
87-25	17448-17460	interactions	_	
87-26	17461-17470	localized	_	
87-27	17471-17477	within	_	
87-28	17478-17481	two	_	
87-29	17482-17485	key	_	
87-30	17486-17504	striatal-cingulate	_	
87-31	17505-17512	circuit	_	
87-32	17513-17523	components	_	
87-33	17523-17524	,	_	
87-34	17525-17528	the	_	
87-35	17529-17531	VS	_	
87-36	17532-17535	and	_	
87-37	17536-17540	dACC	_	
87-38	17540-17541	,	_	
87-39	17542-17546	such	_	
87-40	17547-17551	that	_	
87-41	17552-17555	FCS	_	
87-42	17556-17558	in	_	
87-43	17559-17563	both	_	
87-44	17564-17571	regions	_	
87-45	17572-17575	was	_	
87-46	17576-17583	highest	_	
87-47	17584-17586	in	_	
87-48	17587-17590	the	_	
87-49	17591-17597	normal	_	
87-50	17598-17610	metabolizing	_	
87-51	17611-17618	smokers	_	
87-52	17618-17619	.	_	

#Text=Further, FCS in both regions was negatively correlated with dependence severity, but only in the slow metabolizing group.
88-1	17620-17627	Further	_	
88-2	17627-17628	,	_	
88-3	17629-17632	FCS	_	
88-4	17633-17635	in	_	
88-5	17636-17640	both	_	
88-6	17641-17648	regions	_	
88-7	17649-17652	was	_	
88-8	17653-17663	negatively	_	
88-9	17664-17674	correlated	_	
88-10	17675-17679	with	_	
88-11	17680-17690	dependence	_	
88-12	17691-17699	severity	_	
88-13	17699-17700	,	_	
88-14	17701-17704	but	_	
88-15	17705-17709	only	_	
88-16	17710-17712	in	_	
88-17	17713-17716	the	_	
88-18	17717-17721	slow	_	
88-19	17722-17734	metabolizing	_	
88-20	17735-17740	group	_	
88-21	17740-17741	.	_	

#Text=Both of these findings are remarkably coincident with those reported previously by our group.
89-1	17742-17746	Both	_	
89-2	17747-17749	of	_	
89-3	17750-17755	these	_	
89-4	17756-17764	findings	_	
89-5	17765-17768	are	_	
89-6	17769-17779	remarkably	_	
89-7	17780-17790	coincident	_	
89-8	17791-17795	with	_	
89-9	17796-17801	those	_	
89-10	17802-17810	reported	_	
89-11	17811-17821	previously	_	
89-12	17822-17824	by	_	
89-13	17825-17828	our	_	
89-14	17829-17834	group	_	
89-15	17834-17835	.	_	

#Text=Using independent data sets and, critically, independent analysis strategies, we previously identified a resting state functional circuit between the dACC and VS that was negatively correlated to FTND and was driven, in part, by the nicotinic alpha 5 subunit polymorphism.
90-1	17836-17841	Using	_	
90-2	17842-17853	independent	_	
90-3	17854-17858	data	_	
90-4	17859-17863	sets	_	
90-5	17864-17867	and	_	
90-6	17867-17868	,	_	
90-7	17869-17879	critically	_	
90-8	17879-17880	,	_	
90-9	17881-17892	independent	_	
90-10	17893-17901	analysis	_	
90-11	17902-17912	strategies	_	
90-12	17912-17913	,	_	
90-13	17914-17916	we	_	
90-14	17917-17927	previously	_	
90-15	17928-17938	identified	_	
90-16	17939-17940	a	_	
90-17	17941-17948	resting	_	
90-18	17949-17954	state	_	
90-19	17955-17965	functional	_	
90-20	17966-17973	circuit	_	
90-21	17974-17981	between	_	
90-22	17982-17985	the	_	
90-23	17986-17990	dACC	_	
90-24	17991-17994	and	_	
90-25	17995-17997	VS	_	
90-26	17998-18002	that	_	
90-27	18003-18006	was	_	
90-28	18007-18017	negatively	_	
90-29	18018-18028	correlated	_	
90-30	18029-18031	to	_	
90-31	18032-18036	FTND	_	
90-32	18037-18040	and	_	
90-33	18041-18044	was	_	
90-34	18045-18051	driven	_	
90-35	18051-18052	,	_	
90-36	18053-18055	in	_	
90-37	18056-18060	part	_	
90-38	18060-18061	,	_	
90-39	18062-18064	by	_	
90-40	18065-18068	the	_	
90-41	18069-18078	nicotinic	_	
90-42	18079-18084	alpha	_	
90-43	18085-18086	5	_	
90-44	18087-18094	subunit	_	
90-45	18095-18107	polymorphism	_	
90-46	18107-18108	.	_	

#Text=The current VS and dACC neuroanatomical findings, and their consistent identification across studies implicate their prominent role in drug dependence.
91-1	18109-18112	The	_	
91-2	18113-18120	current	_	
91-3	18121-18123	VS	_	
91-4	18124-18127	and	_	
91-5	18128-18132	dACC	_	
91-6	18133-18148	neuroanatomical	_	
91-7	18149-18157	findings	_	
91-8	18157-18158	,	_	
91-9	18159-18162	and	_	
91-10	18163-18168	their	_	
91-11	18169-18179	consistent	_	
91-12	18180-18194	identification	_	
91-13	18195-18201	across	_	
91-14	18202-18209	studies	_	
91-15	18210-18219	implicate	_	
91-16	18220-18225	their	_	
91-17	18226-18235	prominent	_	
91-18	18236-18240	role	_	
91-19	18241-18243	in	_	
91-20	18244-18248	drug	_	
91-21	18249-18259	dependence	_	
91-22	18259-18260	.	_	

#Text=Notably, the VS receives dopaminergic input from the mesencephalic VTA, while also getting descending glutamatergic afferents from multiple frontal cortical regions, including the cingulate.
92-1	18261-18268	Notably	_	
92-2	18268-18269	,	_	
92-3	18270-18273	the	_	
92-4	18274-18276	VS	_	
92-5	18277-18285	receives	_	
92-6	18286-18298	dopaminergic	_	
92-7	18299-18304	input	_	
92-8	18305-18309	from	_	
92-9	18310-18313	the	_	
92-10	18314-18327	mesencephalic	_	
92-11	18328-18331	VTA	_	
92-12	18331-18332	,	_	
92-13	18333-18338	while	_	
92-14	18339-18343	also	_	
92-15	18344-18351	getting	_	
92-16	18352-18362	descending	_	
92-17	18363-18376	glutamatergic	_	
92-18	18377-18386	afferents	_	
92-19	18387-18391	from	_	
92-20	18392-18400	multiple	_	
92-21	18401-18408	frontal	_	
92-22	18409-18417	cortical	_	
92-23	18418-18425	regions	_	
92-24	18425-18426	,	_	
92-25	18427-18436	including	_	
92-26	18437-18440	the	_	
92-27	18441-18450	cingulate	_	
92-28	18450-18451	.	_	

#Text=The dopaminergic afferents impart a learning signal that identifies a mismatch between an expected and actual reward, while top-down cortical modulation is thought to provide context to these teaching signals.
93-1	18452-18455	The	_	
93-2	18456-18468	dopaminergic	_	
93-3	18469-18478	afferents	_	
93-4	18479-18485	impart	_	
93-5	18486-18487	a	_	
93-6	18488-18496	learning	_	
93-7	18497-18503	signal	_	
93-8	18504-18508	that	_	
93-9	18509-18519	identifies	_	
93-10	18520-18521	a	_	
93-11	18522-18530	mismatch	_	
93-12	18531-18538	between	_	
93-13	18539-18541	an	_	
93-14	18542-18550	expected	_	
93-15	18551-18554	and	_	
93-16	18555-18561	actual	_	
93-17	18562-18568	reward	_	
93-18	18568-18569	,	_	
93-19	18570-18575	while	_	
93-20	18576-18584	top-down	_	
93-21	18585-18593	cortical	_	
93-22	18594-18604	modulation	_	
93-23	18605-18607	is	_	
93-24	18608-18615	thought	_	
93-25	18616-18618	to	_	
93-26	18619-18626	provide	_	
93-27	18627-18634	context	_	
93-28	18635-18637	to	_	
93-29	18638-18643	these	_	
93-30	18644-18652	teaching	_	
93-31	18653-18660	signals	_	
93-32	18660-18661	.	_	

#Text=Since the VS is activated during reward processing and is differentially activated in smokers vs. nonsmokers during reward or to the presentation of smoking-related cues, we next addressed the functional significance of the resting state G × E FCS VS findings.
94-1	18662-18667	Since	_	
94-2	18668-18671	the	_	
94-3	18672-18674	VS	_	
94-4	18675-18677	is	_	
94-5	18678-18687	activated	_	
94-6	18688-18694	during	_	
94-7	18695-18701	reward	_	
94-8	18702-18712	processing	_	
94-9	18713-18716	and	_	
94-10	18717-18719	is	_	
94-11	18720-18734	differentially	_	
94-12	18735-18744	activated	_	
94-13	18745-18747	in	_	
94-14	18748-18755	smokers	_	
94-15	18756-18758	vs	_	
94-16	18758-18759	.	_	
94-17	18760-18770	nonsmokers	_	
94-18	18771-18777	during	_	
94-19	18778-18784	reward	_	
94-20	18785-18787	or	_	
94-21	18788-18790	to	_	
94-22	18791-18794	the	_	
94-23	18795-18807	presentation	_	
94-24	18808-18810	of	_	
94-25	18811-18826	smoking-related	_	
94-26	18827-18831	cues	_	
94-27	18831-18832	,	_	
94-28	18833-18835	we	_	
94-29	18836-18840	next	_	
94-30	18841-18850	addressed	_	
94-31	18851-18854	the	_	
94-32	18855-18865	functional	_	
94-33	18866-18878	significance	_	
94-34	18879-18881	of	_	
94-35	18882-18885	the	_	
94-36	18886-18893	resting	_	
94-37	18894-18899	state	_	
94-38	18900-18901	G	_	
94-39	18902-18903	×	_	
94-40	18904-18905	E	_	
94-41	18906-18909	FCS	_	
94-42	18910-18912	VS	_	
94-43	18913-18921	findings	_	
94-44	18921-18922	.	_	

#Text=We identified an identical G × E pattern of neuronal activity when anticipating a gain during the MID reward task, i.e. genotype had no effect in nonsmokers, while abstinent smokers with the reduced (vs. normal) CYP2A6 genotype demonstrated less VS activation (Fig 1B & Fig 3A).
95-1	18923-18925	We	_	
95-2	18926-18936	identified	_	
95-3	18937-18939	an	_	
95-4	18940-18949	identical	_	
95-5	18950-18951	G	_	
95-6	18952-18953	×	_	
95-7	18954-18955	E	_	
95-8	18956-18963	pattern	_	
95-9	18964-18966	of	_	
95-10	18967-18975	neuronal	_	
95-11	18976-18984	activity	_	
95-12	18985-18989	when	_	
95-13	18990-19002	anticipating	_	
95-14	19003-19004	a	_	
95-15	19005-19009	gain	_	
95-16	19010-19016	during	_	
95-17	19017-19020	the	_	
95-18	19021-19024	MID	_	
95-19	19025-19031	reward	_	
95-20	19032-19036	task	_	
95-21	19036-19037	,	_	
95-22	19038-19041	i.e	_	
95-23	19041-19042	.	_	
95-24	19043-19051	genotype	_	
95-25	19052-19055	had	_	
95-26	19056-19058	no	_	
95-27	19059-19065	effect	_	
95-28	19066-19068	in	_	
95-29	19069-19079	nonsmokers	_	
95-30	19079-19080	,	_	
95-31	19081-19086	while	_	
95-32	19087-19096	abstinent	_	
95-33	19097-19104	smokers	_	
95-34	19105-19109	with	_	
95-35	19110-19113	the	_	
95-36	19114-19121	reduced	_	
95-37	19122-19123	(	_	
95-38	19123-19125	vs	_	
95-39	19125-19126	.	_	
95-40	19127-19133	normal	_	
95-41	19133-19134	)	_	
95-42	19135-19141	CYP2A6	_	
95-43	19142-19150	genotype	_	
95-44	19151-19163	demonstrated	_	
95-45	19164-19168	less	_	
95-46	19169-19171	VS	_	
95-47	19172-19182	activation	_	
95-48	19183-19184	(	_	
95-49	19184-19187	Fig	_	
95-50	19188-19190	1B	_	
95-51	19191-19192	&	_	
95-52	19193-19196	Fig	_	
95-53	19197-19199	3A	_	
95-54	19199-19200	)	_	
95-55	19200-19201	.	_	

#Text=These data suggest that enhanced brain nicotine concentration as a function of genotype modulated striatal circuit plasticity that is manifest both at rest and during dopamine related neuronal computations of reward anticipation.
96-1	19202-19207	These	_	
96-2	19208-19212	data	_	
96-3	19213-19220	suggest	_	
96-4	19221-19225	that	_	
96-5	19226-19234	enhanced	_	
96-6	19235-19240	brain	_	
96-7	19241-19249	nicotine	_	
96-8	19250-19263	concentration	_	
96-9	19264-19266	as	_	
96-10	19267-19268	a	_	
96-11	19269-19277	function	_	
96-12	19278-19280	of	_	
96-13	19281-19289	genotype	_	
96-14	19290-19299	modulated	_	
96-15	19300-19308	striatal	_	
96-16	19309-19316	circuit	_	
96-17	19317-19327	plasticity	_	
96-18	19328-19332	that	_	
96-19	19333-19335	is	_	
96-20	19336-19344	manifest	_	
96-21	19345-19349	both	_	
96-22	19350-19352	at	_	
96-23	19353-19357	rest	_	
96-24	19358-19361	and	_	
96-25	19362-19368	during	_	
96-26	19369-19377	dopamine	_	
96-27	19378-19385	related	_	
96-28	19386-19394	neuronal	_	
96-29	19395-19407	computations	_	
96-30	19408-19410	of	_	
96-31	19411-19417	reward	_	
96-32	19418-19430	anticipation	_	
96-33	19430-19431	.	_	

#Text=Since FCS in the VS is negatively correlated with FTND in slow metabolizers (Fig 1D), these data suggest that such smokers not only have a smaller reward attribution signal during nicotine absence, perhaps speaking to their more rapid development of nicotine dependence, but also have relatively greater success when in treatment.
97-1	19432-19437	Since	_	
97-2	19438-19441	FCS	_	
97-3	19442-19444	in	_	
97-4	19445-19448	the	_	
97-5	19449-19451	VS	_	
97-6	19452-19454	is	_	
97-7	19455-19465	negatively	_	
97-8	19466-19476	correlated	_	
97-9	19477-19481	with	_	
97-10	19482-19486	FTND	_	
97-11	19487-19489	in	_	
97-12	19490-19494	slow	_	
97-13	19495-19507	metabolizers	_	
97-14	19508-19509	(	_	
97-15	19509-19512	Fig	_	
97-16	19513-19515	1D	_	
97-17	19515-19516	)	_	
97-18	19516-19517	,	_	
97-19	19518-19523	these	_	
97-20	19524-19528	data	_	
97-21	19529-19536	suggest	_	
97-22	19537-19541	that	_	
97-23	19542-19546	such	_	
97-24	19547-19554	smokers	_	
97-25	19555-19558	not	_	
97-26	19559-19563	only	_	
97-27	19564-19568	have	_	
97-28	19569-19570	a	_	
97-29	19571-19578	smaller	_	
97-30	19579-19585	reward	_	
97-31	19586-19597	attribution	_	
97-32	19598-19604	signal	_	
97-33	19605-19611	during	_	
97-34	19612-19620	nicotine	_	
97-35	19621-19628	absence	_	
97-36	19628-19629	,	_	
97-37	19630-19637	perhaps	_	
97-38	19638-19646	speaking	_	
97-39	19647-19649	to	_	
97-40	19650-19655	their	_	
97-41	19656-19660	more	_	
97-42	19661-19666	rapid	_	
97-43	19667-19678	development	_	
97-44	19679-19681	of	_	
97-45	19682-19690	nicotine	_	
97-46	19691-19701	dependence	_	
97-47	19701-19702	,	_	
97-48	19703-19706	but	_	
97-49	19707-19711	also	_	
97-50	19712-19716	have	_	
97-51	19717-19727	relatively	_	
97-52	19728-19735	greater	_	
97-53	19736-19743	success	_	
97-54	19744-19748	when	_	
97-55	19749-19751	in	_	
97-56	19752-19761	treatment	_	
97-57	19761-19762	.	_	

#Text=Notably, our VBM analysis did not demonstrate any G × E differences in GMV, suggesting that the functional alterations seen here were not influenced by underlying gray matter anatomy differences as previously reported in smokers.
98-1	19763-19770	Notably	_	
98-2	19770-19771	,	_	
98-3	19772-19775	our	_	
98-4	19776-19779	VBM	_	
98-5	19780-19788	analysis	_	
98-6	19789-19792	did	_	
98-7	19793-19796	not	_	
98-8	19797-19808	demonstrate	_	
98-9	19809-19812	any	_	
98-10	19813-19814	G	_	
98-11	19815-19816	×	_	
98-12	19817-19818	E	_	
98-13	19819-19830	differences	_	
98-14	19831-19833	in	_	
98-15	19834-19837	GMV	_	
98-16	19837-19838	,	_	
98-17	19839-19849	suggesting	_	
98-18	19850-19854	that	_	
98-19	19855-19858	the	_	
98-20	19859-19869	functional	_	
98-21	19870-19881	alterations	_	
98-22	19882-19886	seen	_	
98-23	19887-19891	here	_	
98-24	19892-19896	were	_	
98-25	19897-19900	not	_	
98-26	19901-19911	influenced	_	
98-27	19912-19914	by	_	
98-28	19915-19925	underlying	_	
98-29	19926-19930	gray	_	
98-30	19931-19937	matter	_	
98-31	19938-19945	anatomy	_	
98-32	19946-19957	differences	_	
98-33	19958-19960	as	_	
98-34	19961-19971	previously	_	
98-35	19972-19980	reported	_	
98-36	19981-19983	in	_	
98-37	19984-19991	smokers	_	
98-38	19991-19992	.	_	

#Text=The coherence of both the resting and task data is consistent with the well-known linkage between resting connectivity strength, task activity and behavioral performance.
99-1	19993-19996	The	_	
99-2	19997-20006	coherence	_	
99-3	20007-20009	of	_	
99-4	20010-20014	both	_	
99-5	20015-20018	the	_	
99-6	20019-20026	resting	_	
99-7	20027-20030	and	_	
99-8	20031-20035	task	_	
99-9	20036-20040	data	_	
99-10	20041-20043	is	_	
99-11	20044-20054	consistent	_	
99-12	20055-20059	with	_	
99-13	20060-20063	the	_	
99-14	20064-20074	well-known	_	
99-15	20075-20082	linkage	_	
99-16	20083-20090	between	_	
99-17	20091-20098	resting	_	
99-18	20099-20111	connectivity	_	
99-19	20112-20120	strength	_	
99-20	20120-20121	,	_	
99-21	20122-20126	task	_	
99-22	20127-20135	activity	_	
99-23	20136-20139	and	_	
99-24	20140-20150	behavioral	_	
99-25	20151-20162	performance	_	
99-26	20162-20163	.	_	

#Text=Reduced inhibitory control with diminished action monitoring, which is most often localized to the ACC, and diminished responsivity to one’s errors, represent an executive function profile of addiction that may, at least in part, serve to speed the initiation and perhaps prolong the maintenance of dependence.
100-1	20164-20171	Reduced	_	
100-2	20172-20182	inhibitory	_	
100-3	20183-20190	control	_	
100-4	20191-20195	with	_	
100-5	20196-20206	diminished	_	
100-6	20207-20213	action	_	
100-7	20214-20224	monitoring	_	
100-8	20224-20225	,	_	
100-9	20226-20231	which	_	
100-10	20232-20234	is	_	
100-11	20235-20239	most	_	
100-12	20240-20245	often	_	
100-13	20246-20255	localized	_	
100-14	20256-20258	to	_	
100-15	20259-20262	the	_	
100-16	20263-20266	ACC	_	
100-17	20266-20267	,	_	
100-18	20268-20271	and	_	
100-19	20272-20282	diminished	_	
100-20	20283-20295	responsivity	_	
100-21	20296-20298	to	_	
100-22	20299-20302	one	_	
100-23	20302-20303	’	_	
100-24	20303-20304	s	_	
100-25	20305-20311	errors	_	
100-26	20311-20312	,	_	
100-27	20313-20322	represent	_	
100-28	20323-20325	an	_	
100-29	20326-20335	executive	_	
100-30	20336-20344	function	_	
100-31	20345-20352	profile	_	
100-32	20353-20355	of	_	
100-33	20356-20365	addiction	_	
100-34	20366-20370	that	_	
100-35	20371-20374	may	_	
100-36	20374-20375	,	_	
100-37	20376-20378	at	_	
100-38	20379-20384	least	_	
100-39	20385-20387	in	_	
100-40	20388-20392	part	_	
100-41	20392-20393	,	_	
100-42	20394-20399	serve	_	
100-43	20400-20402	to	_	
100-44	20403-20408	speed	_	
100-45	20409-20412	the	_	
100-46	20413-20423	initiation	_	
100-47	20424-20427	and	_	
100-48	20428-20435	perhaps	_	
100-49	20436-20443	prolong	_	
100-50	20444-20447	the	_	
100-51	20448-20459	maintenance	_	
100-52	20460-20462	of	_	
100-53	20463-20473	dependence	_	
100-54	20473-20474	.	_	

#Text=Reduced metabolizing smokers, but critically not nonsmokers, demonstrated smaller dACC activation when making errors during a response inhibition task, similar to that previously reported in cocaine users.
101-1	20475-20482	Reduced	_	
101-2	20483-20495	metabolizing	_	
101-3	20496-20503	smokers	_	
101-4	20503-20504	,	_	
101-5	20505-20508	but	_	
101-6	20509-20519	critically	_	
101-7	20520-20523	not	_	
101-8	20524-20534	nonsmokers	_	
101-9	20534-20535	,	_	
101-10	20536-20548	demonstrated	_	
101-11	20549-20556	smaller	_	
101-12	20557-20561	dACC	_	
101-13	20562-20572	activation	_	
101-14	20573-20577	when	_	
101-15	20578-20584	making	_	
101-16	20585-20591	errors	_	
101-17	20592-20598	during	_	
101-18	20599-20600	a	_	
101-19	20601-20609	response	_	
101-20	20610-20620	inhibition	_	
101-21	20621-20625	task	_	
101-22	20625-20626	,	_	
101-23	20627-20634	similar	_	
101-24	20635-20637	to	_	
101-25	20638-20642	that	_	
101-26	20643-20653	previously	_	
101-27	20654-20662	reported	_	
101-28	20663-20665	in	_	
101-29	20666-20673	cocaine	_	
101-30	20674-20679	users	_	
101-31	20679-20680	.	_	

#Text=That this profile was only seen in reduced metabolizers suggests that such dysregulated neuronal processing does not predate the development of nicotine addiction but may rather be the consequence of chronic nicotine use.
102-1	20681-20685	That	_	
102-2	20686-20690	this	_	
102-3	20691-20698	profile	_	
102-4	20699-20702	was	_	
102-5	20703-20707	only	_	
102-6	20708-20712	seen	_	
102-7	20713-20715	in	_	
102-8	20716-20723	reduced	_	
102-9	20724-20736	metabolizers	_	
102-10	20737-20745	suggests	_	
102-11	20746-20750	that	_	
102-12	20751-20755	such	_	
102-13	20756-20768	dysregulated	_	
102-14	20769-20777	neuronal	_	
102-15	20778-20788	processing	_	
102-16	20789-20793	does	_	
102-17	20794-20797	not	_	
102-18	20798-20805	predate	_	
102-19	20806-20809	the	_	
102-20	20810-20821	development	_	
102-21	20822-20824	of	_	
102-22	20825-20833	nicotine	_	
102-23	20834-20843	addiction	_	
102-24	20844-20847	but	_	
102-25	20848-20851	may	_	
102-26	20852-20858	rather	_	
102-27	20859-20861	be	_	
102-28	20862-20865	the	_	
102-29	20866-20877	consequence	_	
102-30	20878-20880	of	_	
102-31	20881-20888	chronic	_	
102-32	20889-20897	nicotine	_	
102-33	20898-20901	use	_	
102-34	20901-20902	.	_	

#Text=That acute nicotine administration (in our case, NRT) appears to reverse or ‘normalize’ this reduction in processing in both the dACC and the VS suggests a mechanism wherein acute nicotine intake serves to reduce cognitive deficits and potentiate the addiction.
103-1	20903-20907	That	_	
103-2	20908-20913	acute	_	
103-3	20914-20922	nicotine	_	
103-4	20923-20937	administration	_	
103-5	20938-20939	(	_	
103-6	20939-20941	in	_	
103-7	20942-20945	our	_	
103-8	20946-20950	case	_	
103-9	20950-20951	,	_	
103-10	20952-20955	NRT	_	
103-11	20955-20956	)	_	
103-12	20957-20964	appears	_	
103-13	20965-20967	to	_	
103-14	20968-20975	reverse	_	
103-15	20976-20978	or	_	
103-16	20979-20980	‘	_	
103-17	20980-20989	normalize	_	
103-18	20989-20990	’	_	
103-19	20991-20995	this	_	
103-20	20996-21005	reduction	_	
103-21	21006-21008	in	_	
103-22	21009-21019	processing	_	
103-23	21020-21022	in	_	
103-24	21023-21027	both	_	
103-25	21028-21031	the	_	
103-26	21032-21036	dACC	_	
103-27	21037-21040	and	_	
103-28	21041-21044	the	_	
103-29	21045-21047	VS	_	
103-30	21048-21056	suggests	_	
103-31	21057-21058	a	_	
103-32	21059-21068	mechanism	_	
103-33	21069-21076	wherein	_	
103-34	21077-21082	acute	_	
103-35	21083-21091	nicotine	_	
103-36	21092-21098	intake	_	
103-37	21099-21105	serves	_	
103-38	21106-21108	to	_	
103-39	21109-21115	reduce	_	
103-40	21116-21125	cognitive	_	
103-41	21126-21134	deficits	_	
103-42	21135-21138	and	_	
103-43	21139-21149	potentiate	_	
103-44	21150-21153	the	_	
103-45	21154-21163	addiction	_	
103-46	21163-21164	.	_	

#Text=That said, since slow metabolizers also have higher quit rates when in treatment, our data encourage aggressive treatment intervention.
104-1	21165-21169	That	_	
104-2	21170-21174	said	_	
104-3	21174-21175	,	_	
104-4	21176-21181	since	_	
104-5	21182-21186	slow	_	
104-6	21187-21199	metabolizers	_	
104-7	21200-21204	also	_	
104-8	21205-21209	have	_	
104-9	21210-21216	higher	_	
104-10	21217-21221	quit	_	
104-11	21222-21227	rates	_	
104-12	21228-21232	when	_	
104-13	21233-21235	in	_	
104-14	21236-21245	treatment	_	
104-15	21245-21246	,	_	
104-16	21247-21250	our	_	
104-17	21251-21255	data	_	
104-18	21256-21265	encourage	_	
104-19	21266-21276	aggressive	_	
104-20	21277-21286	treatment	_	
104-21	21287-21299	intervention	_	
104-22	21299-21300	.	_	

#Text=The differences in nicotine PK between slow and normal metabolizers may be directly responsible for differences between genotype smoking patterns (CPD and depth of inhalation), and presumably result in differential receptor signaling and the neuroplasticity observed herein.
105-1	21301-21304	The	_	
105-2	21305-21316	differences	_	
105-3	21317-21319	in	_	
105-4	21320-21328	nicotine	_	
105-5	21329-21331	PK	_	
105-6	21332-21339	between	_	
105-7	21340-21344	slow	_	
105-8	21345-21348	and	_	
105-9	21349-21355	normal	_	
105-10	21356-21368	metabolizers	_	
105-11	21369-21372	may	_	
105-12	21373-21375	be	_	
105-13	21376-21384	directly	_	
105-14	21385-21396	responsible	_	
105-15	21397-21400	for	_	
105-16	21401-21412	differences	_	
105-17	21413-21420	between	_	
105-18	21421-21429	genotype	_	
105-19	21430-21437	smoking	_	
105-20	21438-21446	patterns	_	
105-21	21447-21448	(	_	
105-22	21448-21451	CPD	_	
105-23	21452-21455	and	_	
105-24	21456-21461	depth	_	
105-25	21462-21464	of	_	
105-26	21465-21475	inhalation	_	
105-27	21475-21476	)	_	
105-28	21476-21477	,	_	
105-29	21478-21481	and	_	
105-30	21482-21492	presumably	_	
105-31	21493-21499	result	_	
105-32	21500-21502	in	_	
105-33	21503-21515	differential	_	
105-34	21516-21524	receptor	_	
105-35	21525-21534	signaling	_	
105-36	21535-21538	and	_	
105-37	21539-21542	the	_	
105-38	21543-21558	neuroplasticity	_	
105-39	21559-21567	observed	_	
105-40	21568-21574	herein	_	
105-41	21574-21575	.	_	

#Text=In contrast, during the initiation of smoking, the metabolically induced altered PK may have resulted in differential receptor signaling and neuroplasticity, which in turn altered smoking behaviors.
106-1	21576-21578	In	_	
106-2	21579-21587	contrast	_	
106-3	21587-21588	,	_	
106-4	21589-21595	during	_	
106-5	21596-21599	the	_	
106-6	21600-21610	initiation	_	
106-7	21611-21613	of	_	
106-8	21614-21621	smoking	_	
106-9	21621-21622	,	_	
106-10	21623-21626	the	_	
106-11	21627-21640	metabolically	_	
106-12	21641-21648	induced	_	
106-13	21649-21656	altered	_	
106-14	21657-21659	PK	_	
106-15	21660-21663	may	_	
106-16	21664-21668	have	_	
106-17	21669-21677	resulted	_	
106-18	21678-21680	in	_	
106-19	21681-21693	differential	_	
106-20	21694-21702	receptor	_	
106-21	21703-21712	signaling	_	
106-22	21713-21716	and	_	
106-23	21717-21732	neuroplasticity	_	
106-24	21732-21733	,	_	
106-25	21734-21739	which	_	
106-26	21740-21742	in	_	
106-27	21743-21747	turn	_	
106-28	21748-21755	altered	_	
106-29	21756-21763	smoking	_	
106-30	21764-21773	behaviors	_	
106-31	21773-21774	.	_	

#Text=Though not easy to disambiguate, these alternatives from the current design, extant data support the latter model.
107-1	21775-21781	Though	_	
107-2	21782-21785	not	_	
107-3	21786-21790	easy	_	
107-4	21791-21793	to	_	
107-5	21794-21806	disambiguate	_	
107-6	21806-21807	,	_	
107-7	21808-21813	these	_	
107-8	21814-21826	alternatives	_	
107-9	21827-21831	from	_	
107-10	21832-21835	the	_	
107-11	21836-21843	current	_	
107-12	21844-21850	design	_	
107-13	21850-21851	,	_	
107-14	21852-21858	extant	_	
107-15	21859-21863	data	_	
107-16	21864-21871	support	_	
107-17	21872-21875	the	_	
107-18	21876-21882	latter	_	
107-19	21883-21888	model	_	
107-20	21888-21889	.	_	

#Text=There is a 3.2 hazard ratio increased risk for conversion to tobacco dependence in adolescent slow relative to normal metabolizers, and as there is no evidence of titration of cigarette consumption before dependence, this suggests a change in receptor activation among nicotine smokers, resulting in differential response and neurotransmitter release leading to elevated risk for converting to dependence.
108-1	21890-21895	There	_	
108-2	21896-21898	is	_	
108-3	21899-21900	a	_	
108-4	21901-21904	3.2	_	
108-5	21905-21911	hazard	_	
108-6	21912-21917	ratio	_	
108-7	21918-21927	increased	_	
108-8	21928-21932	risk	_	
108-9	21933-21936	for	_	
108-10	21937-21947	conversion	_	
108-11	21948-21950	to	_	
108-12	21951-21958	tobacco	_	
108-13	21959-21969	dependence	_	
108-14	21970-21972	in	_	
108-15	21973-21983	adolescent	_	
108-16	21984-21988	slow	_	
108-17	21989-21997	relative	_	
108-18	21998-22000	to	_	
108-19	22001-22007	normal	_	
108-20	22008-22020	metabolizers	_	
108-21	22020-22021	,	_	
108-22	22022-22025	and	_	
108-23	22026-22028	as	_	
108-24	22029-22034	there	_	
108-25	22035-22037	is	_	
108-26	22038-22040	no	_	
108-27	22041-22049	evidence	_	
108-28	22050-22052	of	_	
108-29	22053-22062	titration	_	
108-30	22063-22065	of	_	
108-31	22066-22075	cigarette	_	
108-32	22076-22087	consumption	_	
108-33	22088-22094	before	_	
108-34	22095-22105	dependence	_	
108-35	22105-22106	,	_	
108-36	22107-22111	this	_	
108-37	22112-22120	suggests	_	
108-38	22121-22122	a	_	
108-39	22123-22129	change	_	
108-40	22130-22132	in	_	
108-41	22133-22141	receptor	_	
108-42	22142-22152	activation	_	
108-43	22153-22158	among	_	
108-44	22159-22167	nicotine	_	
108-45	22168-22175	smokers	_	
108-46	22175-22176	,	_	
108-47	22177-22186	resulting	_	
108-48	22187-22189	in	_	
108-49	22190-22202	differential	_	
108-50	22203-22211	response	_	
108-51	22212-22215	and	_	
108-52	22216-22232	neurotransmitter	_	
108-53	22233-22240	release	_	
108-54	22241-22248	leading	_	
108-55	22249-22251	to	_	
108-56	22252-22260	elevated	_	
108-57	22261-22265	risk	_	
108-58	22266-22269	for	_	
108-59	22270-22280	converting	_	
108-60	22281-22283	to	_	
108-61	22284-22294	dependence	_	
108-62	22294-22295	.	_	

#Text=As the rates of nicotine inactivation are the same among adolescence and adult smokers, the very low levels of smoking in slow smokers (4.2 versus 1.8 CPD) are not easily compatible with models of nicotine titration based on PK differences alone.
109-1	22296-22298	As	_	
109-2	22299-22302	the	_	
109-3	22303-22308	rates	_	
109-4	22309-22311	of	_	
109-5	22312-22320	nicotine	_	
109-6	22321-22333	inactivation	_	
109-7	22334-22337	are	_	
109-8	22338-22341	the	_	
109-9	22342-22346	same	_	
109-10	22347-22352	among	_	
109-11	22353-22364	adolescence	_	
109-12	22365-22368	and	_	
109-13	22369-22374	adult	_	
109-14	22375-22382	smokers	_	
109-15	22382-22383	,	_	
109-16	22384-22387	the	_	
109-17	22388-22392	very	_	
109-18	22393-22396	low	_	
109-19	22397-22403	levels	_	
109-20	22404-22406	of	_	
109-21	22407-22414	smoking	_	
109-22	22415-22417	in	_	
109-23	22418-22422	slow	_	
109-24	22423-22430	smokers	_	
109-25	22431-22432	(	_	
109-26	22432-22435	4.2	_	
109-27	22436-22442	versus	_	
109-28	22443-22446	1.8	_	
109-29	22447-22450	CPD	_	
109-30	22450-22451	)	_	
109-31	22452-22455	are	_	
109-32	22456-22459	not	_	
109-33	22460-22466	easily	_	
109-34	22467-22477	compatible	_	
109-35	22478-22482	with	_	
109-36	22483-22489	models	_	
109-37	22490-22492	of	_	
109-38	22493-22501	nicotine	_	
109-39	22502-22511	titration	_	
109-40	22512-22517	based	_	
109-41	22518-22520	on	_	
109-42	22521-22523	PK	_	
109-43	22524-22535	differences	_	
109-44	22536-22541	alone	_	
109-45	22541-22542	.	_	

#Text=Examination in those smokers who are not yet dependent might tease apart the PK causal relationship between neurochemical changes and smoking behavioral differences among CYP2A6 genotypes.
110-1	22543-22554	Examination	_	
110-2	22555-22557	in	_	
110-3	22558-22563	those	_	
110-4	22564-22571	smokers	_	
110-5	22572-22575	who	_	
110-6	22576-22579	are	_	
110-7	22580-22583	not	_	
110-8	22584-22587	yet	_	
110-9	22588-22597	dependent	_	
110-10	22598-22603	might	_	
110-11	22604-22609	tease	_	
110-12	22610-22615	apart	_	
110-13	22616-22619	the	_	
110-14	22620-22622	PK	_	
110-15	22623-22629	causal	_	
110-16	22630-22642	relationship	_	
110-17	22643-22650	between	_	
110-18	22651-22664	neurochemical	_	
110-19	22665-22672	changes	_	
110-20	22673-22676	and	_	
110-21	22677-22684	smoking	_	
110-22	22685-22695	behavioral	_	
110-23	22696-22707	differences	_	
110-24	22708-22713	among	_	
110-25	22714-22720	CYP2A6	_	
110-26	22721-22730	genotypes	_	
110-27	22730-22731	.	_	

#Text=The FCS method identifies voxels in the brain that have the greatest connectivity to other brain regions, which can be conceptualized as forming neurocircuit hubs that integrate diverse informational sources.
111-1	22732-22735	The	_	
111-2	22736-22739	FCS	_	
111-3	22740-22746	method	_	
111-4	22747-22757	identifies	_	
111-5	22758-22764	voxels	_	
111-6	22765-22767	in	_	
111-7	22768-22771	the	_	
111-8	22772-22777	brain	_	
111-9	22778-22782	that	_	
111-10	22783-22787	have	_	
111-11	22788-22791	the	_	
111-12	22792-22800	greatest	_	
111-13	22801-22813	connectivity	_	
111-14	22814-22816	to	_	
111-15	22817-22822	other	_	
111-16	22823-22828	brain	_	
111-17	22829-22836	regions	_	
111-18	22836-22837	,	_	
111-19	22838-22843	which	_	
111-20	22844-22847	can	_	
111-21	22848-22850	be	_	
111-22	22851-22865	conceptualized	_	
111-23	22866-22868	as	_	
111-24	22869-22876	forming	_	
111-25	22877-22889	neurocircuit	_	
111-26	22890-22894	hubs	_	
111-27	22895-22899	that	_	
111-28	22900-22909	integrate	_	
111-29	22910-22917	diverse	_	
111-30	22918-22931	informational	_	
111-31	22932-22939	sources	_	
111-32	22939-22940	.	_	

#Text=Aberrant connections to and from or within such hubs may indicate dysregulation across multiple cognitive domains that underlie neuropsychiatric diseases.
112-1	22941-22949	Aberrant	_	
112-2	22950-22961	connections	_	
112-3	22962-22964	to	_	
112-4	22965-22968	and	_	
112-5	22969-22973	from	_	
112-6	22974-22976	or	_	
112-7	22977-22983	within	_	
112-8	22984-22988	such	_	
112-9	22989-22993	hubs	_	
112-10	22994-22997	may	_	
112-11	22998-23006	indicate	_	
112-12	23007-23020	dysregulation	_	
112-13	23021-23027	across	_	
112-14	23028-23036	multiple	_	
112-15	23037-23046	cognitive	_	
112-16	23047-23054	domains	_	
112-17	23055-23059	that	_	
112-18	23060-23068	underlie	_	
112-19	23069-23085	neuropsychiatric	_	
112-20	23086-23094	diseases	_	
112-21	23094-23095	.	_	

#Text=Using the FCS identified hubs as seeds in independent functional connectivity analyzes, we identified circuit linkages between bilateral insula, dACC, and posterior cingulate cortex that underlie the dACC alteration, while insula and dACC constituted circuit linkage alterations between the VS hub.
113-1	23096-23101	Using	_	
113-2	23102-23105	the	_	
113-3	23106-23109	FCS	_	
113-4	23110-23120	identified	_	
113-5	23121-23125	hubs	_	
113-6	23126-23128	as	_	
113-7	23129-23134	seeds	_	
113-8	23135-23137	in	_	
113-9	23138-23149	independent	_	
113-10	23150-23160	functional	_	
113-11	23161-23173	connectivity	_	
113-12	23174-23182	analyzes	_	
113-13	23182-23183	,	_	
113-14	23184-23186	we	_	
113-15	23187-23197	identified	_	
113-16	23198-23205	circuit	_	
113-17	23206-23214	linkages	_	
113-18	23215-23222	between	_	
113-19	23223-23232	bilateral	_	
113-20	23233-23239	insula	_	
113-21	23239-23240	,	_	
113-22	23241-23245	dACC	_	
113-23	23245-23246	,	_	
113-24	23247-23250	and	_	
113-25	23251-23260	posterior	_	
113-26	23261-23270	cingulate	_	
113-27	23271-23277	cortex	_	
113-28	23278-23282	that	_	
113-29	23283-23291	underlie	_	
113-30	23292-23295	the	_	
113-31	23296-23300	dACC	_	
113-32	23301-23311	alteration	_	
113-33	23311-23312	,	_	
113-34	23313-23318	while	_	
113-35	23319-23325	insula	_	
113-36	23326-23329	and	_	
113-37	23330-23334	dACC	_	
113-38	23335-23346	constituted	_	
113-39	23347-23354	circuit	_	
113-40	23355-23362	linkage	_	
113-41	23363-23374	alterations	_	
113-42	23375-23382	between	_	
113-43	23383-23386	the	_	
113-44	23387-23389	VS	_	
113-45	23390-23393	hub	_	
113-46	23393-23394	.	_	

#Text=Together the dACC, insula and VS form the key components of the salience network (SN), which is thought to link the current homeostatic state of the organism with other brain networks to facilitate appropriate, adaptive responding.
114-1	23395-23403	Together	_	
114-2	23404-23407	the	_	
114-3	23408-23412	dACC	_	
114-4	23412-23413	,	_	
114-5	23414-23420	insula	_	
114-6	23421-23424	and	_	
114-7	23425-23427	VS	_	
114-8	23428-23432	form	_	
114-9	23433-23436	the	_	
114-10	23437-23440	key	_	
114-11	23441-23451	components	_	
114-12	23452-23454	of	_	
114-13	23455-23458	the	_	
114-14	23459-23467	salience	_	
114-15	23468-23475	network	_	
114-16	23476-23477	(	_	
114-17	23477-23479	SN	_	
114-18	23479-23480	)	_	
114-19	23480-23481	,	_	
114-20	23482-23487	which	_	
114-21	23488-23490	is	_	
114-22	23491-23498	thought	_	
114-23	23499-23501	to	_	
114-24	23502-23506	link	_	
114-25	23507-23510	the	_	
114-26	23511-23518	current	_	
114-27	23519-23530	homeostatic	_	
114-28	23531-23536	state	_	
114-29	23537-23539	of	_	
114-30	23540-23543	the	_	
114-31	23544-23552	organism	_	
114-32	23553-23557	with	_	
114-33	23558-23563	other	_	
114-34	23564-23569	brain	_	
114-35	23570-23578	networks	_	
114-36	23579-23581	to	_	
114-37	23582-23592	facilitate	_	
114-38	23593-23604	appropriate	_	
114-39	23604-23605	,	_	
114-40	23606-23614	adaptive	_	
114-41	23615-23625	responding	_	
114-42	23625-23626	.	_	

#Text=Sutherland et al proposed a model linking the SN, default-mode network (DMN) and executive control network (ECN) for such adaptive responding in smokers such that the strength of the internetwork linkage varied as a function of smoking status, with acute abstinence strengthening the SN – DMN linkage, to the detriment of the SN-ECN.
115-1	23627-23637	Sutherland	_	
115-2	23638-23640	et	_	
115-3	23641-23643	al	_	
115-4	23644-23652	proposed	_	
115-5	23653-23654	a	_	
115-6	23655-23660	model	_	
115-7	23661-23668	linking	_	
115-8	23669-23672	the	_	
115-9	23673-23675	SN	_	
115-10	23675-23676	,	_	
115-11	23677-23689	default-mode	_	
115-12	23690-23697	network	_	
115-13	23698-23699	(	_	
115-14	23699-23702	DMN	_	
115-15	23702-23703	)	_	
115-16	23704-23707	and	_	
115-17	23708-23717	executive	_	
115-18	23718-23725	control	_	
115-19	23726-23733	network	_	
115-20	23734-23735	(	_	
115-21	23735-23738	ECN	_	
115-22	23738-23739	)	_	
115-23	23740-23743	for	_	
115-24	23744-23748	such	_	
115-25	23749-23757	adaptive	_	
115-26	23758-23768	responding	_	
115-27	23769-23771	in	_	
115-28	23772-23779	smokers	_	
115-29	23780-23784	such	_	
115-30	23785-23789	that	_	
115-31	23790-23793	the	_	
115-32	23794-23802	strength	_	
115-33	23803-23805	of	_	
115-34	23806-23809	the	_	
115-35	23810-23822	internetwork	_	
115-36	23823-23830	linkage	_	
115-37	23831-23837	varied	_	
115-38	23838-23840	as	_	
115-39	23841-23842	a	_	
115-40	23843-23851	function	_	
115-41	23852-23854	of	_	
115-42	23855-23862	smoking	_	
115-43	23863-23869	status	_	
115-44	23869-23870	,	_	
115-45	23871-23875	with	_	
115-46	23876-23881	acute	_	
115-47	23882-23892	abstinence	_	
115-48	23893-23906	strengthening	_	
115-49	23907-23910	the	_	
115-50	23911-23913	SN	_	
115-51	23914-23915	–	_	
115-52	23916-23919	DMN	_	
115-53	23920-23927	linkage	_	
115-54	23927-23928	,	_	
115-55	23929-23931	to	_	
115-56	23932-23935	the	_	
115-57	23936-23945	detriment	_	
115-58	23946-23948	of	_	
115-59	23949-23952	the	_	
115-60	23953-23959	SN-ECN	_	
115-61	23959-23960	.	_	

#Text=Recent empirical evidence supports this model, with SN - DMN strength correlated with enhanced craving and reduced working memory performance in abstinence vs. sated smoking.
116-1	23961-23967	Recent	_	
116-2	23968-23977	empirical	_	
116-3	23978-23986	evidence	_	
116-4	23987-23995	supports	_	
116-5	23996-24000	this	_	
116-6	24001-24006	model	_	
116-7	24006-24007	,	_	
116-8	24008-24012	with	_	
116-9	24013-24015	SN	_	
116-10	24016-24017	-	_	
116-11	24018-24021	DMN	_	
116-12	24022-24030	strength	_	
116-13	24031-24041	correlated	_	
116-14	24042-24046	with	_	
116-15	24047-24055	enhanced	_	
116-16	24056-24063	craving	_	
116-17	24064-24067	and	_	
116-18	24068-24075	reduced	_	
116-19	24076-24083	working	_	
116-20	24084-24090	memory	_	
116-21	24091-24102	performance	_	
116-22	24103-24105	in	_	
116-23	24106-24116	abstinence	_	
116-24	24117-24119	vs	_	
116-25	24119-24120	.	_	
116-26	24121-24126	sated	_	
116-27	24127-24134	smoking	_	
116-28	24134-24135	.	_	

#Text=Consistently, NRT administration in the current study enhanced task induced VS and dACC activation in both genotype groups of smokers.
117-1	24136-24148	Consistently	_	
117-2	24148-24149	,	_	
117-3	24150-24153	NRT	_	
117-4	24154-24168	administration	_	
117-5	24169-24171	in	_	
117-6	24172-24175	the	_	
117-7	24176-24183	current	_	
117-8	24184-24189	study	_	
117-9	24190-24198	enhanced	_	
117-10	24199-24203	task	_	
117-11	24204-24211	induced	_	
117-12	24212-24214	VS	_	
117-13	24215-24218	and	_	
117-14	24219-24223	dACC	_	
117-15	24224-24234	activation	_	
117-16	24235-24237	in	_	
117-17	24238-24242	both	_	
117-18	24243-24251	genotype	_	
117-19	24252-24258	groups	_	
117-20	24259-24261	of	_	
117-21	24262-24269	smokers	_	
117-22	24269-24270	.	_	

#Text=The current findings have clear implications for smoking cessation.
118-1	24271-24274	The	_	
118-2	24275-24282	current	_	
118-3	24283-24291	findings	_	
118-4	24292-24296	have	_	
118-5	24297-24302	clear	_	
118-6	24303-24315	implications	_	
118-7	24316-24319	for	_	
118-8	24320-24327	smoking	_	
118-9	24328-24337	cessation	_	
118-10	24337-24338	.	_	

#Text=Since the nicotine half-life in slow metabolizers is about 50% greater than in normal metabolizers (169 vs 113 minutes), within a day or so of cessation, all of the nicotine in both genotype groups is cleared from the body.
119-1	24339-24344	Since	_	
119-2	24345-24348	the	_	
119-3	24349-24357	nicotine	_	
119-4	24358-24367	half-life	_	
119-5	24368-24370	in	_	
119-6	24371-24375	slow	_	
119-7	24376-24388	metabolizers	_	
119-8	24389-24391	is	_	
119-9	24392-24397	about	_	
119-10	24398-24401	50%	_	
119-11	24402-24409	greater	_	
119-12	24410-24414	than	_	
119-13	24415-24417	in	_	
119-14	24418-24424	normal	_	
119-15	24425-24437	metabolizers	_	
119-16	24438-24439	(	_	
119-17	24439-24442	169	_	
119-18	24443-24445	vs	_	
119-19	24446-24449	113	_	
119-20	24450-24457	minutes	_	
119-21	24457-24458	)	_	
119-22	24458-24459	,	_	
119-23	24460-24466	within	_	
119-24	24467-24468	a	_	
119-25	24469-24472	day	_	
119-26	24473-24475	or	_	
119-27	24476-24478	so	_	
119-28	24479-24481	of	_	
119-29	24482-24491	cessation	_	
119-30	24491-24492	,	_	
119-31	24493-24496	all	_	
119-32	24497-24499	of	_	
119-33	24500-24503	the	_	
119-34	24504-24512	nicotine	_	
119-35	24513-24515	in	_	
119-36	24516-24520	both	_	
119-37	24521-24529	genotype	_	
119-38	24530-24536	groups	_	
119-39	24537-24539	is	_	
119-40	24540-24547	cleared	_	
119-41	24548-24552	from	_	
119-42	24553-24556	the	_	
119-43	24557-24561	body	_	
119-44	24561-24562	.	_	

#Text=If there is no nicotine present for the CYP2A6 to metabolize, how is variation in CYP2A6 mediating these long-term differences in smoking cessation?
120-1	24563-24565	If	_	
120-2	24566-24571	there	_	
120-3	24572-24574	is	_	
120-4	24575-24577	no	_	
120-5	24578-24586	nicotine	_	
120-6	24587-24594	present	_	
120-7	24595-24598	for	_	
120-8	24599-24602	the	_	
120-9	24603-24609	CYP2A6	_	
120-10	24610-24612	to	_	
120-11	24613-24623	metabolize	_	
120-12	24623-24624	,	_	
120-13	24625-24628	how	_	
120-14	24629-24631	is	_	
120-15	24632-24641	variation	_	
120-16	24642-24644	in	_	
120-17	24645-24651	CYP2A6	_	
120-18	24652-24661	mediating	_	
120-19	24662-24667	these	_	
120-20	24668-24677	long-term	_	
120-21	24678-24689	differences	_	
120-22	24690-24692	in	_	
120-23	24693-24700	smoking	_	
120-24	24701-24710	cessation	_	
120-25	24710-24711	?	_	

#Text=Our data for the first time suggests that smoking-induced and genetically modulated nicotine PK differences can alter specific brain circuits and network hubs critically related to nicotine abstinence and recidivism.
121-1	24712-24715	Our	_	
121-2	24716-24720	data	_	
121-3	24721-24724	for	_	
121-4	24725-24728	the	_	
121-5	24729-24734	first	_	
121-6	24735-24739	time	_	
121-7	24740-24748	suggests	_	
121-8	24749-24753	that	_	
121-9	24754-24769	smoking-induced	_	
121-10	24770-24773	and	_	
121-11	24774-24785	genetically	_	
121-12	24786-24795	modulated	_	
121-13	24796-24804	nicotine	_	
121-14	24805-24807	PK	_	
121-15	24808-24819	differences	_	
121-16	24820-24823	can	_	
121-17	24824-24829	alter	_	
121-18	24830-24838	specific	_	
121-19	24839-24844	brain	_	
121-20	24845-24853	circuits	_	
121-21	24854-24857	and	_	
121-22	24858-24865	network	_	
121-23	24866-24870	hubs	_	
121-24	24871-24881	critically	_	
121-25	24882-24889	related	_	
121-26	24890-24892	to	_	
121-27	24893-24901	nicotine	_	
121-28	24902-24912	abstinence	_	
121-29	24913-24916	and	_	
121-30	24917-24927	recidivism	_	
121-31	24927-24928	.	_	

#Text=Slow metabolizers show reduced neural reactivity to smoking related cues.
122-1	24929-24933	Slow	_	
122-2	24934-24946	metabolizers	_	
122-3	24947-24951	show	_	
122-4	24952-24959	reduced	_	
122-5	24960-24966	neural	_	
122-6	24967-24977	reactivity	_	
122-7	24978-24980	to	_	
122-8	24981-24988	smoking	_	
122-9	24989-24996	related	_	
122-10	24997-25001	cues	_	
122-11	25001-25002	.	_	

#Text=Reactivity to smoking cues predicts smoking cessation success, while greater insula-dACC coupling at rest predicts enhanced smoking cue-reactivity.
123-1	25003-25013	Reactivity	_	
123-2	25014-25016	to	_	
123-3	25017-25024	smoking	_	
123-4	25025-25029	cues	_	
123-5	25030-25038	predicts	_	
123-6	25039-25046	smoking	_	
123-7	25047-25056	cessation	_	
123-8	25057-25064	success	_	
123-9	25064-25065	,	_	
123-10	25066-25071	while	_	
123-11	25072-25079	greater	_	
123-12	25080-25091	insula-dACC	_	
123-13	25092-25100	coupling	_	
123-14	25101-25103	at	_	
123-15	25104-25108	rest	_	
123-16	25109-25117	predicts	_	
123-17	25118-25126	enhanced	_	
123-18	25127-25134	smoking	_	
123-19	25135-25149	cue-reactivity	_	
123-20	25149-25150	.	_	

#Text=That smokers with stroke lesions limited to the insula spontaneously quit smoking because their bodies ‘forgot they were smokers’, suggests that the insula (and presumably its regional interconnectivity) process the body sensations and/or perceptions of nicotine withdrawal.
124-1	25151-25155	That	_	
124-2	25156-25163	smokers	_	
124-3	25164-25168	with	_	
124-4	25169-25175	stroke	_	
124-5	25176-25183	lesions	_	
124-6	25184-25191	limited	_	
124-7	25192-25194	to	_	
124-8	25195-25198	the	_	
124-9	25199-25205	insula	_	
124-10	25206-25219	spontaneously	_	
124-11	25220-25224	quit	_	
124-12	25225-25232	smoking	_	
124-13	25233-25240	because	_	
124-14	25241-25246	their	_	
124-15	25247-25253	bodies	_	
124-16	25254-25255	‘	_	
124-17	25255-25261	forgot	_	
124-18	25262-25266	they	_	
124-19	25267-25271	were	_	
124-20	25272-25279	smokers	_	
124-21	25279-25280	’	_	
124-22	25280-25281	,	_	
124-23	25282-25290	suggests	_	
124-24	25291-25295	that	_	
124-25	25296-25299	the	_	
124-26	25300-25306	insula	_	
124-27	25307-25308	(	_	
124-28	25308-25311	and	_	
124-29	25312-25322	presumably	_	
124-30	25323-25326	its	_	
124-31	25327-25335	regional	_	
124-32	25336-25353	interconnectivity	_	
124-33	25353-25354	)	_	
124-34	25355-25362	process	_	
124-35	25363-25366	the	_	
124-36	25367-25371	body	_	
124-37	25372-25382	sensations	_	
124-38	25383-25386	and	_	
124-39	25386-25387	/	_	
124-40	25387-25389	or	_	
124-41	25390-25401	perceptions	_	
124-42	25402-25404	of	_	
124-43	25405-25413	nicotine	_	
124-44	25414-25424	withdrawal	_	
124-45	25424-25425	.	_	

#Text=Thus, the current finding of reduced insula connectivity strength between the VS and dACC (key SN hubs) in the slow metabolizers mechanistically support both the reported reduction in cue responding in this CYP2A6 genotype and helps explain the epidemiological and experimental observations of enhanced cessation success in slow metabolizers.
125-1	25426-25430	Thus	_	
125-2	25430-25431	,	_	
125-3	25432-25435	the	_	
125-4	25436-25443	current	_	
125-5	25444-25451	finding	_	
125-6	25452-25454	of	_	
125-7	25455-25462	reduced	_	
125-8	25463-25469	insula	_	
125-9	25470-25482	connectivity	_	
125-10	25483-25491	strength	_	
125-11	25492-25499	between	_	
125-12	25500-25503	the	_	
125-13	25504-25506	VS	_	
125-14	25507-25510	and	_	
125-15	25511-25515	dACC	_	
125-16	25516-25517	(	_	
125-17	25517-25520	key	_	
125-18	25521-25523	SN	_	
125-19	25524-25528	hubs	_	
125-20	25528-25529	)	_	
125-21	25530-25532	in	_	
125-22	25533-25536	the	_	
125-23	25537-25541	slow	_	
125-24	25542-25554	metabolizers	_	
125-25	25555-25570	mechanistically	_	
125-26	25571-25578	support	_	
125-27	25579-25583	both	_	
125-28	25584-25587	the	_	
125-29	25588-25596	reported	_	
125-30	25597-25606	reduction	_	
125-31	25607-25609	in	_	
125-32	25610-25613	cue	_	
125-33	25614-25624	responding	_	
125-34	25625-25627	in	_	
125-35	25628-25632	this	_	
125-36	25633-25639	CYP2A6	_	
125-37	25640-25648	genotype	_	
125-38	25649-25652	and	_	
125-39	25653-25658	helps	_	
125-40	25659-25666	explain	_	
125-41	25667-25670	the	_	
125-42	25671-25686	epidemiological	_	
125-43	25687-25690	and	_	
125-44	25691-25703	experimental	_	
125-45	25704-25716	observations	_	
125-46	25717-25719	of	_	
125-47	25720-25728	enhanced	_	
125-48	25729-25738	cessation	_	
125-49	25739-25746	success	_	
125-50	25747-25749	in	_	
125-51	25750-25754	slow	_	
125-52	25755-25767	metabolizers	_	
125-53	25767-25768	.	_	

#Text=There is growing evidence that the CYP2A6 genotype differentially contributes to smoking cessation treatments.
126-1	25769-25774	There	_	
126-2	25775-25777	is	_	
126-3	25778-25785	growing	_	
126-4	25786-25794	evidence	_	
126-5	25795-25799	that	_	
126-6	25800-25803	the	_	
126-7	25804-25810	CYP2A6	_	
126-8	25811-25819	genotype	_	
126-9	25820-25834	differentially	_	
126-10	25835-25846	contributes	_	
126-11	25847-25849	to	_	
126-12	25850-25857	smoking	_	
126-13	25858-25867	cessation	_	
126-14	25868-25878	treatments	_	
126-15	25878-25879	.	_	

#Text=Slow metabolizers respond better to NRT when it is administered for an extended period of time, while the additional treatment time provides no incremental benefit to normal metabolizers, even after controlling for genotype differences in baseline CPD, dependence level, and patch-derived plasma nicotine levels.
127-1	25880-25884	Slow	_	
127-2	25885-25897	metabolizers	_	
127-3	25898-25905	respond	_	
127-4	25906-25912	better	_	
127-5	25913-25915	to	_	
127-6	25916-25919	NRT	_	
127-7	25920-25924	when	_	
127-8	25925-25927	it	_	
127-9	25928-25930	is	_	
127-10	25931-25943	administered	_	
127-11	25944-25947	for	_	
127-12	25948-25950	an	_	
127-13	25951-25959	extended	_	
127-14	25960-25966	period	_	
127-15	25967-25969	of	_	
127-16	25970-25974	time	_	
127-17	25974-25975	,	_	
127-18	25976-25981	while	_	
127-19	25982-25985	the	_	
127-20	25986-25996	additional	_	
127-21	25997-26006	treatment	_	
127-22	26007-26011	time	_	
127-23	26012-26020	provides	_	
127-24	26021-26023	no	_	
127-25	26024-26035	incremental	_	
127-26	26036-26043	benefit	_	
127-27	26044-26046	to	_	
127-28	26047-26053	normal	_	
127-29	26054-26066	metabolizers	_	
127-30	26066-26067	,	_	
127-31	26068-26072	even	_	
127-32	26073-26078	after	_	
127-33	26079-26090	controlling	_	
127-34	26091-26094	for	_	
127-35	26095-26103	genotype	_	
127-36	26104-26115	differences	_	
127-37	26116-26118	in	_	
127-38	26119-26127	baseline	_	
127-39	26128-26131	CPD	_	
127-40	26131-26132	,	_	
127-41	26133-26143	dependence	_	
127-42	26144-26149	level	_	
127-43	26149-26150	,	_	
127-44	26151-26154	and	_	
127-45	26155-26168	patch-derived	_	
127-46	26169-26175	plasma	_	
127-47	26176-26184	nicotine	_	
127-48	26185-26191	levels	_	
127-49	26191-26192	.	_	

#Text=These observations suggest that the PK of NRT may more closely resemble the smoking-induced nicotine PK in slow metabolizers that originally shaped the neural circuits, replacing downstream nicotine signaling from cigarettes more effectively than among normal metabolizers.
128-1	26193-26198	These	_	
128-2	26199-26211	observations	_	
128-3	26212-26219	suggest	_	
128-4	26220-26224	that	_	
128-5	26225-26228	the	_	
128-6	26229-26231	PK	_	
128-7	26232-26234	of	_	
128-8	26235-26238	NRT	_	
128-9	26239-26242	may	_	
128-10	26243-26247	more	_	
128-11	26248-26255	closely	_	
128-12	26256-26264	resemble	_	
128-13	26265-26268	the	_	
128-14	26269-26284	smoking-induced	_	
128-15	26285-26293	nicotine	_	
128-16	26294-26296	PK	_	
128-17	26297-26299	in	_	
128-18	26300-26304	slow	_	
128-19	26305-26317	metabolizers	_	
128-20	26318-26322	that	_	
128-21	26323-26333	originally	_	
128-22	26334-26340	shaped	_	
128-23	26341-26344	the	_	
128-24	26345-26351	neural	_	
128-25	26352-26360	circuits	_	
128-26	26360-26361	,	_	
128-27	26362-26371	replacing	_	
128-28	26372-26382	downstream	_	
128-29	26383-26391	nicotine	_	
128-30	26392-26401	signaling	_	
128-31	26402-26406	from	_	
128-32	26407-26417	cigarettes	_	
128-33	26418-26422	more	_	
128-34	26423-26434	effectively	_	
128-35	26435-26439	than	_	
128-36	26440-26445	among	_	
128-37	26446-26452	normal	_	
128-38	26453-26465	metabolizers	_	
128-39	26465-26466	.	_	

#Text=In contrast, normal metabolizers respond more favorably to varenicline than NRT, report fewer drug related side effects and greater cognitive improvement.
129-1	26467-26469	In	_	
129-2	26470-26478	contrast	_	
129-3	26478-26479	,	_	
129-4	26480-26486	normal	_	
129-5	26487-26499	metabolizers	_	
129-6	26500-26507	respond	_	
129-7	26508-26512	more	_	
129-8	26513-26522	favorably	_	
129-9	26523-26525	to	_	
129-10	26526-26537	varenicline	_	
129-11	26538-26542	than	_	
129-12	26543-26546	NRT	_	
129-13	26546-26547	,	_	
129-14	26548-26554	report	_	
129-15	26555-26560	fewer	_	
129-16	26561-26565	drug	_	
129-17	26566-26573	related	_	
129-18	26574-26578	side	_	
129-19	26579-26586	effects	_	
129-20	26587-26590	and	_	
129-21	26591-26598	greater	_	
129-22	26599-26608	cognitive	_	
129-23	26609-26620	improvement	_	
129-24	26620-26621	.	_	

#Text=This metabolism group-specific responding is supported in part by the knowledge that varenicline is not a substrate for CYP2A6; thus one might have anticipated identical responses to varenicline among slow and normal metabolizers if not for genotype differences in neurobiological adaptation as reported herein that must have occurred before cessation treatment.
130-1	26622-26626	This	_	
130-2	26627-26637	metabolism	_	
130-3	26638-26652	group-specific	_	
130-4	26653-26663	responding	_	
130-5	26664-26666	is	_	
130-6	26667-26676	supported	_	
130-7	26677-26679	in	_	
130-8	26680-26684	part	_	
130-9	26685-26687	by	_	
130-10	26688-26691	the	_	
130-11	26692-26701	knowledge	_	
130-12	26702-26706	that	_	
130-13	26707-26718	varenicline	_	
130-14	26719-26721	is	_	
130-15	26722-26725	not	_	
130-16	26726-26727	a	_	
130-17	26728-26737	substrate	_	
130-18	26738-26741	for	_	
130-19	26742-26748	CYP2A6	_	
130-20	26748-26749	;	_	
130-21	26750-26754	thus	_	
130-22	26755-26758	one	_	
130-23	26759-26764	might	_	
130-24	26765-26769	have	_	
130-25	26770-26781	anticipated	_	
130-26	26782-26791	identical	_	
130-27	26792-26801	responses	_	
130-28	26802-26804	to	_	
130-29	26805-26816	varenicline	_	
130-30	26817-26822	among	_	
130-31	26823-26827	slow	_	
130-32	26828-26831	and	_	
130-33	26832-26838	normal	_	
130-34	26839-26851	metabolizers	_	
130-35	26852-26854	if	_	
130-36	26855-26858	not	_	
130-37	26859-26862	for	_	
130-38	26863-26871	genotype	_	
130-39	26872-26883	differences	_	
130-40	26884-26886	in	_	
130-41	26887-26902	neurobiological	_	
130-42	26903-26913	adaptation	_	
130-43	26914-26916	as	_	
130-44	26917-26925	reported	_	
130-45	26926-26932	herein	_	
130-46	26933-26937	that	_	
130-47	26938-26942	must	_	
130-48	26943-26947	have	_	
130-49	26948-26956	occurred	_	
130-50	26957-26963	before	_	
130-51	26964-26973	cessation	_	
130-52	26974-26983	treatment	_	
130-53	26983-26984	.	_	

#Text=Taken together, this genetic imaging study demonstrated a strong Gene × Environment interaction in cingulate and ventral striatal network hubs supported by circuits that prominently implicate the insula.
131-1	26985-26990	Taken	_	
131-2	26991-26999	together	_	
131-3	26999-27000	,	_	
131-4	27001-27005	this	_	
131-5	27006-27013	genetic	_	
131-6	27014-27021	imaging	_	
131-7	27022-27027	study	_	
131-8	27028-27040	demonstrated	_	
131-9	27041-27042	a	_	
131-10	27043-27049	strong	_	
131-11	27050-27054	Gene	_	
131-12	27055-27056	×	_	
131-13	27057-27068	Environment	_	
131-14	27069-27080	interaction	_	
131-15	27081-27083	in	_	
131-16	27084-27093	cingulate	_	
131-17	27094-27097	and	_	
131-18	27098-27105	ventral	_	
131-19	27106-27114	striatal	_	
131-20	27115-27122	network	_	
131-21	27123-27127	hubs	_	
131-22	27128-27137	supported	_	
131-23	27138-27140	by	_	
131-24	27141-27149	circuits	_	
131-25	27150-27154	that	_	
131-26	27155-27166	prominently	_	
131-27	27167-27176	implicate	_	
131-28	27177-27180	the	_	
131-29	27181-27187	insula	_	
131-30	27187-27188	.	_	

#Text=The ability of these network hubs to process reward signals and stimulus response inhibition are also compromised (although due to the limited sized cohort that performed the MID and Go/NoGo tasks, replication with larger samples is encouraged).
132-1	27189-27192	The	_	
132-2	27193-27200	ability	_	
132-3	27201-27203	of	_	
132-4	27204-27209	these	_	
132-5	27210-27217	network	_	
132-6	27218-27222	hubs	_	
132-7	27223-27225	to	_	
132-8	27226-27233	process	_	
132-9	27234-27240	reward	_	
132-10	27241-27248	signals	_	
132-11	27249-27252	and	_	
132-12	27253-27261	stimulus	_	
132-13	27262-27270	response	_	
132-14	27271-27281	inhibition	_	
132-15	27282-27285	are	_	
132-16	27286-27290	also	_	
132-17	27291-27302	compromised	_	
132-18	27303-27304	(	_	
132-19	27304-27312	although	_	
132-20	27313-27316	due	_	
132-21	27317-27319	to	_	
132-22	27320-27323	the	_	
132-23	27324-27331	limited	_	
132-24	27332-27337	sized	_	
132-25	27338-27344	cohort	_	
132-26	27345-27349	that	_	
132-27	27350-27359	performed	_	
132-28	27360-27363	the	_	
132-29	27364-27367	MID	_	
132-30	27368-27371	and	_	
132-31	27372-27374	Go	_	
132-32	27374-27375	/	_	
132-33	27375-27379	NoGo	_	
132-34	27380-27385	tasks	_	
132-35	27385-27386	,	_	
132-36	27387-27398	replication	_	
132-37	27399-27403	with	_	
132-38	27404-27410	larger	_	
132-39	27411-27418	samples	_	
132-40	27419-27421	is	_	
132-41	27422-27432	encouraged	_	
132-42	27432-27433	)	_	
132-43	27433-27434	.	_	

#Text=Nevertheless, the genetic influence on both task activation and network hubs was seen only in smokers, suggesting that variable brain nicotine levels established during smoking can significantly and differentially modify brain circuits linked to, and perhaps enhance, subsequent nicotine dependence.
133-1	27435-27447	Nevertheless	_	
133-2	27447-27448	,	_	
133-3	27449-27452	the	_	
133-4	27453-27460	genetic	_	
133-5	27461-27470	influence	_	
133-6	27471-27473	on	_	
133-7	27474-27478	both	_	
133-8	27479-27483	task	_	
133-9	27484-27494	activation	_	
133-10	27495-27498	and	_	
133-11	27499-27506	network	_	
133-12	27507-27511	hubs	_	
133-13	27512-27515	was	_	
133-14	27516-27520	seen	_	
133-15	27521-27525	only	_	
133-16	27526-27528	in	_	
133-17	27529-27536	smokers	_	
133-18	27536-27537	,	_	
133-19	27538-27548	suggesting	_	
133-20	27549-27553	that	_	
133-21	27554-27562	variable	_	
133-22	27563-27568	brain	_	
133-23	27569-27577	nicotine	_	
133-24	27578-27584	levels	_	
133-25	27585-27596	established	_	
133-26	27597-27603	during	_	
133-27	27604-27611	smoking	_	
133-28	27612-27615	can	_	
133-29	27616-27629	significantly	_	
133-30	27630-27633	and	_	
133-31	27634-27648	differentially	_	
133-32	27649-27655	modify	_	
133-33	27656-27661	brain	_	
133-34	27662-27670	circuits	_	
133-35	27671-27677	linked	_	
133-36	27678-27680	to	_	
133-37	27680-27681	,	_	
133-38	27682-27685	and	_	
133-39	27686-27693	perhaps	_	
133-40	27694-27701	enhance	_	
133-41	27701-27702	,	_	
133-42	27703-27713	subsequent	_	
133-43	27714-27722	nicotine	_	
133-44	27723-27733	dependence	_	
133-45	27733-27734	.	_	

#Text=Our data further suggest that these circuit alterations are a result of, rather than predisposing to, nicotine dependence.
134-1	27735-27738	Our	_	
134-2	27739-27743	data	_	
134-3	27744-27751	further	_	
134-4	27752-27759	suggest	_	
134-5	27760-27764	that	_	
134-6	27765-27770	these	_	
134-7	27771-27778	circuit	_	
134-8	27779-27790	alterations	_	
134-9	27791-27794	are	_	
134-10	27795-27796	a	_	
134-11	27797-27803	result	_	
134-12	27804-27806	of	_	
134-13	27806-27807	,	_	
134-14	27808-27814	rather	_	
134-15	27815-27819	than	_	
134-16	27820-27832	predisposing	_	
134-17	27833-27835	to	_	
134-18	27835-27836	,	_	
134-19	27837-27845	nicotine	_	
134-20	27846-27856	dependence	_	
134-21	27856-27857	.	_	

#Text=This conjecture is further supported by the enhanced BOLD signal seen following acute nicotine administration in nonsmokers.
135-1	27858-27862	This	_	
135-2	27863-27873	conjecture	_	
135-3	27874-27876	is	_	
135-4	27877-27884	further	_	
135-5	27885-27894	supported	_	
135-6	27895-27897	by	_	
135-7	27898-27901	the	_	
135-8	27902-27910	enhanced	_	
135-9	27911-27915	BOLD	_	
135-10	27916-27922	signal	_	
135-11	27923-27927	seen	_	
135-12	27928-27937	following	_	
135-13	27938-27943	acute	_	
135-14	27944-27952	nicotine	_	
135-15	27953-27967	administration	_	
135-16	27968-27970	in	_	
135-17	27971-27981	nonsmokers	_	
135-18	27981-27982	.	_	

#Text=If indeed the identified striatal and cingulate hubs and circuits are altered by chronic nicotine use, they may serve as reversible biomarkers and novel targets for the development of medications to differentially treat nicotine addiction based upon the CYP2A6 genotype.
136-1	27983-27985	If	_	
136-2	27986-27992	indeed	_	
136-3	27993-27996	the	_	
136-4	27997-28007	identified	_	
136-5	28008-28016	striatal	_	
136-6	28017-28020	and	_	
136-7	28021-28030	cingulate	_	
136-8	28031-28035	hubs	_	
136-9	28036-28039	and	_	
136-10	28040-28048	circuits	_	
136-11	28049-28052	are	_	
136-12	28053-28060	altered	_	
136-13	28061-28063	by	_	
136-14	28064-28071	chronic	_	
136-15	28072-28080	nicotine	_	
136-16	28081-28084	use	_	
136-17	28084-28085	,	_	
136-18	28086-28090	they	_	
136-19	28091-28094	may	_	
136-20	28095-28100	serve	_	
136-21	28101-28103	as	_	
136-22	28104-28114	reversible	_	
136-23	28115-28125	biomarkers	_	
136-24	28126-28129	and	_	
136-25	28130-28135	novel	_	
136-26	28136-28143	targets	_	
136-27	28144-28147	for	_	
136-28	28148-28151	the	_	
136-29	28152-28163	development	_	
136-30	28164-28166	of	_	
136-31	28167-28178	medications	_	
136-32	28179-28181	to	_	
136-33	28182-28196	differentially	_	
136-34	28197-28202	treat	_	
136-35	28203-28211	nicotine	_	
136-36	28212-28221	addiction	_	
136-37	28222-28227	based	_	
136-38	28228-28232	upon	_	
136-39	28233-28236	the	_	
136-40	28237-28243	CYP2A6	_	
136-41	28244-28252	genotype	_	
136-42	28252-28253	.	_	

#Text=Supplementary Material
#Text=This is a PDF file of an unedited manuscript that has been accepted for publication.
137-1	28254-28267	Supplementary	_	
137-2	28268-28276	Material	_	
137-3	28277-28281	This	_	
137-4	28282-28284	is	_	
137-5	28285-28286	a	_	
137-6	28287-28290	PDF	_	
137-7	28291-28295	file	_	
137-8	28296-28298	of	_	
137-9	28299-28301	an	_	
137-10	28302-28310	unedited	_	
137-11	28311-28321	manuscript	_	
137-12	28322-28326	that	_	
137-13	28327-28330	has	_	
137-14	28331-28335	been	_	
137-15	28336-28344	accepted	_	
137-16	28345-28348	for	_	
137-17	28349-28360	publication	_	
137-18	28360-28361	.	_	

#Text=As a service to our customers we are providing this early version of the manuscript.
138-1	28362-28364	As	_	
138-2	28365-28366	a	_	
138-3	28367-28374	service	_	
138-4	28375-28377	to	_	
138-5	28378-28381	our	_	
138-6	28382-28391	customers	_	
138-7	28392-28394	we	_	
138-8	28395-28398	are	_	
138-9	28399-28408	providing	_	
138-10	28409-28413	this	_	
138-11	28414-28419	early	_	
138-12	28420-28427	version	_	
138-13	28428-28430	of	_	
138-14	28431-28434	the	_	
138-15	28435-28445	manuscript	_	
138-16	28445-28446	.	_	

#Text=The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form.
139-1	28447-28450	The	_	
139-2	28451-28461	manuscript	_	
139-3	28462-28466	will	_	
139-4	28467-28474	undergo	_	
139-5	28475-28486	copyediting	_	
139-6	28486-28487	,	_	
139-7	28488-28499	typesetting	_	
139-8	28499-28500	,	_	
139-9	28501-28504	and	_	
139-10	28505-28511	review	_	
139-11	28512-28514	of	_	
139-12	28515-28518	the	_	
139-13	28519-28528	resulting	_	
139-14	28529-28534	proof	_	
139-15	28535-28541	before	_	
139-16	28542-28544	it	_	
139-17	28545-28547	is	_	
139-18	28548-28557	published	_	
139-19	28558-28560	in	_	
139-20	28561-28564	its	_	
139-21	28565-28570	final	_	
139-22	28571-28578	citable	_	
139-23	28579-28583	form	_	
139-24	28583-28584	.	_	

#Text=Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
140-1	28585-28591	Please	_	
140-2	28592-28596	note	_	
140-3	28597-28601	that	_	
140-4	28602-28608	during	_	
140-5	28609-28612	the	_	
140-6	28613-28623	production	_	
140-7	28624-28631	process	_	
140-8	28632-28638	errors	_	
140-9	28639-28642	may	_	
140-10	28643-28645	be	_	
140-11	28646-28656	discovered	_	
140-12	28657-28662	which	_	
140-13	28663-28668	could	_	
140-14	28669-28675	affect	_	
140-15	28676-28679	the	_	
140-16	28680-28687	content	_	
140-17	28687-28688	,	_	
140-18	28689-28692	and	_	
140-19	28693-28696	all	_	
140-20	28697-28702	legal	_	
140-21	28703-28714	disclaimers	_	
140-22	28715-28719	that	_	
140-23	28720-28725	apply	_	
140-24	28726-28728	to	_	
140-25	28729-28732	the	_	
140-26	28733-28740	journal	_	
140-27	28741-28748	pertain	_	
140-28	28748-28749	.	_	

#Text=Financial Disclosures         
#Text=All other authors report no biomedical financial interests or potential conflicts of interest.
141-1	28761-28770	Financial	_	
141-2	28771-28782	Disclosures	_	
141-3	28792-28795	All	_	
141-4	28796-28801	other	_	
141-5	28802-28809	authors	_	
141-6	28810-28816	report	_	
141-7	28817-28819	no	_	
141-8	28820-28830	biomedical	_	
141-9	28831-28840	financial	_	
141-10	28841-28850	interests	_	
141-11	28851-28853	or	_	
141-12	28854-28863	potential	_	
141-13	28864-28873	conflicts	_	
141-14	28874-28876	of	_	
141-15	28877-28885	interest	_	
141-16	28885-28886	.	_	

#Text=References
#Text=Resting state functional connectivity in addiction: Lessons learned and a road ahead
#Text=Addiction becomes a brain disease
#Text=Antidepressants for smoking cessation
#Text=A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes
#Text=Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function
#Text=The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics
#Text=CYP2A6 genotype and the metabolism and disposition kinetics of nicotine
#Text=The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit
#Text=Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers
#Text=Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians
#Text=Associations of CYP2A6 genotype with smoking behaviors in southern China
#Text=CYP2A6 genotype and smoking behavior in current smokers screened for lung cancer
#Text=Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy
#Text=CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers
#Text=Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion
#Text=Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy
#Text=Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial
#Text=Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation
#Text=Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI
#Text=How fast and how often: The pharmacokinetics of drug use are decisive in addiction
#Text=Why does the rapid delivery of drugs to the brain promote addiction?
142-1	28887-28897	References	_	
142-2	28898-28905	Resting	_	
142-3	28906-28911	state	_	
142-4	28912-28922	functional	_	
142-5	28923-28935	connectivity	_	
142-6	28936-28938	in	_	
142-7	28939-28948	addiction	_	
142-8	28948-28949	:	_	
142-9	28950-28957	Lessons	_	
142-10	28958-28965	learned	_	
142-11	28966-28969	and	_	
142-12	28970-28971	a	_	
142-13	28972-28976	road	_	
142-14	28977-28982	ahead	_	
142-15	28983-28992	Addiction	_	
142-16	28993-29000	becomes	_	
142-17	29001-29002	a	_	
142-18	29003-29008	brain	_	
142-19	29009-29016	disease	_	
142-20	29017-29032	Antidepressants	_	
142-21	29033-29036	for	_	
142-22	29037-29044	smoking	_	
142-23	29045-29054	cessation	_	
142-24	29055-29056	A	_	
142-25	29057-29062	major	_	
142-26	29063-29067	role	_	
142-27	29068-29071	for	_	
142-28	29072-29078	CYP2A6	_	
142-29	29079-29081	in	_	
142-30	29082-29090	nicotine	_	
142-31	29091-29102	C-oxidation	_	
142-32	29103-29105	by	_	
142-33	29106-29111	human	_	
142-34	29112-29117	liver	_	
142-35	29118-29128	microsomes	_	
142-36	29129-29152	Xenobiotic-metabolizing	_	
142-37	29153-29160	enzymes	_	
142-38	29161-29164	and	_	
142-39	29165-29177	transporters	_	
142-40	29178-29180	in	_	
142-41	29181-29184	the	_	
142-42	29185-29191	normal	_	
142-43	29192-29197	human	_	
142-44	29198-29203	brain	_	
142-45	29203-29204	:	_	
142-46	29205-29213	regional	_	
142-47	29214-29217	and	_	
142-48	29218-29226	cellular	_	
142-49	29227-29234	mapping	_	
142-50	29235-29237	as	_	
142-51	29238-29239	a	_	
142-52	29240-29245	basis	_	
142-53	29246-29249	for	_	
142-54	29250-29258	putative	_	
142-55	29259-29264	roles	_	
142-56	29265-29267	in	_	
142-57	29268-29276	cerebral	_	
142-58	29277-29285	function	_	
142-59	29286-29289	The	_	
142-60	29290-29296	unique	_	
142-61	29297-29307	regulation	_	
142-62	29308-29310	of	_	
142-63	29311-29316	brain	_	
142-64	29317-29327	cytochrome	_	
142-65	29328-29332	P450	_	
142-66	29333-29334	2	_	
142-67	29335-29336	(	_	
142-68	29336-29340	CYP2	_	
142-69	29340-29341	)	_	
142-70	29342-29348	family	_	
142-71	29349-29356	enzymes	_	
142-72	29357-29359	by	_	
142-73	29360-29365	drugs	_	
142-74	29366-29369	and	_	
142-75	29370-29378	genetics	_	
142-76	29379-29385	CYP2A6	_	
142-77	29386-29394	genotype	_	
142-78	29395-29398	and	_	
142-79	29399-29402	the	_	
142-80	29403-29413	metabolism	_	
142-81	29414-29417	and	_	
142-82	29418-29429	disposition	_	
142-83	29430-29438	kinetics	_	
142-84	29439-29441	of	_	
142-85	29442-29450	nicotine	_	
142-86	29451-29454	The	_	
142-87	29455-29458	use	_	
142-88	29459-29461	of	_	
142-89	29462-29466	long	_	
142-90	29467-29470	PCR	_	
142-91	29471-29473	to	_	
142-92	29474-29481	confirm	_	
142-93	29482-29487	three	_	
142-94	29488-29494	common	_	
142-95	29495-29502	alleles	_	
142-96	29503-29505	at	_	
142-97	29506-29509	the	_	
142-98	29510-29516	CYP2A6	_	
142-99	29517-29522	locus	_	
142-100	29523-29526	and	_	
142-101	29527-29530	the	_	
142-102	29531-29543	relationship	_	
142-103	29544-29551	between	_	
142-104	29552-29560	genotype	_	
142-105	29561-29564	and	_	
142-106	29565-29572	smoking	_	
142-107	29573-29578	habit	_	
142-108	29579-29590	Genetically	_	
142-109	29591-29600	decreased	_	
142-110	29601-29607	CYP2A6	_	
142-111	29608-29611	and	_	
142-112	29612-29615	the	_	
142-113	29616-29620	risk	_	
142-114	29621-29623	of	_	
142-115	29624-29631	tobacco	_	
142-116	29632-29642	dependence	_	
142-117	29642-29643	:	_	
142-118	29644-29645	a	_	
142-119	29646-29657	prospective	_	
142-120	29658-29663	study	_	
142-121	29664-29666	of	_	
142-122	29667-29673	novice	_	
142-123	29674-29681	smokers	_	
142-124	29682-29688	Ethnic	_	
142-125	29689-29698	variation	_	
142-126	29699-29701	in	_	
142-127	29702-29708	CYP2A6	_	
142-128	29709-29712	and	_	
142-129	29713-29724	association	_	
142-130	29725-29727	of	_	
142-131	29728-29739	genetically	_	
142-132	29740-29744	slow	_	
142-133	29745-29753	nicotine	_	
142-134	29754-29764	metabolism	_	
142-135	29765-29768	and	_	
142-136	29769-29776	smoking	_	
142-137	29777-29779	in	_	
142-138	29780-29785	adult	_	
142-139	29786-29796	Caucasians	_	
142-140	29797-29809	Associations	_	
142-141	29810-29812	of	_	
142-142	29813-29819	CYP2A6	_	
142-143	29820-29828	genotype	_	
142-144	29829-29833	with	_	
142-145	29834-29841	smoking	_	
142-146	29842-29851	behaviors	_	
142-147	29852-29854	in	_	
142-148	29855-29863	southern	_	
142-149	29864-29869	China	_	
142-150	29870-29876	CYP2A6	_	
142-151	29877-29885	genotype	_	
142-152	29886-29889	and	_	
142-153	29890-29897	smoking	_	
142-154	29898-29906	behavior	_	
142-155	29907-29909	in	_	
142-156	29910-29917	current	_	
142-157	29918-29925	smokers	_	
142-158	29926-29934	screened	_	
142-159	29935-29938	for	_	
142-160	29939-29943	lung	_	
142-161	29944-29950	cancer	_	
142-162	29951-29957	Impact	_	
142-163	29958-29960	of	_	
142-164	29961-29967	CYP2A6	_	
142-165	29968-29976	genotype	_	
142-166	29977-29979	on	_	
142-167	29980-29992	pretreatment	_	
142-168	29993-30000	smoking	_	
142-169	30001-30010	behaviour	_	
142-170	30011-30014	and	_	
142-171	30015-30023	nicotine	_	
142-172	30024-30030	levels	_	
142-173	30031-30035	from	_	
142-174	30036-30039	and	_	
142-175	30040-30045	usage	_	
142-176	30046-30048	of	_	
142-177	30049-30057	nicotine	_	
142-178	30058-30069	replacement	_	
142-179	30070-30077	therapy	_	
142-180	30078-30084	CYP2A6	_	
142-181	30085-30089	slow	_	
142-182	30090-30098	nicotine	_	
142-183	30099-30109	metabolism	_	
142-184	30110-30112	is	_	
142-185	30113-30123	associated	_	
142-186	30124-30128	with	_	
142-187	30129-30138	increased	_	
142-188	30139-30147	quitting	_	
142-189	30148-30150	by	_	
142-190	30151-30161	adolescent	_	
142-191	30162-30169	smokers	_	
142-192	30170-30176	Toward	_	
142-193	30177-30189	personalized	_	
142-194	30190-30197	therapy	_	
142-195	30198-30201	for	_	
142-196	30202-30209	smoking	_	
142-197	30210-30219	cessation	_	
142-198	30219-30220	:	_	
142-199	30221-30222	a	_	
142-200	30223-30233	randomized	_	
142-201	30234-30252	placebo-controlled	_	
142-202	30253-30258	trial	_	
142-203	30259-30261	of	_	
142-204	30262-30271	bupropion	_	
142-205	30272-30279	Genetic	_	
142-206	30280-30289	variation	_	
142-207	30290-30292	in	_	
142-208	30293-30301	nicotine	_	
142-209	30302-30312	metabolism	_	
142-210	30313-30321	predicts	_	
142-211	30322-30325	the	_	
142-212	30326-30334	efficacy	_	
142-213	30335-30337	of	_	
142-214	30338-30355	extended-duration	_	
142-215	30356-30367	transdermal	_	
142-216	30368-30376	nicotine	_	
142-217	30377-30384	therapy	_	
142-218	30385-30388	Use	_	
142-219	30389-30391	of	_	
142-220	30392-30395	the	_	
142-221	30396-30404	nicotine	_	
142-222	30405-30415	metabolite	_	
142-223	30416-30421	ratio	_	
142-224	30422-30424	as	_	
142-225	30425-30426	a	_	
142-226	30427-30438	genetically	_	
142-227	30439-30447	informed	_	
142-228	30448-30457	biomarker	_	
142-229	30458-30460	of	_	
142-230	30461-30469	response	_	
142-231	30470-30472	to	_	
142-232	30473-30481	nicotine	_	
142-233	30482-30487	patch	_	
142-234	30488-30490	or	_	
142-235	30491-30502	varenicline	_	
142-236	30503-30506	for	_	
142-237	30507-30514	smoking	_	
142-238	30515-30524	cessation	_	
142-239	30524-30525	:	_	
142-240	30526-30527	a	_	
142-241	30528-30538	randomised	_	
142-242	30538-30539	,	_	
142-243	30540-30552	double-blind	_	
142-244	30553-30571	placebo-controlled	_	
142-245	30572-30577	trial	_	
142-246	30578-30586	Nicotine	_	
142-247	30587-30597	metabolite	_	
142-248	30598-30603	ratio	_	
142-249	30604-30612	predicts	_	
142-250	30613-30621	efficacy	_	
142-251	30622-30624	of	_	
142-252	30625-30636	transdermal	_	
142-253	30637-30645	nicotine	_	
142-254	30646-30649	for	_	
142-255	30650-30657	smoking	_	
142-256	30658-30667	cessation	_	
142-257	30668-30675	Genetic	_	
142-258	30676-30685	variation	_	
142-259	30686-30688	in	_	
142-260	30689-30695	CYP2A6	_	
142-261	30696-30704	predicts	_	
142-262	30705-30711	neural	_	
142-263	30712-30722	reactivity	_	
142-264	30723-30725	to	_	
142-265	30726-30733	smoking	_	
142-266	30734-30738	cues	_	
142-267	30739-30741	as	_	
142-268	30742-30750	measured	_	
142-269	30751-30756	using	_	
142-270	30757-30761	fMRI	_	
142-271	30762-30765	How	_	
142-272	30766-30770	fast	_	
142-273	30771-30774	and	_	
142-274	30775-30778	how	_	
142-275	30779-30784	often	_	
142-276	30784-30785	:	_	
142-277	30786-30789	The	_	
142-278	30790-30806	pharmacokinetics	_	
142-279	30807-30809	of	_	
142-280	30810-30814	drug	_	
142-281	30815-30818	use	_	
142-282	30819-30822	are	_	
142-283	30823-30831	decisive	_	
142-284	30832-30834	in	_	
142-285	30835-30844	addiction	_	
142-286	30845-30848	Why	_	
142-287	30849-30853	does	_	
142-288	30854-30857	the	_	
142-289	30858-30863	rapid	_	
142-290	30864-30872	delivery	_	
142-291	30873-30875	of	_	
142-292	30876-30881	drugs	_	
142-293	30882-30884	to	_	
142-294	30885-30888	the	_	
142-295	30889-30894	brain	_	
142-296	30895-30902	promote	_	
142-297	30903-30912	addiction	_	
142-298	30912-30913	?	_	

#Text=Benzodiazepine use, abuse, and dependence
#Text=Cocaine addiction: hypothesis derived from imaging studies with PET
#Text=Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity
#Text=The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour
#Text=Resting-state functional connectivity in neuropsychiatric disorders
#Text=Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease
#Text=Coupling of functional connectivity and regional cerebral blood flow reveals a physiological basis for network hubs of the human brain
#Text=Energetic cost of brain functional connectivity
#Text=The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire
#Text=Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo
#Text=A region of mesial prefrontal cortex tracks monetarily rewarding outcomes: characterization with rapid event-related fMRI
#Text=Right hemispheric dominance of inhibitory control: an event-related functional MRI study
#Text=Acute nicotine differentially impacts anticipatory valence- and magnitude-related striatal activity
#Text=Cingulate hypoactivity in cocaine users during a GO-NOGO task as revealed by event-related functional magnetic resonance imaging
#Text=Reward Anticipation Is Differentially Modulated by Varenicline and Nicotine in Smokers
#Text=Association of nicotine addiction and nicotine's actions with separate cingulate cortex functional circuits
#Text=A genetically modulated, intrinsic cingulate circuit supports human nicotine addiction
#Text=Genetic and environmental contributions to smoking
#Text=The role of CYP2A6 in the emergence of nicotine dependence in adolescents
#Text=Impaired functional connectivity within and between frontostriatal circuits and its association with compulsive drug use and trait impulsivity in cocaine addiction
#Text=Cortico-striatal circuits: Novel therapeutic targets for substance use disorders
#Text=Fronto-striatal circuits in response-inhibition: Relevance to addiction
#Text=The reward circuit: linking primate anatomy and human imaging
#Text=Reward prediction in primate basal ganglia and frontal cortex
#Text=Risk-dependent reward value signal in human prefrontal cortex
#Text=Dissociable roles of ventral and dorsal striatum in instrumental conditioning
#Text=Limbic activation to cigarette smoking cues independent of nicotine withdrawal: a perfusion fMRI study
#Text=Ventral striatum/nucleus accumbens activation to smoking-related pictorial cues in smokers and nonsmokers: a functional magnetic resonance imaging study
#Text=Insula-Dorsal Anterior Cingulate Cortex Coupling is Associated with Enhanced Brain Reactivity to Smoking Cues
#Text=Factors underlying prefrontal and insula structural alterations in smokers
#Text=Brain connectivity related to working memory performance
#Text=Intrinsic resting-state activity predicts working memory brain activation and behavioral performance
#Text=Anterior cingulate cortex, error detection, and the online monitoring of performance
#Text=Subprocesses of performance monitoring: a dissociation of error processing and response competition revealed by event-related fMRI and ERPs
#Text=Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications
#Text=An association of CYP2A6 genotype and smoking topography
#Text=Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors
#Text=Dissociable intrinsic connectivity networks for salience processing and executive control
#Text=Large-scale brain network coupling predicts acute nicotine abstinence effects on craving and cognitive function
#Text=Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence
#Text=Pretreatment cue reactivity predicts end-of-treatment smoking
#Text=Damage to the insula disrupts addiction to cigarette smoking
#Text=Significance of the insula for the evolution of human awareness of feelings from the body
#Text=How do you feel--now?
143-1	30914-30928	Benzodiazepine	_	
143-2	30929-30932	use	_	
143-3	30932-30933	,	_	
143-4	30934-30939	abuse	_	
143-5	30939-30940	,	_	
143-6	30941-30944	and	_	
143-7	30945-30955	dependence	_	
143-8	30956-30963	Cocaine	_	
143-9	30964-30973	addiction	_	
143-10	30973-30974	:	_	
143-11	30975-30985	hypothesis	_	
143-12	30986-30993	derived	_	
143-13	30994-30998	from	_	
143-14	30999-31006	imaging	_	
143-15	31007-31014	studies	_	
143-16	31015-31019	with	_	
143-17	31020-31023	PET	_	
143-18	31024-31032	Nicotine	_	
143-19	31033-31043	metabolite	_	
143-20	31044-31049	ratio	_	
143-21	31050-31052	as	_	
143-22	31053-31055	an	_	
143-23	31056-31061	index	_	
143-24	31062-31064	of	_	
143-25	31065-31075	cytochrome	_	
143-26	31076-31080	P450	_	
143-27	31081-31084	2A6	_	
143-28	31085-31094	metabolic	_	
143-29	31095-31103	activity	_	
143-30	31104-31107	The	_	
143-31	31108-31120	neurobiology	_	
143-32	31121-31123	of	_	
143-33	31124-31132	nicotine	_	
143-34	31133-31142	addiction	_	
143-35	31142-31143	:	_	
143-36	31144-31152	bridging	_	
143-37	31153-31156	the	_	
143-38	31157-31160	gap	_	
143-39	31161-31165	from	_	
143-40	31166-31175	molecules	_	
143-41	31176-31178	to	_	
143-42	31179-31188	behaviour	_	
143-43	31189-31202	Resting-state	_	
143-44	31203-31213	functional	_	
143-45	31214-31226	connectivity	_	
143-46	31227-31229	in	_	
143-47	31230-31246	neuropsychiatric	_	
143-48	31247-31256	disorders	_	
143-49	31257-31265	Cortical	_	
143-50	31266-31270	hubs	_	
143-51	31271-31279	revealed	_	
143-52	31280-31282	by	_	
143-53	31283-31292	intrinsic	_	
143-54	31293-31303	functional	_	
143-55	31304-31316	connectivity	_	
143-56	31316-31317	:	_	
143-57	31318-31325	mapping	_	
143-58	31325-31326	,	_	
143-59	31327-31337	assessment	_	
143-60	31338-31340	of	_	
143-61	31341-31350	stability	_	
143-62	31350-31351	,	_	
143-63	31352-31355	and	_	
143-64	31356-31364	relation	_	
143-65	31365-31367	to	_	
143-66	31368-31379	Alzheimer's	_	
143-67	31380-31387	disease	_	
143-68	31388-31396	Coupling	_	
143-69	31397-31399	of	_	
143-70	31400-31410	functional	_	
143-71	31411-31423	connectivity	_	
143-72	31424-31427	and	_	
143-73	31428-31436	regional	_	
143-74	31437-31445	cerebral	_	
143-75	31446-31451	blood	_	
143-76	31452-31456	flow	_	
143-77	31457-31464	reveals	_	
143-78	31465-31466	a	_	
143-79	31467-31480	physiological	_	
143-80	31481-31486	basis	_	
143-81	31487-31490	for	_	
143-82	31491-31498	network	_	
143-83	31499-31503	hubs	_	
143-84	31504-31506	of	_	
143-85	31507-31510	the	_	
143-86	31511-31516	human	_	
143-87	31517-31522	brain	_	
143-88	31523-31532	Energetic	_	
143-89	31533-31537	cost	_	
143-90	31538-31540	of	_	
143-91	31541-31546	brain	_	
143-92	31547-31557	functional	_	
143-93	31558-31570	connectivity	_	
143-94	31571-31574	The	_	
143-95	31575-31585	Fagerström	_	
143-96	31586-31590	Test	_	
143-97	31591-31594	for	_	
143-98	31595-31603	Nicotine	_	
143-99	31604-31614	Dependence	_	
143-100	31614-31615	:	_	
143-101	31616-31617	a	_	
143-102	31618-31626	revision	_	
143-103	31627-31629	of	_	
143-104	31630-31633	the	_	
143-105	31634-31644	Fagerström	_	
143-106	31645-31654	Tolerance	_	
143-107	31655-31668	Questionnaire	_	
143-108	31669-31674	Novel	_	
143-109	31675-31681	CYP2A6	_	
143-110	31682-31690	variants	_	
143-111	31691-31701	identified	_	
143-112	31702-31704	in	_	
143-113	31705-31712	African	_	
143-114	31713-31722	Americans	_	
143-115	31723-31726	are	_	
143-116	31727-31737	associated	_	
143-117	31738-31742	with	_	
143-118	31743-31747	slow	_	
143-119	31748-31756	nicotine	_	
143-120	31757-31767	metabolism	_	
143-121	31768-31770	in	_	
143-122	31771-31776	vitro	_	
143-123	31777-31780	and	_	
143-124	31781-31783	in	_	
143-125	31784-31788	vivo	_	
143-126	31789-31790	A	_	
143-127	31791-31797	region	_	
143-128	31798-31800	of	_	
143-129	31801-31807	mesial	_	
143-130	31808-31818	prefrontal	_	
143-131	31819-31825	cortex	_	
143-132	31826-31832	tracks	_	
143-133	31833-31843	monetarily	_	
143-134	31844-31853	rewarding	_	
143-135	31854-31862	outcomes	_	
143-136	31862-31863	:	_	
143-137	31864-31880	characterization	_	
143-138	31881-31885	with	_	
143-139	31886-31891	rapid	_	
143-140	31892-31905	event-related	_	
143-141	31906-31910	fMRI	_	
143-142	31911-31916	Right	_	
143-143	31917-31928	hemispheric	_	
143-144	31929-31938	dominance	_	
143-145	31939-31941	of	_	
143-146	31942-31952	inhibitory	_	
143-147	31953-31960	control	_	
143-148	31960-31961	:	_	
143-149	31962-31964	an	_	
143-150	31965-31978	event-related	_	
143-151	31979-31989	functional	_	
143-152	31990-31993	MRI	_	
143-153	31994-31999	study	_	
143-154	32000-32005	Acute	_	
143-155	32006-32014	nicotine	_	
143-156	32015-32029	differentially	_	
143-157	32030-32037	impacts	_	
143-158	32038-32050	anticipatory	_	
143-159	32051-32058	valence	_	
143-160	32058-32059	-	_	
143-161	32060-32063	and	_	
143-162	32064-32081	magnitude-related	_	
143-163	32082-32090	striatal	_	
143-164	32091-32099	activity	_	
143-165	32100-32109	Cingulate	_	
143-166	32110-32122	hypoactivity	_	
143-167	32123-32125	in	_	
143-168	32126-32133	cocaine	_	
143-169	32134-32139	users	_	
143-170	32140-32146	during	_	
143-171	32147-32148	a	_	
143-172	32149-32156	GO-NOGO	_	
143-173	32157-32161	task	_	
143-174	32162-32164	as	_	
143-175	32165-32173	revealed	_	
143-176	32174-32176	by	_	
143-177	32177-32190	event-related	_	
143-178	32191-32201	functional	_	
143-179	32202-32210	magnetic	_	
143-180	32211-32220	resonance	_	
143-181	32221-32228	imaging	_	
143-182	32229-32235	Reward	_	
143-183	32236-32248	Anticipation	_	
143-184	32249-32251	Is	_	
143-185	32252-32266	Differentially	_	
143-186	32267-32276	Modulated	_	
143-187	32277-32279	by	_	
143-188	32280-32291	Varenicline	_	
143-189	32292-32295	and	_	
143-190	32296-32304	Nicotine	_	
143-191	32305-32307	in	_	
143-192	32308-32315	Smokers	_	
143-193	32316-32327	Association	_	
143-194	32328-32330	of	_	
143-195	32331-32339	nicotine	_	
143-196	32340-32349	addiction	_	
143-197	32350-32353	and	_	
143-198	32354-32364	nicotine's	_	
143-199	32365-32372	actions	_	
143-200	32373-32377	with	_	
143-201	32378-32386	separate	_	
143-202	32387-32396	cingulate	_	
143-203	32397-32403	cortex	_	
143-204	32404-32414	functional	_	
143-205	32415-32423	circuits	_	
143-206	32424-32425	A	_	
143-207	32426-32437	genetically	_	
143-208	32438-32447	modulated	_	
143-209	32447-32448	,	_	
143-210	32449-32458	intrinsic	_	
143-211	32459-32468	cingulate	_	
143-212	32469-32476	circuit	_	
143-213	32477-32485	supports	_	
143-214	32486-32491	human	_	
143-215	32492-32500	nicotine	_	
143-216	32501-32510	addiction	_	
143-217	32511-32518	Genetic	_	
143-218	32519-32522	and	_	
143-219	32523-32536	environmental	_	
143-220	32537-32550	contributions	_	
143-221	32551-32553	to	_	
143-222	32554-32561	smoking	_	
143-223	32562-32565	The	_	
143-224	32566-32570	role	_	
143-225	32571-32573	of	_	
143-226	32574-32580	CYP2A6	_	
143-227	32581-32583	in	_	
143-228	32584-32587	the	_	
143-229	32588-32597	emergence	_	
143-230	32598-32600	of	_	
143-231	32601-32609	nicotine	_	
143-232	32610-32620	dependence	_	
143-233	32621-32623	in	_	
143-234	32624-32635	adolescents	_	
143-235	32636-32644	Impaired	_	
143-236	32645-32655	functional	_	
143-237	32656-32668	connectivity	_	
143-238	32669-32675	within	_	
143-239	32676-32679	and	_	
143-240	32680-32687	between	_	
143-241	32688-32702	frontostriatal	_	
143-242	32703-32711	circuits	_	
143-243	32712-32715	and	_	
143-244	32716-32719	its	_	
143-245	32720-32731	association	_	
143-246	32732-32736	with	_	
143-247	32737-32747	compulsive	_	
143-248	32748-32752	drug	_	
143-249	32753-32756	use	_	
143-250	32757-32760	and	_	
143-251	32761-32766	trait	_	
143-252	32767-32778	impulsivity	_	
143-253	32779-32781	in	_	
143-254	32782-32789	cocaine	_	
143-255	32790-32799	addiction	_	
143-256	32800-32816	Cortico-striatal	_	
143-257	32817-32825	circuits	_	
143-258	32825-32826	:	_	
143-259	32827-32832	Novel	_	
143-260	32833-32844	therapeutic	_	
143-261	32845-32852	targets	_	
143-262	32853-32856	for	_	
143-263	32857-32866	substance	_	
143-264	32867-32870	use	_	
143-265	32871-32880	disorders	_	
143-266	32881-32896	Fronto-striatal	_	
143-267	32897-32905	circuits	_	
143-268	32906-32908	in	_	
143-269	32909-32928	response-inhibition	_	
143-270	32928-32929	:	_	
143-271	32930-32939	Relevance	_	
143-272	32940-32942	to	_	
143-273	32943-32952	addiction	_	
143-274	32953-32956	The	_	
143-275	32957-32963	reward	_	
143-276	32964-32971	circuit	_	
143-277	32971-32972	:	_	
143-278	32973-32980	linking	_	
143-279	32981-32988	primate	_	
143-280	32989-32996	anatomy	_	
143-281	32997-33000	and	_	
143-282	33001-33006	human	_	
143-283	33007-33014	imaging	_	
143-284	33015-33021	Reward	_	
143-285	33022-33032	prediction	_	
143-286	33033-33035	in	_	
143-287	33036-33043	primate	_	
143-288	33044-33049	basal	_	
143-289	33050-33057	ganglia	_	
143-290	33058-33061	and	_	
143-291	33062-33069	frontal	_	
143-292	33070-33076	cortex	_	
143-293	33077-33091	Risk-dependent	_	
143-294	33092-33098	reward	_	
143-295	33099-33104	value	_	
143-296	33105-33111	signal	_	
143-297	33112-33114	in	_	
143-298	33115-33120	human	_	
143-299	33121-33131	prefrontal	_	
143-300	33132-33138	cortex	_	
143-301	33139-33150	Dissociable	_	
143-302	33151-33156	roles	_	
143-303	33157-33159	of	_	
143-304	33160-33167	ventral	_	
143-305	33168-33171	and	_	
143-306	33172-33178	dorsal	_	
143-307	33179-33187	striatum	_	
143-308	33188-33190	in	_	
143-309	33191-33203	instrumental	_	
143-310	33204-33216	conditioning	_	
143-311	33217-33223	Limbic	_	
143-312	33224-33234	activation	_	
143-313	33235-33237	to	_	
143-314	33238-33247	cigarette	_	
143-315	33248-33255	smoking	_	
143-316	33256-33260	cues	_	
143-317	33261-33272	independent	_	
143-318	33273-33275	of	_	
143-319	33276-33284	nicotine	_	
143-320	33285-33295	withdrawal	_	
143-321	33295-33296	:	_	
143-322	33297-33298	a	_	
143-323	33299-33308	perfusion	_	
143-324	33309-33313	fMRI	_	
143-325	33314-33319	study	_	
143-326	33320-33327	Ventral	_	
143-327	33328-33336	striatum	_	
143-328	33336-33337	/	_	
143-329	33337-33344	nucleus	_	
143-330	33345-33354	accumbens	_	
143-331	33355-33365	activation	_	
143-332	33366-33368	to	_	
143-333	33369-33384	smoking-related	_	
143-334	33385-33394	pictorial	_	
143-335	33395-33399	cues	_	
143-336	33400-33402	in	_	
143-337	33403-33410	smokers	_	
143-338	33411-33414	and	_	
143-339	33415-33425	nonsmokers	_	
143-340	33425-33426	:	_	
143-341	33427-33428	a	_	
143-342	33429-33439	functional	_	
143-343	33440-33448	magnetic	_	
143-344	33449-33458	resonance	_	
143-345	33459-33466	imaging	_	
143-346	33467-33472	study	_	
143-347	33473-33486	Insula-Dorsal	_	
143-348	33487-33495	Anterior	_	
143-349	33496-33505	Cingulate	_	
143-350	33506-33512	Cortex	_	
143-351	33513-33521	Coupling	_	
143-352	33522-33524	is	_	
143-353	33525-33535	Associated	_	
143-354	33536-33540	with	_	
143-355	33541-33549	Enhanced	_	
143-356	33550-33555	Brain	_	
143-357	33556-33566	Reactivity	_	
143-358	33567-33569	to	_	
143-359	33570-33577	Smoking	_	
143-360	33578-33582	Cues	_	
143-361	33583-33590	Factors	_	
143-362	33591-33601	underlying	_	
143-363	33602-33612	prefrontal	_	
143-364	33613-33616	and	_	
143-365	33617-33623	insula	_	
143-366	33624-33634	structural	_	
143-367	33635-33646	alterations	_	
143-368	33647-33649	in	_	
143-369	33650-33657	smokers	_	
143-370	33658-33663	Brain	_	
143-371	33664-33676	connectivity	_	
143-372	33677-33684	related	_	
143-373	33685-33687	to	_	
143-374	33688-33695	working	_	
143-375	33696-33702	memory	_	
143-376	33703-33714	performance	_	
143-377	33715-33724	Intrinsic	_	
143-378	33725-33738	resting-state	_	
143-379	33739-33747	activity	_	
143-380	33748-33756	predicts	_	
143-381	33757-33764	working	_	
143-382	33765-33771	memory	_	
143-383	33772-33777	brain	_	
143-384	33778-33788	activation	_	
143-385	33789-33792	and	_	
143-386	33793-33803	behavioral	_	
143-387	33804-33815	performance	_	
143-388	33816-33824	Anterior	_	
143-389	33825-33834	cingulate	_	
143-390	33835-33841	cortex	_	
143-391	33841-33842	,	_	
143-392	33843-33848	error	_	
143-393	33849-33858	detection	_	
143-394	33858-33859	,	_	
143-395	33860-33863	and	_	
143-396	33864-33867	the	_	
143-397	33868-33874	online	_	
143-398	33875-33885	monitoring	_	
143-399	33886-33888	of	_	
143-400	33889-33900	performance	_	
143-401	33901-33913	Subprocesses	_	
143-402	33914-33916	of	_	
143-403	33917-33928	performance	_	
143-404	33929-33939	monitoring	_	
143-405	33939-33940	:	_	
143-406	33941-33942	a	_	
143-407	33943-33955	dissociation	_	
143-408	33956-33958	of	_	
143-409	33959-33964	error	_	
143-410	33965-33975	processing	_	
143-411	33976-33979	and	_	
143-412	33980-33988	response	_	
143-413	33989-34000	competition	_	
143-414	34001-34009	revealed	_	
143-415	34010-34012	by	_	
143-416	34013-34026	event-related	_	
143-417	34027-34031	fMRI	_	
143-418	34032-34035	and	_	
143-419	34036-34040	ERPs	_	
143-420	34041-34052	Dysfunction	_	
143-421	34053-34055	of	_	
143-422	34056-34059	the	_	
143-423	34060-34070	prefrontal	_	
143-424	34071-34077	cortex	_	
143-425	34078-34080	in	_	
143-426	34081-34090	addiction	_	
143-427	34090-34091	:	_	
143-428	34092-34104	neuroimaging	_	
143-429	34105-34113	findings	_	
143-430	34114-34117	and	_	
143-431	34118-34126	clinical	_	
143-432	34127-34139	implications	_	
143-433	34140-34142	An	_	
143-434	34143-34154	association	_	
143-435	34155-34157	of	_	
143-436	34158-34164	CYP2A6	_	
143-437	34165-34173	genotype	_	
143-438	34174-34177	and	_	
143-439	34178-34185	smoking	_	
143-440	34186-34196	topography	_	
143-441	34197-34204	Hepatic	_	
143-442	34205-34211	CYP2A6	_	
143-443	34212-34218	levels	_	
143-444	34219-34222	and	_	
143-445	34223-34231	nicotine	_	
143-446	34232-34242	metabolism	_	
143-447	34242-34243	:	_	
143-448	34244-34250	impact	_	
143-449	34251-34253	of	_	
143-450	34254-34261	genetic	_	
143-451	34261-34262	,	_	
143-452	34263-34276	physiological	_	
143-453	34276-34277	,	_	
143-454	34278-34291	environmental	_	
143-455	34291-34292	,	_	
143-456	34293-34296	and	_	
143-457	34297-34307	epigenetic	_	
143-458	34308-34315	factors	_	
143-459	34316-34327	Dissociable	_	
143-460	34328-34337	intrinsic	_	
143-461	34338-34350	connectivity	_	
143-462	34351-34359	networks	_	
143-463	34360-34363	for	_	
143-464	34364-34372	salience	_	
143-465	34373-34383	processing	_	
143-466	34384-34387	and	_	
143-467	34388-34397	executive	_	
143-468	34398-34405	control	_	
143-469	34406-34417	Large-scale	_	
143-470	34418-34423	brain	_	
143-471	34424-34431	network	_	
143-472	34432-34440	coupling	_	
143-473	34441-34449	predicts	_	
143-474	34450-34455	acute	_	
143-475	34456-34464	nicotine	_	
143-476	34465-34475	abstinence	_	
143-477	34476-34483	effects	_	
143-478	34484-34486	on	_	
143-479	34487-34494	craving	_	
143-480	34495-34498	and	_	
143-481	34499-34508	cognitive	_	
143-482	34509-34517	function	_	
143-483	34518-34523	Brain	_	
143-484	34524-34534	reactivity	_	
143-485	34535-34537	to	_	
143-486	34538-34545	smoking	_	
143-487	34546-34550	cues	_	
143-488	34551-34556	prior	_	
143-489	34557-34559	to	_	
143-490	34560-34567	smoking	_	
143-491	34568-34577	cessation	_	
143-492	34578-34586	predicts	_	
143-493	34587-34594	ability	_	
143-494	34595-34597	to	_	
143-495	34598-34606	maintain	_	
143-496	34607-34614	tobacco	_	
143-497	34615-34625	abstinence	_	
143-498	34626-34638	Pretreatment	_	
143-499	34639-34642	cue	_	
143-500	34643-34653	reactivity	_	
143-501	34654-34662	predicts	_	
143-502	34663-34679	end-of-treatment	_	
143-503	34680-34687	smoking	_	
143-504	34688-34694	Damage	_	
143-505	34695-34697	to	_	
143-506	34698-34701	the	_	
143-507	34702-34708	insula	_	
143-508	34709-34717	disrupts	_	
143-509	34718-34727	addiction	_	
143-510	34728-34730	to	_	
143-511	34731-34740	cigarette	_	
143-512	34741-34748	smoking	_	
143-513	34749-34761	Significance	_	
143-514	34762-34764	of	_	
143-515	34765-34768	the	_	
143-516	34769-34775	insula	_	
143-517	34776-34779	for	_	
143-518	34780-34783	the	_	
143-519	34784-34793	evolution	_	
143-520	34794-34796	of	_	
143-521	34797-34802	human	_	
143-522	34803-34812	awareness	_	
143-523	34813-34815	of	_	
143-524	34816-34824	feelings	_	
143-525	34825-34829	from	_	
143-526	34830-34833	the	_	
143-527	34834-34838	body	_	
143-528	34839-34842	How	_	
143-529	34843-34845	do	_	
143-530	34846-34849	you	_	
143-531	34850-34854	feel	_	
143-532	34854-34855	-	_	
143-533	34855-34856	-	_	
143-534	34856-34859	now	_	
143-535	34859-34860	?	_	

#Text=The anterior insula and human awareness
#Text=Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro
#Text=Interaction between CYP2A6 genotype and smoking status
#Text=A) FCS network analysis illustrating the interaction between the CYP2A6 genotype and smoking status in the dorsal anterior cingulate (dACC) and left ventral striatum (VS).
144-1	34861-34864	The	_	
144-2	34865-34873	anterior	_	
144-3	34874-34880	insula	_	
144-4	34881-34884	and	_	
144-5	34885-34890	human	_	
144-6	34891-34900	awareness	_	
144-7	34901-34911	Metabolism	_	
144-8	34912-34915	and	_	
144-9	34916-34927	disposition	_	
144-10	34928-34930	of	_	
144-11	34931-34942	varenicline	_	
144-12	34942-34943	,	_	
144-13	34944-34945	a	_	
144-14	34946-34955	selective	_	
144-15	34956-34967	alpha4beta2	_	
144-16	34968-34981	acetylcholine	_	
144-17	34982-34990	receptor	_	
144-18	34991-34998	partial	_	
144-19	34999-35006	agonist	_	
144-20	35006-35007	,	_	
144-21	35008-35010	in	_	
144-22	35011-35015	vivo	_	
144-23	35016-35019	and	_	
144-24	35020-35022	in	_	
144-25	35023-35028	vitro	_	
144-26	35029-35040	Interaction	_	
144-27	35041-35048	between	_	
144-28	35049-35055	CYP2A6	_	
144-29	35056-35064	genotype	_	
144-30	35065-35068	and	_	
144-31	35069-35076	smoking	_	
144-32	35077-35083	status	_	
144-33	35084-35085	A	_	
144-34	35085-35086	)	_	
144-35	35087-35090	FCS	_	
144-36	35091-35098	network	_	
144-37	35099-35107	analysis	_	
144-38	35108-35120	illustrating	_	
144-39	35121-35124	the	_	
144-40	35125-35136	interaction	_	
144-41	35137-35144	between	_	
144-42	35145-35148	the	_	
144-43	35149-35155	CYP2A6	_	
144-44	35156-35164	genotype	_	
144-45	35165-35168	and	_	
144-46	35169-35176	smoking	_	
144-47	35177-35183	status	_	
144-48	35184-35186	in	_	
144-49	35187-35190	the	_	
144-50	35191-35197	dorsal	_	
144-51	35198-35206	anterior	_	
144-52	35207-35216	cingulate	_	
144-53	35217-35218	(	_	
144-54	35218-35222	dACC	_	
144-55	35222-35223	)	_	
144-56	35224-35227	and	_	
144-57	35228-35232	left	_	
144-58	35233-35240	ventral	_	
144-59	35241-35249	striatum	_	
144-60	35250-35251	(	_	
144-61	35251-35253	VS	_	
144-62	35253-35254	)	_	
144-63	35254-35255	.	_	

#Text=B–C) Mean FCS values in the dACC and VS in each of the six groups.
145-1	35256-35259	B–C	_	
145-2	35259-35260	)	_	
145-3	35261-35265	Mean	_	
145-4	35266-35269	FCS	_	
145-5	35270-35276	values	_	
145-6	35277-35279	in	_	
145-7	35280-35283	the	_	
145-8	35284-35288	dACC	_	
145-9	35289-35292	and	_	
145-10	35293-35295	VS	_	
145-11	35296-35298	in	_	
145-12	35299-35303	each	_	
145-13	35304-35306	of	_	
145-14	35307-35310	the	_	
145-15	35311-35314	six	_	
145-16	35315-35321	groups	_	
145-17	35321-35322	.	_	

#Text=In both brain regions smokers with the normal metabolizing genotype had higher FCS than all nonsmoker groups and smokers with the slow metabolizing genotype.
146-1	35323-35325	In	_	
146-2	35326-35330	both	_	
146-3	35331-35336	brain	_	
146-4	35337-35344	regions	_	
146-5	35345-35352	smokers	_	
146-6	35353-35357	with	_	
146-7	35358-35361	the	_	
146-8	35362-35368	normal	_	
146-9	35369-35381	metabolizing	_	
146-10	35382-35390	genotype	_	
146-11	35391-35394	had	_	
146-12	35395-35401	higher	_	
146-13	35402-35405	FCS	_	
146-14	35406-35410	than	_	
146-15	35411-35414	all	_	
146-16	35415-35424	nonsmoker	_	
146-17	35425-35431	groups	_	
146-18	35432-35435	and	_	
146-19	35436-35443	smokers	_	
146-20	35444-35448	with	_	
146-21	35449-35452	the	_	
146-22	35453-35457	slow	_	
146-23	35458-35470	metabolizing	_	
146-24	35471-35479	genotype	_	
146-25	35479-35480	.	_	

#Text=There was no effect of the CYP2A6 genotype on FCS among nonsmokers.
147-1	35481-35486	There	_	
147-2	35487-35490	was	_	
147-3	35491-35493	no	_	
147-4	35494-35500	effect	_	
147-5	35501-35503	of	_	
147-6	35504-35507	the	_	
147-7	35508-35514	CYP2A6	_	
147-8	35515-35523	genotype	_	
147-9	35524-35526	on	_	
147-10	35527-35530	FCS	_	
147-11	35531-35536	among	_	
147-12	35537-35547	nonsmokers	_	
147-13	35547-35548	.	_	

#Text=D–E) There was a negative correlation in both hubs in the slow but not in the normal or intermediate genotype groups, i.e. as smoking dependence increased, FCS decreased in both VS (r = −0.51, P = 0.01) and dACC (r = −0.44, P = 0.04).
148-1	35549-35552	D–E	_	
148-2	35552-35553	)	_	
148-3	35554-35559	There	_	
148-4	35560-35563	was	_	
148-5	35564-35565	a	_	
148-6	35566-35574	negative	_	
148-7	35575-35586	correlation	_	
148-8	35587-35589	in	_	
148-9	35590-35594	both	_	
148-10	35595-35599	hubs	_	
148-11	35600-35602	in	_	
148-12	35603-35606	the	_	
148-13	35607-35611	slow	_	
148-14	35612-35615	but	_	
148-15	35616-35619	not	_	
148-16	35620-35622	in	_	
148-17	35623-35626	the	_	
148-18	35627-35633	normal	_	
148-19	35634-35636	or	_	
148-20	35637-35649	intermediate	_	
148-21	35650-35658	genotype	_	
148-22	35659-35665	groups	_	
148-23	35665-35666	,	_	
148-24	35667-35670	i.e	_	
148-25	35670-35671	.	_	
148-26	35672-35674	as	_	
148-27	35675-35682	smoking	_	
148-28	35683-35693	dependence	_	
148-29	35694-35703	increased	_	
148-30	35703-35704	,	_	
148-31	35705-35708	FCS	_	
148-32	35709-35718	decreased	_	
148-33	35719-35721	in	_	
148-34	35722-35726	both	_	
148-35	35727-35729	VS	_	
148-36	35730-35731	(	_	
148-37	35731-35732	r	_	
148-38	35733-35734	=	_	
148-39	35735-35736	−	_	
148-40	35736-35740	0.51	_	
148-41	35740-35741	,	_	
148-42	35742-35743	P	_	
148-43	35744-35745	=	_	
148-44	35746-35750	0.01	_	
148-45	35750-35751	)	_	
148-46	35752-35755	and	_	
148-47	35756-35760	dACC	_	
148-48	35761-35762	(	_	
148-49	35762-35763	r	_	
148-50	35764-35765	=	_	
148-51	35766-35767	−	_	
148-52	35767-35771	0.44	_	
148-53	35771-35772	,	_	
148-54	35773-35774	P	_	
148-55	35775-35776	=	_	
148-56	35777-35781	0.04	_	
148-57	35781-35782	)	_	
148-58	35782-35783	.	_	

#Text=*P < 0.05.
149-1	35784-35785	*	_	
149-2	35785-35786	P	_	
149-3	35787-35788	<	_	
149-4	35789-35793	0.05	_	
149-5	35793-35794	.	_	

#Text=Seed-based resting state functional connectivity
#Text=A) The dACC seed based on the CYP2A6 × smoking interaction from Fig. 1 (green) was significantly connected to (1) dACC (2, 3) bilateral insula and (4) posterior cingulate cortex.
150-1	35795-35805	Seed-based	_	
150-2	35806-35813	resting	_	
150-3	35814-35819	state	_	
150-4	35820-35830	functional	_	
150-5	35831-35843	connectivity	_	
150-6	35844-35845	A	_	
150-7	35845-35846	)	_	
150-8	35847-35850	The	_	
150-9	35851-35855	dACC	_	
150-10	35856-35860	seed	_	
150-11	35861-35866	based	_	
150-12	35867-35869	on	_	
150-13	35870-35873	the	_	
150-14	35874-35880	CYP2A6	_	
150-15	35881-35882	×	_	
150-16	35883-35890	smoking	_	
150-17	35891-35902	interaction	_	
150-18	35903-35907	from	_	
150-19	35908-35911	Fig	_	
150-20	35911-35912	.	_	
150-21	35913-35914	1	_	
150-22	35915-35916	(	_	
150-23	35916-35921	green	_	
150-24	35921-35922	)	_	
150-25	35923-35926	was	_	
150-26	35927-35940	significantly	_	
150-27	35941-35950	connected	_	
150-28	35951-35953	to	_	
150-29	35954-35955	(	_	
150-30	35955-35956	1	_	
150-31	35956-35957	)	_	
150-32	35958-35962	dACC	_	
150-33	35963-35964	(	_	
150-34	35964-35965	2	_	
150-35	35965-35966	,	_	
150-36	35967-35968	3	_	
150-37	35968-35969	)	_	
150-38	35970-35979	bilateral	_	
150-39	35980-35986	insula	_	
150-40	35987-35990	and	_	
150-41	35991-35992	(	_	
150-42	35992-35993	4	_	
150-43	35993-35994	)	_	
150-44	35995-36004	posterior	_	
150-45	36005-36014	cingulate	_	
150-46	36015-36021	cortex	_	
150-47	36021-36022	.	_	

#Text=B) The VS seed based on the CYP2A6 × smoking interaction from Fig. 1 (green) was significantly connected with (1) dACC and (2, 3) bilateral insula.
151-1	36023-36024	B	_	
151-2	36024-36025	)	_	
151-3	36026-36029	The	_	
151-4	36030-36032	VS	_	
151-5	36033-36037	seed	_	
151-6	36038-36043	based	_	
151-7	36044-36046	on	_	
151-8	36047-36050	the	_	
151-9	36051-36057	CYP2A6	_	
151-10	36058-36059	×	_	
151-11	36060-36067	smoking	_	
151-12	36068-36079	interaction	_	
151-13	36080-36084	from	_	
151-14	36085-36088	Fig	_	
151-15	36088-36089	.	_	
151-16	36090-36091	1	_	
151-17	36092-36093	(	_	
151-18	36093-36098	green	_	
151-19	36098-36099	)	_	
151-20	36100-36103	was	_	
151-21	36104-36117	significantly	_	
151-22	36118-36127	connected	_	
151-23	36128-36132	with	_	
151-24	36133-36134	(	_	
151-25	36134-36135	1	_	
151-26	36135-36136	)	_	
151-27	36137-36141	dACC	_	
151-28	36142-36145	and	_	
151-29	36146-36147	(	_	
151-30	36147-36148	2	_	
151-31	36148-36149	,	_	
151-32	36150-36151	3	_	
151-33	36151-36152	)	_	
151-34	36153-36162	bilateral	_	
151-35	36163-36169	insula	_	
151-36	36169-36170	.	_	

#Text=CYP2A6 genotype alters neural activation during the MID-R and Go/NoGo task
#Text=A) Coronal section illustrating the task map from all subjects when performing the MID task with significant activation in bilateral VS when anticipating a gain (vs. neutral) condition.
152-1	36171-36177	CYP2A6	_	
152-2	36178-36186	genotype	_	
152-3	36187-36193	alters	_	
152-4	36194-36200	neural	_	
152-5	36201-36211	activation	_	
152-6	36212-36218	during	_	
152-7	36219-36222	the	_	
152-8	36223-36228	MID-R	_	
152-9	36229-36232	and	_	
152-10	36233-36235	Go	_	
152-11	36235-36236	/	_	
152-12	36236-36240	NoGo	_	
152-13	36241-36245	task	_	
152-14	36246-36247	A	_	
152-15	36247-36248	)	_	
152-16	36249-36256	Coronal	_	
152-17	36257-36264	section	_	
152-18	36265-36277	illustrating	_	
152-19	36278-36281	the	_	
152-20	36282-36286	task	_	
152-21	36287-36290	map	_	
152-22	36291-36295	from	_	
152-23	36296-36299	all	_	
152-24	36300-36308	subjects	_	
152-25	36309-36313	when	_	
152-26	36314-36324	performing	_	
152-27	36325-36328	the	_	
152-28	36329-36332	MID	_	
152-29	36333-36337	task	_	
152-30	36338-36342	with	_	
152-31	36343-36354	significant	_	
152-32	36355-36365	activation	_	
152-33	36366-36368	in	_	
152-34	36369-36378	bilateral	_	
152-35	36379-36381	VS	_	
152-36	36382-36386	when	_	
152-37	36387-36399	anticipating	_	
152-38	36400-36401	a	_	
152-39	36402-36406	gain	_	
152-40	36407-36408	(	_	
152-41	36408-36410	vs	_	
152-42	36410-36411	.	_	
152-43	36412-36419	neutral	_	
152-44	36419-36420	)	_	
152-45	36421-36430	condition	_	
152-46	36430-36431	.	_	

#Text=Smokers (but not nonsmokers) with the reduced (slow and intermediate) genotype showed less BOLD signal change compared with those with the normal genotype under the placebo patch condition (i.e. acute abstinence).
153-1	36432-36439	Smokers	_	
153-2	36440-36441	(	_	
153-3	36441-36444	but	_	
153-4	36445-36448	not	_	
153-5	36449-36459	nonsmokers	_	
153-6	36459-36460	)	_	
153-7	36461-36465	with	_	
153-8	36466-36469	the	_	
153-9	36470-36477	reduced	_	
153-10	36478-36479	(	_	
153-11	36479-36483	slow	_	
153-12	36484-36487	and	_	
153-13	36488-36500	intermediate	_	
153-14	36500-36501	)	_	
153-15	36502-36510	genotype	_	
153-16	36511-36517	showed	_	
153-17	36518-36522	less	_	
153-18	36523-36527	BOLD	_	
153-19	36528-36534	signal	_	
153-20	36535-36541	change	_	
153-21	36542-36550	compared	_	
153-22	36551-36555	with	_	
153-23	36556-36561	those	_	
153-24	36562-36566	with	_	
153-25	36567-36570	the	_	
153-26	36571-36577	normal	_	
153-27	36578-36586	genotype	_	
153-28	36587-36592	under	_	
153-29	36593-36596	the	_	
153-30	36597-36604	placebo	_	
153-31	36605-36610	patch	_	
153-32	36611-36620	condition	_	
153-33	36621-36622	(	_	
153-34	36622-36625	i.e	_	
153-35	36625-36626	.	_	
153-36	36627-36632	acute	_	
153-37	36633-36643	abstinence	_	
153-38	36643-36644	)	_	
153-39	36644-36645	.	_	

#Text=Acute nicotine patch administration normalized the genotype effect in smokers and appeared to also enhance activity in nonsmokers with the reduced genotype.
154-1	36646-36651	Acute	_	
154-2	36652-36660	nicotine	_	
154-3	36661-36666	patch	_	
154-4	36667-36681	administration	_	
154-5	36682-36692	normalized	_	
154-6	36693-36696	the	_	
154-7	36697-36705	genotype	_	
154-8	36706-36712	effect	_	
154-9	36713-36715	in	_	
154-10	36716-36723	smokers	_	
154-11	36724-36727	and	_	
154-12	36728-36736	appeared	_	
154-13	36737-36739	to	_	
154-14	36740-36744	also	_	
154-15	36745-36752	enhance	_	
154-16	36753-36761	activity	_	
154-17	36762-36764	in	_	
154-18	36765-36775	nonsmokers	_	
154-19	36776-36780	with	_	
154-20	36781-36784	the	_	
154-21	36785-36792	reduced	_	
154-22	36793-36801	genotype	_	
154-23	36801-36802	.	_	

#Text=B) Similarly, dACC activation was smaller in reduced metabolizing smokers (but not nonsmokers) following unsuccessful inhibitions in the Go/NoGo task under the placebo patch condition.
155-1	36803-36804	B	_	
155-2	36804-36805	)	_	
155-3	36806-36815	Similarly	_	
155-4	36815-36816	,	_	
155-5	36817-36821	dACC	_	
155-6	36822-36832	activation	_	
155-7	36833-36836	was	_	
155-8	36837-36844	smaller	_	
155-9	36845-36847	in	_	
155-10	36848-36855	reduced	_	
155-11	36856-36868	metabolizing	_	
155-12	36869-36876	smokers	_	
155-13	36877-36878	(	_	
155-14	36878-36881	but	_	
155-15	36882-36885	not	_	
155-16	36886-36896	nonsmokers	_	
155-17	36896-36897	)	_	
155-18	36898-36907	following	_	
155-19	36908-36920	unsuccessful	_	
155-20	36921-36932	inhibitions	_	
155-21	36933-36935	in	_	
155-22	36936-36939	the	_	
155-23	36940-36942	Go	_	
155-24	36942-36943	/	_	
155-25	36943-36947	NoGo	_	
155-26	36948-36952	task	_	
155-27	36953-36958	under	_	
155-28	36959-36962	the	_	
155-29	36963-36970	placebo	_	
155-30	36971-36976	patch	_	
155-31	36977-36986	condition	_	
155-32	36986-36987	.	_	

#Text=Once again, nicotine patch administration appeared to normalize this effect in reduced metabolizing smokers, while also increasing dACC activity in reduced metabolizing nonsmokers.
156-1	36988-36992	Once	_	
156-2	36993-36998	again	_	
156-3	36998-36999	,	_	
156-4	37000-37008	nicotine	_	
156-5	37009-37014	patch	_	
156-6	37015-37029	administration	_	
156-7	37030-37038	appeared	_	
156-8	37039-37041	to	_	
156-9	37042-37051	normalize	_	
156-10	37052-37056	this	_	
156-11	37057-37063	effect	_	
156-12	37064-37066	in	_	
156-13	37067-37074	reduced	_	
156-14	37075-37087	metabolizing	_	
156-15	37088-37095	smokers	_	
156-16	37095-37096	,	_	
156-17	37097-37102	while	_	
156-18	37103-37107	also	_	
156-19	37108-37118	increasing	_	
156-20	37119-37123	dACC	_	
156-21	37124-37132	activity	_	
156-22	37133-37135	in	_	
156-23	37136-37143	reduced	_	
156-24	37144-37156	metabolizing	_	
156-25	37157-37167	nonsmokers	_	
156-26	37167-37168	.	_	

#Text=ANCOVA results demonstrating main effect of CYP2A6 genotype and smoking status
#Text=A–B) Main effect of CYP2A6 genotype, demonstrating that both the slow and intermediate genotype groups showed significantly smaller FCS in bilateral precentral gyrus and bilateral insula than the normal genotype group, regardless of smoking status.
157-1	37169-37175	ANCOVA	_	
157-2	37176-37183	results	_	
157-3	37184-37197	demonstrating	_	
157-4	37198-37202	main	_	
157-5	37203-37209	effect	_	
157-6	37210-37212	of	_	
157-7	37213-37219	CYP2A6	_	
157-8	37220-37228	genotype	_	
157-9	37229-37232	and	_	
157-10	37233-37240	smoking	_	
157-11	37241-37247	status	_	
157-12	37248-37251	A–B	_	
157-13	37251-37252	)	_	
157-14	37253-37257	Main	_	
157-15	37258-37264	effect	_	
157-16	37265-37267	of	_	
157-17	37268-37274	CYP2A6	_	
157-18	37275-37283	genotype	_	
157-19	37283-37284	,	_	
157-20	37285-37298	demonstrating	_	
157-21	37299-37303	that	_	
157-22	37304-37308	both	_	
157-23	37309-37312	the	_	
157-24	37313-37317	slow	_	
157-25	37318-37321	and	_	
157-26	37322-37334	intermediate	_	
157-27	37335-37343	genotype	_	
157-28	37344-37350	groups	_	
157-29	37351-37357	showed	_	
157-30	37358-37371	significantly	_	
157-31	37372-37379	smaller	_	
157-32	37380-37383	FCS	_	
157-33	37384-37386	in	_	
157-34	37387-37396	bilateral	_	
157-35	37397-37407	precentral	_	
157-36	37408-37413	gyrus	_	
157-37	37414-37417	and	_	
157-38	37418-37427	bilateral	_	
157-39	37428-37434	insula	_	
157-40	37435-37439	than	_	
157-41	37440-37443	the	_	
157-42	37444-37450	normal	_	
157-43	37451-37459	genotype	_	
157-44	37460-37465	group	_	
157-45	37465-37466	,	_	
157-46	37467-37477	regardless	_	
157-47	37478-37480	of	_	
157-48	37481-37488	smoking	_	
157-49	37489-37495	status	_	
157-50	37495-37496	.	_	

#Text=C–D) Main effect of smoking status, demonstrating that smokers showed significantly less FCS in the bilateral superior temporal gyrus than nonsmokers, regardless of genotype.
158-1	37497-37500	C–D	_	
158-2	37500-37501	)	_	
158-3	37502-37506	Main	_	
158-4	37507-37513	effect	_	
158-5	37514-37516	of	_	
158-6	37517-37524	smoking	_	
158-7	37525-37531	status	_	
158-8	37531-37532	,	_	
158-9	37533-37546	demonstrating	_	
158-10	37547-37551	that	_	
158-11	37552-37559	smokers	_	
158-12	37560-37566	showed	_	
158-13	37567-37580	significantly	_	
158-14	37581-37585	less	_	
158-15	37586-37589	FCS	_	
158-16	37590-37592	in	_	
158-17	37593-37596	the	_	
158-18	37597-37606	bilateral	_	
158-19	37607-37615	superior	_	
158-20	37616-37624	temporal	_	
158-21	37625-37630	gyrus	_	
158-22	37631-37635	than	_	
158-23	37636-37646	nonsmokers	_	
158-24	37646-37647	,	_	
158-25	37648-37658	regardless	_	
158-26	37659-37661	of	_	
158-27	37662-37670	genotype	_	
158-28	37670-37671	.	_	

#Text=L, left; R, right; PCG, Precentral gyrus; STG, superior temporal gyrus; *, Pcorrected < 0.05.
159-1	37672-37673	L	_	
159-2	37673-37674	,	_	
159-3	37675-37679	left	_	
159-4	37679-37680	;	_	
159-5	37681-37682	R	_	
159-6	37682-37683	,	_	
159-7	37684-37689	right	_	
159-8	37689-37690	;	_	
159-9	37691-37694	PCG	_	
159-10	37694-37695	,	_	
159-11	37696-37706	Precentral	_	
159-12	37707-37712	gyrus	_	
159-13	37712-37713	;	_	
159-14	37714-37717	STG	_	
159-15	37717-37718	,	_	
159-16	37719-37727	superior	_	
159-17	37728-37736	temporal	_	
159-18	37737-37742	gyrus	_	
159-19	37742-37743	;	_	
159-20	37744-37745	*	_	
159-21	37745-37746	,	_	
159-22	37747-37757	Pcorrected	_	
159-23	37758-37759	<	_	
159-24	37760-37764	0.05	_	
159-25	37764-37765	.	_	

#Text=Demographic characteristics (entire cohort)
#Text=\tNONSMOKERS(n=92)\tSMOKERS(n=66)\tStatisticalAnalysis\t \tCYP2A6\tNormal\tIntermediate\tSlow\tNormal\tIntermediate\tSlow\tP\t \tNumber of subjects\t28\t21\t43\t25\t18\t23\t0.36\t \tAge (years)\t34.2±9.6\t29.8±7.9\t32.4±8.5\t36.5±11.0\t30.7±10.4\t34.5±8.4\tall Ps > 0.09\t \tGender (M:F)\t13:15\t12:9\t24:19\t11:14\t10:8\t15:8\tall Ps > 0.29\t \tRace\t\t\t\t\t\t\t\t \tBlack/AfricanAmerican\t13\t10\t35\t7\t4\t17\t\t \tCaucasian\t12\t8\t5\t18\t14\t5\t\t \tOthers\t3\t3\t3\t--\t--\t1\t\t \tYears of educationa\t14.1±1.8\t14.5±1.2\t14.0±2.1\t13.2±2.3\t13.1±1.6\t13.1±1.7\tall Ps > 0.88\t \tIQ (Verbal)b\t59.8±8.2\t59.9±9.0\t58.6±10.0\t57.6±8.6\t53.9±7.5\t54.0±6.8\tall Ps > 0.36\t \tFTND\t\t\t\t5.4±2.1\t5.3±2.0\t4.6±1.9\t0.33\t \tCPDc\t\t\t\t20.7+7.4\t17.6+8.5\t14.5+3.7\t0.04\t \tCO\t\t\t\t22.4+14.6\t14.6+9.2\t17.4+8.7\t0.12\t \tInterval (hours)\t\t\t\t5.3+5.0\t3.6+1.2\t5.0+4.8\t0.62\t \t
#Text=Pearson’s χ2-test was used to compare the frequency/gender distribution of the three CYP2A6 genotype groups between smokers and nonsmokers.
160-1	37766-37777	Demographic	_	
160-2	37778-37793	characteristics	_	
160-3	37794-37795	(	_	
160-4	37795-37801	entire	_	
160-5	37802-37808	cohort	_	
160-6	37808-37809	)	_	
160-7	37811-37821	NONSMOKERS	_	
160-8	37821-37822	(	_	
160-9	37822-37823	n	_	
160-10	37823-37824	=	_	
160-11	37824-37826	92	_	
160-12	37826-37827	)	_	
160-13	37828-37835	SMOKERS	_	
160-14	37835-37836	(	_	
160-15	37836-37837	n	_	
160-16	37837-37838	=	_	
160-17	37838-37840	66	_	
160-18	37840-37841	)	_	
160-19	37842-37861	StatisticalAnalysis	_	
160-20	37864-37870	CYP2A6	_	
160-21	37871-37877	Normal	_	
160-22	37878-37890	Intermediate	_	
160-23	37891-37895	Slow	_	
160-24	37896-37902	Normal	_	
160-25	37903-37915	Intermediate	_	
160-26	37916-37920	Slow	_	
160-27	37921-37922	P	_	
160-28	37925-37931	Number	_	
160-29	37932-37934	of	_	
160-30	37935-37943	subjects	_	
160-31	37944-37946	28	_	
160-32	37947-37949	21	_	
160-33	37950-37952	43	_	
160-34	37953-37955	25	_	
160-35	37956-37958	18	_	
160-36	37959-37961	23	_	
160-37	37962-37966	0.36	_	
160-38	37969-37972	Age	_	
160-39	37973-37974	(	_	
160-40	37974-37979	years	_	
160-41	37979-37980	)	_	
160-42	37981-37985	34.2	_	
160-43	37985-37986	±	_	
160-44	37986-37989	9.6	_	
160-45	37990-37994	29.8	_	
160-46	37994-37995	±	_	
160-47	37995-37998	7.9	_	
160-48	37999-38003	32.4	_	
160-49	38003-38004	±	_	
160-50	38004-38007	8.5	_	
160-51	38008-38012	36.5	_	
160-52	38012-38013	±	_	
160-53	38013-38017	11.0	_	
160-54	38018-38022	30.7	_	
160-55	38022-38023	±	_	
160-56	38023-38027	10.4	_	
160-57	38028-38032	34.5	_	
160-58	38032-38033	±	_	
160-59	38033-38036	8.4	_	
160-60	38037-38040	all	_	
160-61	38041-38043	Ps	_	
160-62	38044-38045	>	_	
160-63	38046-38050	0.09	_	
160-64	38053-38059	Gender	_	
160-65	38060-38061	(	_	
160-66	38061-38062	M	_	
160-67	38062-38063	:	_	
160-68	38063-38064	F	_	
160-69	38064-38065	)	_	
160-70	38066-38068	13	_	
160-71	38068-38069	:	_	
160-72	38069-38071	15	_	
160-73	38072-38074	12	_	
160-74	38074-38075	:	_	
160-75	38075-38076	9	_	
160-76	38077-38079	24	_	
160-77	38079-38080	:	_	
160-78	38080-38082	19	_	
160-79	38083-38085	11	_	
160-80	38085-38086	:	_	
160-81	38086-38088	14	_	
160-82	38089-38091	10	_	
160-83	38091-38092	:	_	
160-84	38092-38093	8	_	
160-85	38094-38096	15	_	
160-86	38096-38097	:	_	
160-87	38097-38098	8	_	
160-88	38099-38102	all	_	
160-89	38103-38105	Ps	_	
160-90	38106-38107	>	_	
160-91	38108-38112	0.29	_	
160-92	38115-38119	Race	_	
160-93	38129-38134	Black	_	
160-94	38134-38135	/	_	
160-95	38135-38150	AfricanAmerican	_	
160-96	38151-38153	13	_	
160-97	38154-38156	10	_	
160-98	38157-38159	35	_	
160-99	38160-38161	7	_	
160-100	38162-38163	4	_	
160-101	38164-38166	17	_	
160-102	38170-38179	Caucasian	_	
160-103	38180-38182	12	_	
160-104	38183-38184	8	_	
160-105	38185-38186	5	_	
160-106	38187-38189	18	_	
160-107	38190-38192	14	_	
160-108	38193-38194	5	_	
160-109	38198-38204	Others	_	
160-110	38205-38206	3	_	
160-111	38207-38208	3	_	
160-112	38209-38210	3	_	
160-113	38211-38212	-	_	
160-114	38212-38213	-	_	
160-115	38214-38215	-	_	
160-116	38215-38216	-	_	
160-117	38217-38218	1	_	
160-118	38222-38227	Years	_	
160-119	38228-38230	of	_	
160-120	38231-38241	educationa	_	
160-121	38242-38246	14.1	_	
160-122	38246-38247	±	_	
160-123	38247-38250	1.8	_	
160-124	38251-38255	14.5	_	
160-125	38255-38256	±	_	
160-126	38256-38259	1.2	_	
160-127	38260-38264	14.0	_	
160-128	38264-38265	±	_	
160-129	38265-38268	2.1	_	
160-130	38269-38273	13.2	_	
160-131	38273-38274	±	_	
160-132	38274-38277	2.3	_	
160-133	38278-38282	13.1	_	
160-134	38282-38283	±	_	
160-135	38283-38286	1.6	_	
160-136	38287-38291	13.1	_	
160-137	38291-38292	±	_	
160-138	38292-38295	1.7	_	
160-139	38296-38299	all	_	
160-140	38300-38302	Ps	_	
160-141	38303-38304	>	_	
160-142	38305-38309	0.88	_	
160-143	38312-38314	IQ	_	
160-144	38315-38316	(	_	
160-145	38316-38322	Verbal	_	
160-146	38322-38323	)	_	
160-147	38323-38324	b	_	
160-148	38325-38329	59.8	_	
160-149	38329-38330	±	_	
160-150	38330-38333	8.2	_	
160-151	38334-38338	59.9	_	
160-152	38338-38339	±	_	
160-153	38339-38342	9.0	_	
160-154	38343-38347	58.6	_	
160-155	38347-38348	±	_	
160-156	38348-38352	10.0	_	
160-157	38353-38357	57.6	_	
160-158	38357-38358	±	_	
160-159	38358-38361	8.6	_	
160-160	38362-38366	53.9	_	
160-161	38366-38367	±	_	
160-162	38367-38370	7.5	_	
160-163	38371-38375	54.0	_	
160-164	38375-38376	±	_	
160-165	38376-38379	6.8	_	
160-166	38380-38383	all	_	
160-167	38384-38386	Ps	_	
160-168	38387-38388	>	_	
160-169	38389-38393	0.36	_	
160-170	38396-38400	FTND	_	
160-171	38404-38407	5.4	_	
160-172	38407-38408	±	_	
160-173	38408-38411	2.1	_	
160-174	38412-38415	5.3	_	
160-175	38415-38416	±	_	
160-176	38416-38419	2.0	_	
160-177	38420-38423	4.6	_	
160-178	38423-38424	±	_	
160-179	38424-38427	1.9	_	
160-180	38428-38432	0.33	_	
160-181	38435-38439	CPDc	_	
160-182	38443-38447	20.7	_	
160-183	38447-38448	+	_	
160-184	38448-38451	7.4	_	
160-185	38452-38456	17.6	_	
160-186	38456-38457	+	_	
160-187	38457-38460	8.5	_	
160-188	38461-38465	14.5	_	
160-189	38465-38466	+	_	
160-190	38466-38469	3.7	_	
160-191	38470-38474	0.04	_	
160-192	38477-38479	CO	_	
160-193	38483-38487	22.4	_	
160-194	38487-38488	+	_	
160-195	38488-38492	14.6	_	
160-196	38493-38497	14.6	_	
160-197	38497-38498	+	_	
160-198	38498-38501	9.2	_	
160-199	38502-38506	17.4	_	
160-200	38506-38507	+	_	
160-201	38507-38510	8.7	_	
160-202	38511-38515	0.12	_	
160-203	38518-38526	Interval	_	
160-204	38527-38528	(	_	
160-205	38528-38533	hours	_	
160-206	38533-38534	)	_	
160-207	38538-38541	5.3	_	
160-208	38541-38542	+	_	
160-209	38542-38545	5.0	_	
160-210	38546-38549	3.6	_	
160-211	38549-38550	+	_	
160-212	38550-38553	1.2	_	
160-213	38554-38557	5.0	_	
160-214	38557-38558	+	_	
160-215	38558-38561	4.8	_	
160-216	38562-38566	0.62	_	
160-217	38570-38577	Pearson	_	
160-218	38577-38578	’	_	
160-219	38578-38579	s	_	
160-220	38580-38582	χ2	_	
160-221	38582-38583	-	_	
160-222	38583-38587	test	_	
160-223	38588-38591	was	_	
160-224	38592-38596	used	_	
160-225	38597-38599	to	_	
160-226	38600-38607	compare	_	
160-227	38608-38611	the	_	
160-228	38612-38621	frequency	_	
160-229	38621-38622	/	_	
160-230	38622-38628	gender	_	
160-231	38629-38641	distribution	_	
160-232	38642-38644	of	_	
160-233	38645-38648	the	_	
160-234	38649-38654	three	_	
160-235	38655-38661	CYP2A6	_	
160-236	38662-38670	genotype	_	
160-237	38671-38677	groups	_	
160-238	38678-38685	between	_	
160-239	38686-38693	smokers	_	
160-240	38694-38697	and	_	
160-241	38698-38708	nonsmokers	_	
160-242	38708-38709	.	_	

#Text=Two-way ANOVAs were conducted to compare the six groups in age, years of education, and IQ.
161-1	38710-38717	Two-way	_	
161-2	38718-38724	ANOVAs	_	
161-3	38725-38729	were	_	
161-4	38730-38739	conducted	_	
161-5	38740-38742	to	_	
161-6	38743-38750	compare	_	
161-7	38751-38754	the	_	
161-8	38755-38758	six	_	
161-9	38759-38765	groups	_	
161-10	38766-38768	in	_	
161-11	38769-38772	age	_	
161-12	38772-38773	,	_	
161-13	38774-38779	years	_	
161-14	38780-38782	of	_	
161-15	38783-38792	education	_	
161-16	38792-38793	,	_	
161-17	38794-38797	and	_	
161-18	38798-38800	IQ	_	
161-19	38800-38801	.	_	

#Text=One-way ANOVA was used to compare differences in FTND, CPD, CO, and interval among the three genotype smokers.
162-1	38802-38809	One-way	_	
162-2	38810-38815	ANOVA	_	
162-3	38816-38819	was	_	
162-4	38820-38824	used	_	
162-5	38825-38827	to	_	
162-6	38828-38835	compare	_	
162-7	38836-38847	differences	_	
162-8	38848-38850	in	_	
162-9	38851-38855	FTND	_	
162-10	38855-38856	,	_	
162-11	38857-38860	CPD	_	
162-12	38860-38861	,	_	
162-13	38862-38864	CO	_	
162-14	38864-38865	,	_	
162-15	38866-38869	and	_	
162-16	38870-38878	interval	_	
162-17	38879-38884	among	_	
162-18	38885-38888	the	_	
162-19	38889-38894	three	_	
162-20	38895-38903	genotype	_	
162-21	38904-38911	smokers	_	
162-22	38911-38912	.	_	

#Text=Tukey’s t-test was used for multiple comparisons.
163-1	38913-38918	Tukey	_	
163-2	38918-38919	’	_	
163-3	38919-38920	s	_	
163-4	38921-38927	t-test	_	
163-5	38928-38931	was	_	
163-6	38932-38936	used	_	
163-7	38937-38940	for	_	
163-8	38941-38949	multiple	_	
163-9	38950-38961	comparisons	_	
163-10	38961-38962	.	_	

#Text=Data represents mean + SD.
164-1	38963-38967	Data	_	
164-2	38968-38978	represents	_	
164-3	38979-38983	mean	_	
164-4	38984-38985	+	_	
164-5	38986-38988	SD	_	
164-6	38988-38989	.	_	

#Text=FTND, Fagerström Test for Nicotine Dependence; CPD, cigarettes per day; M, male; F, female; CO, exhaled carbon monoxide level (ppm); Interval, time from last cigarette smoked to data acquisition beginning.
165-1	38990-38994	FTND	_	
165-2	38994-38995	,	_	
165-3	38996-39006	Fagerström	_	
165-4	39007-39011	Test	_	
165-5	39012-39015	for	_	
165-6	39016-39024	Nicotine	_	
165-7	39025-39035	Dependence	_	
165-8	39035-39036	;	_	
165-9	39037-39040	CPD	_	
165-10	39040-39041	,	_	
165-11	39042-39052	cigarettes	_	
165-12	39053-39056	per	_	
165-13	39057-39060	day	_	
165-14	39060-39061	;	_	
165-15	39062-39063	M	_	
165-16	39063-39064	,	_	
165-17	39065-39069	male	_	
165-18	39069-39070	;	_	
165-19	39071-39072	F	_	
165-20	39072-39073	,	_	
165-21	39074-39080	female	_	
165-22	39080-39081	;	_	
165-23	39082-39084	CO	_	
165-24	39084-39085	,	_	
165-25	39086-39093	exhaled	_	
165-26	39094-39100	carbon	_	
165-27	39101-39109	monoxide	_	
165-28	39110-39115	level	_	
165-29	39116-39117	(	_	
165-30	39117-39120	ppm	_	
165-31	39120-39121	)	_	
165-32	39121-39122	;	_	
165-33	39123-39131	Interval	_	
165-34	39131-39132	,	_	
165-35	39133-39137	time	_	
165-36	39138-39142	from	_	
165-37	39143-39147	last	_	
165-38	39148-39157	cigarette	_	
165-39	39158-39164	smoked	_	
165-40	39165-39167	to	_	
165-41	39168-39172	data	_	
165-42	39173-39184	acquisition	_	
165-43	39185-39194	beginning	_	
165-44	39194-39195	.	_	

#Text=Significant difference in education years between smokers and nonsmokers (P = 0.004).
166-1	39196-39207	Significant	_	
166-2	39208-39218	difference	_	
166-3	39219-39221	in	_	
166-4	39222-39231	education	_	
166-5	39232-39237	years	_	
166-6	39238-39245	between	_	
166-7	39246-39253	smokers	_	
166-8	39254-39257	and	_	
166-9	39258-39268	nonsmokers	_	
166-10	39269-39270	(	_	
166-11	39270-39271	P	_	
166-12	39272-39273	=	_	
166-13	39274-39279	0.004	_	
166-14	39279-39280	)	_	
166-15	39280-39281	.	_	

#Text=Significant difference in IQ score between smokers and nonsmokers (P = 0.002).
167-1	39282-39293	Significant	_	
167-2	39294-39304	difference	_	
167-3	39305-39307	in	_	
167-4	39308-39310	IQ	_	
167-5	39311-39316	score	_	
167-6	39317-39324	between	_	
167-7	39325-39332	smokers	_	
167-8	39333-39336	and	_	
167-9	39337-39347	nonsmokers	_	
167-10	39348-39349	(	_	
167-11	39349-39350	P	_	
167-12	39351-39352	=	_	
167-13	39353-39358	0.002	_	
167-14	39358-39359	)	_	
167-15	39359-39360	.	_	

#Text=Significant difference in CPD between normal and slow metabolizers (P = 0.003).
168-1	39361-39372	Significant	_	
168-2	39373-39383	difference	_	
168-3	39384-39386	in	_	
168-4	39387-39390	CPD	_	
168-5	39391-39398	between	_	
168-6	39399-39405	normal	_	
168-7	39406-39409	and	_	
168-8	39410-39414	slow	_	
168-9	39415-39427	metabolizers	_	
168-10	39428-39429	(	_	
168-11	39429-39430	P	_	
168-12	39431-39432	=	_	
168-13	39433-39438	0.003	_	
168-14	39438-39439	)	_	
168-15	39439-39440	.	_	

#Text=Demographic characteristics (MID task and Go/NoGo cohort)
#Text=\tNONSMOKERS\tSMOKERS\tStatistical Analysis\t \t\t\tP\t \t\t(n=20)\t(n=23)\t\t \t\t \tCYP2A6\tNormal\tReduced\tNormal\tReduced\t\t \tNumber of subjects\t9\t11\t15\t8\t0.18\t \tAge\t30.7±7.8\t30.2±6.9\t35.5±10.5\t35.6±9.4\tall Ps > 0.08\t \tRace\t\t\t\t\t\t \tBlack or African American\t1\t5\t2\t4\t\t \tCaucasian\t7\t3\t10\t3\t\t \tOthers\t1\t3\t3\t1\t\t \tGender (M:F)\t5:4\t5:6\t6:9\t5:3\t0.23\t \tIQ (Verbal)a\t64.9±8.9\t58.6±3.3\t58.3±10.8\t51.4±5.9\tall Ps > 0.01\t \tYears of educationb\t15.6±0.9\t14.4±1.6\t13.8±1.8\t13.2±2.0\tall Ps > 0.007\t \tFTND\t\t\t4.8±1.9\t5.0±2.2\t0.82\t \tCPD\t\t\t16.8±7.0\t13.1±9.0\t0.94\t \tCO\t\t\t6.8±2.8\t7.5±4.9\t0.68\t \t
#Text=Pearson’s χ2-test was used to compare the frequency/gender distribution of the two CYP2A6 genotype groups between smokers and nonsmokers.
169-1	39441-39452	Demographic	_	
169-2	39453-39468	characteristics	_	
169-3	39469-39470	(	_	
169-4	39470-39473	MID	_	
169-5	39474-39478	task	_	
169-6	39479-39482	and	_	
169-7	39483-39485	Go	_	
169-8	39485-39486	/	_	
169-9	39486-39490	NoGo	_	
169-10	39491-39497	cohort	_	
169-11	39497-39498	)	_	
169-12	39500-39510	NONSMOKERS	_	
169-13	39511-39518	SMOKERS	_	
169-14	39519-39530	Statistical	_	
169-15	39531-39539	Analysis	_	
169-16	39544-39545	P	_	
169-17	39549-39550	(	_	
169-18	39550-39551	n	_	
169-19	39551-39552	=	_	
169-20	39552-39554	20	_	
169-21	39554-39555	)	_	
169-22	39556-39557	(	_	
169-23	39557-39558	n	_	
169-24	39558-39559	=	_	
169-25	39559-39561	23	_	
169-26	39561-39562	)	_	
169-27	39569-39575	CYP2A6	_	
169-28	39576-39582	Normal	_	
169-29	39583-39590	Reduced	_	
169-30	39591-39597	Normal	_	
169-31	39598-39605	Reduced	_	
169-32	39609-39615	Number	_	
169-33	39616-39618	of	_	
169-34	39619-39627	subjects	_	
169-35	39628-39629	9	_	
169-36	39630-39632	11	_	
169-37	39633-39635	15	_	
169-38	39636-39637	8	_	
169-39	39638-39642	0.18	_	
169-40	39645-39648	Age	_	
169-41	39649-39653	30.7	_	
169-42	39653-39654	±	_	
169-43	39654-39657	7.8	_	
169-44	39658-39662	30.2	_	
169-45	39662-39663	±	_	
169-46	39663-39666	6.9	_	
169-47	39667-39671	35.5	_	
169-48	39671-39672	±	_	
169-49	39672-39676	10.5	_	
169-50	39677-39681	35.6	_	
169-51	39681-39682	±	_	
169-52	39682-39685	9.4	_	
169-53	39686-39689	all	_	
169-54	39690-39692	Ps	_	
169-55	39693-39694	>	_	
169-56	39695-39699	0.08	_	
169-57	39702-39706	Race	_	
169-58	39714-39719	Black	_	
169-59	39720-39722	or	_	
169-60	39723-39730	African	_	
169-61	39731-39739	American	_	
169-62	39740-39741	1	_	
169-63	39742-39743	5	_	
169-64	39744-39745	2	_	
169-65	39746-39747	4	_	
169-66	39751-39760	Caucasian	_	
169-67	39761-39762	7	_	
169-68	39763-39764	3	_	
169-69	39765-39767	10	_	
169-70	39768-39769	3	_	
169-71	39773-39779	Others	_	
169-72	39780-39781	1	_	
169-73	39782-39783	3	_	
169-74	39784-39785	3	_	
169-75	39786-39787	1	_	
169-76	39791-39797	Gender	_	
169-77	39798-39799	(	_	
169-78	39799-39800	M	_	
169-79	39800-39801	:	_	
169-80	39801-39802	F	_	
169-81	39802-39803	)	_	
169-82	39804-39805	5	_	
169-83	39805-39806	:	_	
169-84	39806-39807	4	_	
169-85	39808-39809	5	_	
169-86	39809-39810	:	_	
169-87	39810-39811	6	_	
169-88	39812-39813	6	_	
169-89	39813-39814	:	_	
169-90	39814-39815	9	_	
169-91	39816-39817	5	_	
169-92	39817-39818	:	_	
169-93	39818-39819	3	_	
169-94	39820-39824	0.23	_	
169-95	39827-39829	IQ	_	
169-96	39830-39831	(	_	
169-97	39831-39837	Verbal	_	
169-98	39837-39838	)	_	
169-99	39838-39839	a	_	
169-100	39840-39844	64.9	_	
169-101	39844-39845	±	_	
169-102	39845-39848	8.9	_	
169-103	39849-39853	58.6	_	
169-104	39853-39854	±	_	
169-105	39854-39857	3.3	_	
169-106	39858-39862	58.3	_	
169-107	39862-39863	±	_	
169-108	39863-39867	10.8	_	
169-109	39868-39872	51.4	_	
169-110	39872-39873	±	_	
169-111	39873-39876	5.9	_	
169-112	39877-39880	all	_	
169-113	39881-39883	Ps	_	
169-114	39884-39885	>	_	
169-115	39886-39890	0.01	_	
169-116	39893-39898	Years	_	
169-117	39899-39901	of	_	
169-118	39902-39912	educationb	_	
169-119	39913-39917	15.6	_	
169-120	39917-39918	±	_	
169-121	39918-39921	0.9	_	
169-122	39922-39926	14.4	_	
169-123	39926-39927	±	_	
169-124	39927-39930	1.6	_	
169-125	39931-39935	13.8	_	
169-126	39935-39936	±	_	
169-127	39936-39939	1.8	_	
169-128	39940-39944	13.2	_	
169-129	39944-39945	±	_	
169-130	39945-39948	2.0	_	
169-131	39949-39952	all	_	
169-132	39953-39955	Ps	_	
169-133	39956-39957	>	_	
169-134	39958-39963	0.007	_	
169-135	39966-39970	FTND	_	
169-136	39973-39976	4.8	_	
169-137	39976-39977	±	_	
169-138	39977-39980	1.9	_	
169-139	39981-39984	5.0	_	
169-140	39984-39985	±	_	
169-141	39985-39988	2.2	_	
169-142	39989-39993	0.82	_	
169-143	39996-39999	CPD	_	
169-144	40002-40006	16.8	_	
169-145	40006-40007	±	_	
169-146	40007-40010	7.0	_	
169-147	40011-40015	13.1	_	
169-148	40015-40016	±	_	
169-149	40016-40019	9.0	_	
169-150	40020-40024	0.94	_	
169-151	40027-40029	CO	_	
169-152	40032-40035	6.8	_	
169-153	40035-40036	±	_	
169-154	40036-40039	2.8	_	
169-155	40040-40043	7.5	_	
169-156	40043-40044	±	_	
169-157	40044-40047	4.9	_	
169-158	40048-40052	0.68	_	
169-159	40056-40063	Pearson	_	
169-160	40063-40064	’	_	
169-161	40064-40065	s	_	
169-162	40066-40068	χ2	_	
169-163	40068-40069	-	_	
169-164	40069-40073	test	_	
169-165	40074-40077	was	_	
169-166	40078-40082	used	_	
169-167	40083-40085	to	_	
169-168	40086-40093	compare	_	
169-169	40094-40097	the	_	
169-170	40098-40107	frequency	_	
169-171	40107-40108	/	_	
169-172	40108-40114	gender	_	
169-173	40115-40127	distribution	_	
169-174	40128-40130	of	_	
169-175	40131-40134	the	_	
169-176	40135-40138	two	_	
169-177	40139-40145	CYP2A6	_	
169-178	40146-40154	genotype	_	
169-179	40155-40161	groups	_	
169-180	40162-40169	between	_	
169-181	40170-40177	smokers	_	
169-182	40178-40181	and	_	
169-183	40182-40192	nonsmokers	_	
169-184	40192-40193	.	_	

#Text=Two-way ANOVAs were conducted to compare the four groups in age, years of education, and IQ.
170-1	40194-40201	Two-way	_	
170-2	40202-40208	ANOVAs	_	
170-3	40209-40213	were	_	
170-4	40214-40223	conducted	_	
170-5	40224-40226	to	_	
170-6	40227-40234	compare	_	
170-7	40235-40238	the	_	
170-8	40239-40243	four	_	
170-9	40244-40250	groups	_	
170-10	40251-40253	in	_	
170-11	40254-40257	age	_	
170-12	40257-40258	,	_	
170-13	40259-40264	years	_	
170-14	40265-40267	of	_	
170-15	40268-40277	education	_	
170-16	40277-40278	,	_	
170-17	40279-40282	and	_	
170-18	40283-40285	IQ	_	
170-19	40285-40286	.	_	

#Text=Tukey’s t-tests were used to compare differences in FTND, CPD, and CO between the two genotype smokers, and also were used for multiple comparisons.
171-1	40287-40292	Tukey	_	
171-2	40292-40293	’	_	
171-3	40293-40294	s	_	
171-4	40295-40302	t-tests	_	
171-5	40303-40307	were	_	
171-6	40308-40312	used	_	
171-7	40313-40315	to	_	
171-8	40316-40323	compare	_	
171-9	40324-40335	differences	_	
171-10	40336-40338	in	_	
171-11	40339-40343	FTND	_	
171-12	40343-40344	,	_	
171-13	40345-40348	CPD	_	
171-14	40348-40349	,	_	
171-15	40350-40353	and	_	
171-16	40354-40356	CO	_	
171-17	40357-40364	between	_	
171-18	40365-40368	the	_	
171-19	40369-40372	two	_	
171-20	40373-40381	genotype	_	
171-21	40382-40389	smokers	_	
171-22	40389-40390	,	_	
171-23	40391-40394	and	_	
171-24	40395-40399	also	_	
171-25	40400-40404	were	_	
171-26	40405-40409	used	_	
171-27	40410-40413	for	_	
171-28	40414-40422	multiple	_	
171-29	40423-40434	comparisons	_	
171-30	40434-40435	.	_	

#Text=Reduced: slow and intermediate.
172-1	40436-40443	Reduced	_	
172-2	40443-40444	:	_	
172-3	40445-40449	slow	_	
172-4	40450-40453	and	_	
172-5	40454-40466	intermediate	_	
172-6	40466-40467	.	_	

#Text=Data represents mean ± SD; FTND, Fagerström Test for Nicotine Dependence; CPD, cigarettes per day; M, male; F, female; CO, exhaled carbon monoxide level (ppm).
173-1	40468-40472	Data	_	
173-2	40473-40483	represents	_	
173-3	40484-40488	mean	_	
173-4	40489-40490	±	_	
173-5	40491-40493	SD	_	
173-6	40493-40494	;	_	
173-7	40495-40499	FTND	_	
173-8	40499-40500	,	_	
173-9	40501-40511	Fagerström	_	
173-10	40512-40516	Test	_	
173-11	40517-40520	for	_	
173-12	40521-40529	Nicotine	_	
173-13	40530-40540	Dependence	_	
173-14	40540-40541	;	_	
173-15	40542-40545	CPD	_	
173-16	40545-40546	,	_	
173-17	40547-40557	cigarettes	_	
173-18	40558-40561	per	_	
173-19	40562-40565	day	_	
173-20	40565-40566	;	_	
173-21	40567-40568	M	_	
173-22	40568-40569	,	_	
173-23	40570-40574	male	_	
173-24	40574-40575	;	_	
173-25	40576-40577	F	_	
173-26	40577-40578	,	_	
173-27	40579-40585	female	_	
173-28	40585-40586	;	_	
173-29	40587-40589	CO	_	
173-30	40589-40590	,	_	
173-31	40591-40598	exhaled	_	
173-32	40599-40605	carbon	_	
173-33	40606-40614	monoxide	_	
173-34	40615-40620	level	_	
173-35	40621-40622	(	_	
173-36	40622-40625	ppm	_	
173-37	40625-40626	)	_	
173-38	40626-40627	.	_	

#Text=Smokers had lower IQ than nonsmokers (P = 0.011), and reduced genotype individuals had lower IQ score than those with normal genotype (P = 0.015).
174-1	40628-40635	Smokers	_	
174-2	40636-40639	had	_	
174-3	40640-40645	lower	_	
174-4	40646-40648	IQ	_	
174-5	40649-40653	than	_	
174-6	40654-40664	nonsmokers	_	
174-7	40665-40666	(	_	
174-8	40666-40667	P	_	
174-9	40668-40669	=	_	
174-10	40670-40675	0.011	_	
174-11	40675-40676	)	_	
174-12	40676-40677	,	_	
174-13	40678-40681	and	_	
174-14	40682-40689	reduced	_	
174-15	40690-40698	genotype	_	
174-16	40699-40710	individuals	_	
174-17	40711-40714	had	_	
174-18	40715-40720	lower	_	
174-19	40721-40723	IQ	_	
174-20	40724-40729	score	_	
174-21	40730-40734	than	_	
174-22	40735-40740	those	_	
174-23	40741-40745	with	_	
174-24	40746-40752	normal	_	
174-25	40753-40761	genotype	_	
174-26	40762-40763	(	_	
174-27	40763-40764	P	_	
174-28	40765-40766	=	_	
174-29	40767-40772	0.015	_	
174-30	40772-40773	)	_	
174-31	40773-40774	.	_	

#Text=Smokers had fewer years of education than nonsmokers (P = 0.007).
175-1	40775-40782	Smokers	_	
175-2	40783-40786	had	_	
175-3	40787-40792	fewer	_	
175-4	40793-40798	years	_	
175-5	40799-40801	of	_	
175-6	40802-40811	education	_	
175-7	40812-40816	than	_	
175-8	40817-40827	nonsmokers	_	
175-9	40828-40829	(	_	
175-10	40829-40830	P	_	
175-11	40831-40832	=	_	
175-12	40833-40838	0.007	_	
175-13	40838-40839	)	_	
175-14	40839-40840	.	_	
